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Abstract
Cell transplantation is a promising strategy for treating heart failure but the me-
chanisms effecting functional improvements remain unknown. The hypothesis that
cell transplantation influences the contractile properties and excitation-contraction
(EC) coupling of recipient cardiomyocytes by paracrine mechanisms was tested.
Adult rats underwent myocardial infarction and subsequently developed chronic
heart failure. They then received intra-myocardial injections of either skeletal myo-
blasts or bone marrow mononuclear cells which were harvested from transgenic rats
constitutively expressing green fluorescent protein. Four weeks after injection, both
cell types increased ejection fraction and reduced cardiomyocyte size. Isolated car-
diomyocytes emitted low levels of green fluorescence, indicating that they originated
from the recipient heart. The cardiomyocytes were then studied using sarcomere
length measurements, indo-1 fluorescence and whole-cell patch-clamping techniques.
Injection of either bone marrow cells or skeletal myoblasts normalized the impaired
contractile performance and the prolonged time-to-peak of the Ca2+ transients that
were observed in failing cardiomyocytes. The smaller and slower L-type Ca2+ current
observed in heart failure returned to normal values after skeletal myoblast, but not
bone marrow mononuclear cell, transplantation. Analysis of Ca2+ sparks in isolated
cardiomyocytes using confocal microscopy revealed that SR Ca2+ leak had increased
in failing cardiomyocytes, but was normalized by skeletal myoblast transplantation.
In order to test the hypothesis that these effects observed in vivo are mediated by
paracrine substances secreted from the transplanted cells further experiments were
performed. Cardiomyocytes were isolated from failing hearts and cultured for 48
hours. Co-culturing with either skeletal myoblasts or bone marrow mononuclear
cells during this period improved cardiomyocyte contraction and Ca2+ handling.
This effect was maintained even when the different cell populations were mechan-
ically separated by means of a porous membrane, demonstrating that cell-to-cell
contact was not required and that soluble substances mediated the effect. Analysis
of the supernates obtained from these co-culture experiments identified four candi-
date substances as possible mediators, but confirmation of their importance requires
further experimental investigation.
In addition to the work described above, experiments were performed during the
preparation of the whole-cell patch-clamping system. The system was tested by
measuring the Na+/Ca2+ exchanger current densities in cardiomyocytes isolated
from normal rat hearts. Using this system the acute effects of various β-adrenergic
agonists was assessed. The results obtained from this separate study are presented
in Chapter 6.
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Chapter 1
Introduction
1.1 Heart failure
“A state in which the heart fails to maintain an adequate circulation for the needs
of the body despite a satisfactory filling pressure” – Paul Wood, 1950.
“Ventricular dysfunction with symptoms” – ANON.
1.1.1 The clinical syndrome
The pattern of symptoms resulting from heart failure depend on which side of the
heart is affected (Braunwald 2007). If the left ventricle is performing inadequately
blood flow becomes stagnant in the lungs, leading to worsening shortness of breath
(dyspnœa) and fatigue. In comparison, symptoms of right-sided heart failure in-
clude peripheral œdema, ascites, and those relating to congestive liver failure. It
is common for patients to have deteriorating function on both sides of the heart,
either because of shared underlying pathology, or because failure of one side of the
heart can impose a mechanical burden on the other: congestive cardiac failure.
The manifestations of heart failure are progressive (Pfeffer & Braunwald 1990),
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and in its advanced stages can be extremely debilitating. In up to one third of pa-
tients dyspnœa and fatigue can limit exercise tolerance to walking only a few yards.
Patients may end up severely dyspnœic even at rest, and find that they cannot
maintain a supine position (orthopnœa). Paroxysmal nocturnal dyspnœa is a night
time attack of severe breathlessness, usually several hours after going to sleep.
Other symptoms of heart failure include lack of appetite and weight loss, noc-
turia, impaired cognition, and an increased susceptibility to chest infections. The
symptoms lead to a poor overall quality of life, when compared to other chronic
diseases (Hobbs et al. 2002). The prognosis for congestive heart failure has been
found to correlate closely with decreasing left ventricular ejection fraction, and is
very poor in the end stages of the disease (McKee et al. 1971, Ho et al. 1993). Ap-
proximately 43% of men and 36% of women die within 1 year of initial diagnosis
(Rector & Cohn 1994). The 5 year mortality rates are 75% and 62%, respectively
(Levy et al. 2002). To put this in context, congestive heart failure carries a worse
prognosis than many common malignancies including those of breast, colorectal, re-
nal, and prostate. Of the deaths in patients with heart failure up to 50% are sudden
(sudden cardiac death, or SCD). Alternatively, it may be due to worsening pump
failure. The proportion due to the latter gradually increases during the later stages
of the disease (The DEFIBRILAT Study Group 1991).
1.1.2 Epidemiology
Heart failure is a common disease in Western countries and represents an enor-
mous burden to society. In the United Kingdom, at least 24,000 people die from
the disease annually1. Approximately 2% of the National Health Service budget is
consumed by heart failure, and it accounts for at least 5% of admissions to general
medical and geriatric wards in British hospitals (Davis et al. 2000). These figures
are steadily increasing despite advances in medication therapy, probably due to the
prevalence of hypertension and obesity in the community and also the large numbers
1Source : British Heart Foundation; The Hillingdon Heart Failure Study 2001
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of survivors of acute myocardial infarction who have been spared death in the acute
phase (Braunwald 1997).
Heart failure is a disease predominantly affecting the elderly population. A study
carried out in Scotland revealed that 78% of patients admitted with heart failure
were aged 65 years or more (McMurray et al. 1993). The same study and others
showed that men and women are equally at risk (MacIntyre et al. 2000). However,
there have also been reports suggesting that the incidence might be higher in men
than in women (Cowie et al. 1999). Studies in the United Kingdom (Lip et al. 1997)
and those in North America (Dries et al. 1999) showed that black men and women
are at a 33 ∼ 50% higher risk of developing heart failure.
1.1.3 Aetiology
There are many underlying causes for heart failure. In general, heart failure results
when there is a loss of cardiomyocytes from the heart (Olivetti et al. 1995), usually
with alterations in their mechanical properties (Beuckelmann et al. 1992) to a degree
that adequate cardiac output cannot be maintained. It has been suggested that car-
diomyocytes are lost at a background rate in normal individuals, and that the rate
of loss increases with age (Olivetti et al. 1995). Certain pathological conditions
may accelerate this process, either acutely or chronically. There is no doubt that
myocardial infarctions cause a substantial loss of cardiomyocytes acutely. However,
coronary artery disease can impair the performance of the ventricle in the long term,
even without acute infarctions (Cowie et al. 1999).
In patients with long-term hypertension, the development of hypertrophy is well
recognized. In addition, it has been postulated that apoptotic cell loss may be
exacerbated in such cases (Bing 1994). In Western societies including the United
Kingdom myocardial infarction and hypertension are thought to be the two leading
causes of the increasing incidence of heart failure. In developing countries, other
causes such as rheumatic heart disease are also a common cause (Amoah & Kallen
2000).
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In addition to these factors, there are numerous other pathologies that are recog-
nized as causes of heart failure (Oakley 1997, Lip et al. 2000, Jessup & Brozena 2003,
Cowie et al. 1999) . These are summarized in Table. 1.1 on page 24. It is worth
noting that in many patients these factors often co-exist. For example, many pa-
tients who have suffered a myocardial infarction often also have hypertension. Some
of the identified risk-factors for coronary artery disease are now also recognized as
being independent risk factors for heart failure. These include, for example, diabetes
mellitus, cigarette smoking, and obesity (the Framingham Heart Study, Kenchaiah
et al. 2002). The recent recognition from this study that obese people had double
the risk of developing heart failure compared to those with a normal body mass
index is of particular importance, given the endemic and increasing prevalence of
obesity in Western countries.
23
Table 1.1: The causes of heart failure
Ischæmic heart disease
Hypertension
Rheumatic heart disease
Valvular heart disease
Arrhythmias
Excessive consumption of alcohol
Connective tissue disorders (e.g. SLE, scleroderma)
Structural abnormalities within the heart (septal defects)
Cardiomyopathies
• Familial dilated
• Familial hypertrophic
• Restrictive (e.g. amyloidosis, sarcoidosis)
• Obstructive
Infection
• Viral (e.g. coxsackie B, cytomegalovirus, HIV)
• Rickettsia
• Bacteria (e.g. diphtheria)
• Mycobacteria
• Fungus
• Parasites (e.g. Chagas’ disease, toxoplasmosis)
Muscular dystrophy
Cardiotoxic drugs (e.g. adriamycin, doxorubicin)
Endocrine disease (e.g. myxœdema, thyrotoxicosis, acromegaly)
Idiopathic
From Oakley (1997), Cowie et al. (1999), Lip et al. (2000), Jessup & Brozena (2003).
Abbreviations: SLE systemic lupus erythematosus. HIV human immunodeficiency virus.
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Fig. 1.1: Two-dimensional short-axis echocardiographic view illustrating infarct expansion
and thinning of asynergic compared to normally contracting region. Figure taken from Jugdutt
& Michorowski (1987).
1.1.4 Ventricular remodeling
The tissue necrosis and inflammation that occurs during the first few hours of a
myocardial infarction is followed by a phase of scar formation that is completed over
several weeks. During the period of resorption of necrotic tissue, but before there
has been extensive deposition of collagen, the transient decrease in tensile strength
can result in the infarcted region becoming thinner and longer. This phenomenon is
called infarct expansion (Hutchins & Bulkley 1978, Jugdutt & Michorowski 1987),
and is not accompanied by additional cardiomyocyte death. As can be seen in
Fig.1.1, infarct expansion directly increases the LV dimensions.
In addition to infarct expansion, the non-infarcted region also undergoes gradual
lengthening, even at sites remote to the infarcted area. This was first noted in canine
models of myocardial infarction (Theroux et al. 1977) and subsequently confirmed in
patients monitored after myocardial infarction using echocardiography (Erlebacher
et al. 1982). These two changes both contribute towards LV dilation, and can ini-
tially enable the LV to maintain a normal stroke volume despite a decreased ejection
fraction (Pfeffer & Braunwald 1990). However, this dilation substantially increases
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the LV wall stress throughout the cardiac cycle (by the Law of LaPlace2), which then
stimulates further ventricular enlargement (Grossman et al. 1975). A vicious cycle
can be entered in which initial dilatation begets dilatation. The ventricle also often
becomes more spherical in its shape as it dilates, and the collective pattern of alter-
ations to the ventricular architecture is often referred to as ventricular remodeling
(Braunwald & Pfeffer 1991).
Remodeling has been found to be associated with hypertrophy of cardiomyo-
cytes (Olivetti et al. 1991). Although cardiomyocyte hypertrophy in such circum-
stances can help maintain wall tension, it is associated with maladaptive changes in
excitation-contraction coupling (EC coupling) and dynamics of cardiomyocyte con-
traction and relaxation (these are discussed further in section 1.3). Consequently,
remodeling is correlated with deterioration of ventricular function (Cohn 1995, Mann
& Bristow 2005), and adversely affects patient prognosis. White et al. (1987) found
that survivors of myocardial infarction with LV end-systolic volumes of 75 and 125 ml
had their relative risks of death increased by approximately 2.5 times and five times,
respectively, compared to survivors who had their LV end-systolic volumes main-
tained within normal limits. In fact, the study identified LV end-systolic volumes
as the single most powerful predictor of survival in patients after myocardial infarc-
tion. There is increasing recognition of the importance of myocardial remodeling in
the pathophysiology of heart failure (Cohn et al. 2000). Consequently, myocardial
remodeling is increasingly becoming identified as a major therapeutic target (Mann
et al. 2002).
2LaPlace’s Law describes the relationship between the transmural pressure difference and the
tension, radius, and thickness of a vessel wall. Where T is the tension in the walls, P is the pressure
difference across the wall, R is the radius of the cylinder, and M is the thickness of the wall, the
relationship between these variables is T = P×RM .
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1.1.5 Treatment
Modification of lifestyle
In all patients with cardiovascular disease, including heart failure, control of the
modifiable risk factors has been shown to decrease the incidence and hinder the
progression of disease, ultimately improving prognosis (Jessup & Brozena 2003).
The major risk factors such as hypertension and diabetes must be adequately man-
aged. Current guidelines indicate a target diastolic blood pressure below 80 mmHg
(Mosterd et al. 1999). Modifications of lifestyle, particularly those leading to reduc-
tion of body weight in obese patients should be encouraged by doctors.
In addition dietary modifications should be recommended specifically to reduce
the intake of salt and alcohol. The intake of alcohol in patients should be limited
to less than two units per day, whilst those who have developed heart failure as a
direct consequence of alcohol abuse must abstain completely (Gould et al. 1971).
Medication therapy
A variety of classes of drugs are indicated for improving the symptoms and prognoses
of heart failure patients (Fig.1.2). Since heart failure is a syndrome of intravascular
volume overload diuretics are commonly used for controlling circulatory congestion
and peripheral œdema in symptomatic patients (Brater 1998). By reducing preload,
diuretics such as thiazides and the loop diuretics can reduce the diastolic stress on
the atrial and ventricular walls, inhibiting the progression of ventricular dysfunction.
A class of diuretics, the aldosterone antagonists, are especially indicated in
the advanced stages of heart failure, when patients show New York Heart Association
(NYHA) class III or IV symptoms (i.e. marked limitation of activity: patients are
comfortable only at rest or suffer even when resting.). In these patients circulating
levels of aldosterone are elevated due to increased stimulation from the angiotensin-
II pathway. Furthermore, impaired liver function due to venous congestion may lead
to inhibited hepatic clearance. The elevation of aldosterone can be measured even
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VAD,transplantation
Hospice
Inotropes
Consider multidisciplinary team
Aldosterone antagonist, nesiritide
Revascularization, mitral-valve surgery
Cardiac resynchronization if bundle-branch block present
Dietary sodium restriction, diuretics, and digoxin
ACE inhibitors and beta-blockers in all patients
ACE inhibitors or ARBs in all patients; beta-blockers in selected patients
Treat hypertension, diabetes, dyslipidemia; ACE inhibitors or ARBs in some patients
Risk-factor reduction, patient and family education
Stage B
Structural
heart
disease, no
symptoms
Stage C
Structural
disease,
previous or
current
symptoms
Stage D
Refractory
symptoms
requiring
special
intervention
Stage A
High risk
with no
symptoms
Fig. 1.2: Stages of heart failure and treatment options. Lifestyle and risk factor modifications
are important during the early stages of disease. With developing heart failure symptoms a
variety of medication therapy is given. During the later stages interventional procedures are
necessary, with transplantation ultimately becoming the only available cure. Adapted from
Jessup & Brozena 2003.
when angiotensin-converting enzyme (ACE) inhibitors are administered, via an “es-
cape” phenomenon of aldosterone production (Pitt 1995). Aldosterone stimulates
the retention of salt and excretion of potassium, and exacerbates myocardial hyper-
trophy. Administration of an aldosterone antagonist such as spironolactone coun-
teracts these responses (Pitt et al. 1999, The RALES Investigators 1996). Despite
these advantages, and the fact that spironolactone decreases myocardial fibrosis, the
use of spironolactone is limited to patients with advanced disease due to unwanted
anti-androgenic side effects.
ACE inhibitors such as enalapril and ramipril inhibit the renin-angiotensin
system of the body at the level of conversion of angiotensin-I to angiotensin-II.
They therefore minimize the multiple pathophysiological effects of angiotensin II,
and decrease the degradation of bradykinin. Bradykinin promotes vasodilatation
and causes natriuresis in the kidney. The notion that LV remodeling after myo-
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cardial infarction might be attenuated by reducing the pressure load has led to the
study of ACE inhibitors in animal models, which demonstrated smaller LV volumes
along with improved cardiac output and survival (Pfeffer & Pfeffer 1987). The
beneficial effects of ACE inhibitors in patients after myocardial infarction include
improvements in cardiac performance and survival (Levine et al. 1984, The SOLVD
Investigators 1991). In addition, there is reverse remodeling and a decrease in hos-
pitalization (Garg & Yusuf 1995). ACE inhibitors are currently recommended for
many patients with heart failure, even during early disease.
As an alternative to ACE inhibitors the renin-angiotensin system can be blocked
at the level of angiotensin-II binding to its receptor (subtype 1) by the use of an-
giotensin receptor antagonists, such as valsartan or candesartan. These should
not be used as first-line therapy for heart failure of any stage but are a valuable
alternative in patients who cannot tolerate ACE inhibitors because of severe cough
or angio-œdema (Hunt et al. 2005). Several trials involving patients with heart fail-
ure have shown that angiotensin receptor antagonists have efficacy similar to that
of ACE inhibitors but are not superior (Pitt et al. 2000). On the other hand, in a
randomized trial of patients with symptomatic left ventricular systolic dysfunction,
the addition of valsartan to ACE inhibitor treatment reduced the rate of death and
development of cardiovascular events as well as improving the symptoms of heart
failure (Cohn & Tognoni 2001).
Digoxin is a drug that inhibits the Na+/K+ ATPase in cardiomyocytes, increas-
ing their contractility. Its therapeutic efficacy in heart failure patients with normal
sinus rhythm has been disputed for many years, and it was only in 1997 that a large,
randomized, placebo-controlled study of digoxin for symptomatic patients with a low
ejection fraction was completed (The Digitalis Investigation Group 1997). There was
no difference in mortality between patients receiving digoxin and patients receiving
placebo, but there were decreases in the digoxin group in the rates of worsening
heart failure and hospitalization.
Drugs such as atenolol and carvedilol inhibit the β-adrenergic receptors in the
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heart (Foody et al. 2002). They have long been used for the treatment of hyper-
tension, angina, and arrhythmias as well as for prophylaxis in patients who have
had a myocardial infarction. By inhibiting the harmful effects of the sympathetic
nervous system that are activated during heart failure β-blockers confer remark-
able benefits, as demonstrated in trials involving patients with heart failure from
various causes and of all stages (Farrell et al. 2002). These include improvements in
quality of life, survival, and left ventricular ejection fraction and remodeling as well
as decreased incidences of hospitalization and sudden death. β-blockers are now
recommended to be used in all stable patients without substantial fluid retention
and without recent exacerbations of heart failure requiring inotropic therapy (Mann
et al. 2002).
Re-synchronization therapy
Approximately one third of heart failure patients show widened QRS complexes on
12-lead electrocardiography (ECG) in addition to LV dilation (Wilensky et al. 1988).
The underlying ventricular dyssynchrony resulting from intra-ventricular conduc-
tion defects puts the already failing LV at further disadvantage. In such patients
cardiac re-synchronization therapy using a percutaneous, three-lead, biventricular
pacemaker system can be of benefit. It can reduce the pathological mechanical in-
terventricular dyssynchrony between the right and the left ventricle and the dyssyn-
chrony within the left ventricle, improving global LV function and cardiac output
without increasing myocardial oxygen consumption (Kass et al. 1999). These acute
mechanical effects of cardiac re-synchronization therapy result in immediate symp-
tomatic improvements and can be accompanied by more chronic adaptations that
lead to long-term benefit. NYHA class, exercise capacity, and quality of life of pa-
tients have been demonstrated to increase (Linde et al. 2002, Young et al. 2003).
There is measurable reverse-remodeling of the LV with re-synchronization therapy
(Stellbrink et al. 2001), ultimately leading to improved patient survival (Cleland
et al. 2005, Bristow et al. 2004).
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Surgical therapy
Despite the significant advances in a variety of drugs and interventions such as re-
synchronization therapy for the failing heart as described above, mortality remains
high and the disease progresses. There is a growing understanding that, in addition
to new and evolving surgical approaches old surgical procedures formerly contraindi-
cated for the failing heart can combat ventricular remodeling and improve cardiac
function (for a review, see Zeltsman & Acker 2002).
Cardiac transplantation was first performed in 1967 in South Africa by Chris-
tiaan Barnard. This was followed two months later by Norman Shumway in the
United States (Hunt 2006). However, poor survival became evident soon after, with
patient survival rates usually measured in days or weeks. This was not because of
poor surgical technique, but an inadequate understanding of the type of postopera-
tive complications that would affect heart recipients. The main problems affecting
patients, such as immunological rejection of the donor heart and opportunistic in-
fections were the subject of much research during the 1970s and 80s. During the
1970s improved methods for the cold preservation of donor hearts became available,
enabling the procurement of hearts from distant donors. In addition, the intro-
duction of endomyocardial biopsy to confirm a clinical diagnosis of acute allograft
rejection (Caves et al. 1974) and of a new immunosuppressant, cyclosporine (Reitz
et al. 1980), led to a new resurgence in cardiac transplantation. Most cardiac trans-
plant centres around the world now employ a combination of immunosuppressants,
usually consisting of corticosteroids (such as prednisolone), a calcineurin inhibitor
such as cyclosporine, and an anti-proliferative agent such as azathioprine (Al Khaldi
& Robbins 2006).
The one-year survival after heart transplantation is approximately 85% and at
five years survival is 68.5% (Fig.1.3). Patients can generally expect a very good
quality of life (Grady et al. 2005, Taylor et al. 2005) and cardiac transplantation
remains the gold standard of surgical therapies for advanced and end-stage heart
failure refractory to medication therapy.
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Fig. 1.3: One year transplant survival of patients after heart only transplant in the UK. The
overall figure is similar worldwide. Source : NHS Blood and Transplant.
Despite the cumulative technological advances over the last 40 years, however,
there is a severe and worsening shortage of organ donors worldwide. There has been
a gradual decline in the number of heart transplants (Fig.1.4), and compared to
the number of patients who are suffering from severe heart failure transplantation
is offered to only a tiny proportion of individuals.
Where there is an underlying structural cause to the heart failure, surgical cor-
rection is increasingly considered an option, where it may have been previously
contraindicated. As illustrated in Table 1.1 the commonest cause of heart failure
is ischæmic heart disease, and coronary artery bypass grafting for patients with LV
ejection fractions < 20% to recruit the poorly perfused myocardium that is viable
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Fig. 1.4: Number of heart transplants performed worldwide between 1982 and 2003. There
has been a gradual decline in the number of heart transplants since 1995 due to decreasing
availability of donor organs. Source: Registry of the International Society for Heart & Lung
Transplantation: Twenty-second Official Adult Heart Transplant Report 2005.
but not contracting optimally (“hibernating” myocardium) is becoming common-
place. In such patients peri-operative survival is in the region of 85%, and one-year
survival ∼ 72% (Dreyfus et al. 1994). Surgical repair is also increasingly performed
for severe mitral valve regurgitation in patients with dilated left ventricles and ejec-
tion fractions of < 25%. Mitral valve annuloplasty can be performed in patients
suffering from severe mitral valve regurgitation (either regurgitant fraction > 60%
or regurgitant orifice area > 0.3 cm2) causing NYHA class IV symptoms, with
symptomatic improvements and operative mortality of approximately 5% (Bolling
et al. 1998).
Surgical procedures have been performed with the aim of reversing the remod-
eling process directly, particularly in idiopathic dilated cardiomyopathy patients.
Batista et al. (1996) described an operation in which normal myocardium between
the anterior and posterior papillary muscles is resected to restore the left ventri-
cle to a more normal volume. The reduction in ventricular diameter, according to
LaPlace’s Law, results in decreased ventricular wall tension and improved systolic
performance. Surgical ventricular restoration has also been performed in patients
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who have suffered large anterior myocardial infarctions using endoventricular circular
patch plasty (Dor et al. 1998). The akinetic portion of the left ventricle is excluded
by deployment of an endoventricular polyester fibre (Dacron™) patch to restore a
more normal ventricular geometry and improved overall systolic performance. The
enthusiasm for these procedures have waned recently (Zeltsman & Acker 2002). It
appears that carefully controlled studies are needed to determine if there are hæ-
modynamic improvements without diastolic compromise, if the reported increases
in ejection fraction combined with decreased ventricular volumes translate to an
increase in stroke volume, and most importantly, the degree of long-term clinical
benefit. An additional recent approach for reversal of cardiac remodeling is implan-
tation of external constraint devices which girdle the heart from its outside and limit
ventricular remodeling (e.g. CardioCorr “Acorn Jacket”). Initial pre-clinical studies
in canine models of dilated cardiomyopathy demonstrated their safety and a halt-
ing of the remodeling process together with preservation of ventricular performance.
The latest three-year follow-up data in heart failure patients reveal decreased left
ventricular end-diastolic and end-systolic volumes (Starling et al. 2007) along with
improvement in NYHA class and quality of life (Mann et al. 2007). However, there
is no data showing a survival benefit of these external constraint devices.
Ventricular assist devices (VADs) can unload the failing heart mechanically by
drawing blood from the left ventricle and delivering it into a major artery, usually
the aorta. Their use as a “bridge to transplantation” is now an established thera-
py. VADs are most often inserted into patients in extreme cardiogenic shock with
multiple organ failure. Operations are associated with high rates of mortality due
to bleeding, decreased vascular resistance or multiple organ failure in the early post-
operative phase, and infection and thromboembolism later. Nonetheless, surviving
patients can recover enough to become mobile and rehabilitate whilst waiting for
their transplant, sometimes even at home. Of patients surviving the first 30 days of
support, 84% survive to either transplantation or explantation of the device (Mancini
& Burkhoff 2005).
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Patients other than those with severe, chronic heart failure waiting for a trans-
plant but might benefit from device placement are those with sudden cardiac failure.
These patients include those unable to be weaned from cardiopulmonary bypass dur-
ing heart surgery and patients with heart failure due to acute myocarditis. Some
of these patients, particularly those with a short but aggressive history of failure or
myocarditis, sometimes recover so that the VAD can be removed and heart trans-
plantation avoided (“bridge to recovery”, Muller et al. 1997). The presence of a VAD
can often cause marked atrophy of the ventricle, which then prevents its explant.
To minimize this effect a combination therapy including clenbuterol, a β2-receptor
agonist, together with high dose ACE inhibitors and spironolactone has been intro-
duced (Yacoub 2001). A number of patients who had received such combination
therapy together with an implanted LVAD showed high rates of recovery to the de-
gree of VAD explantation with nearly normal quality of life at three years thereafter
(Birks et al. 2006).
The success of VADs as a bridge to transplantation has also led to its consider-
ation as a permanent device, particularly in patients ineligible for transplantation.
Such chronic support is termed “destination therapy”. REMATCH was a trial
study of the efficacy of destination therapy in patients who were not candidates for
transplantation (Rose et al. 2001). Patient survival with a VAD was significantly
better than maximum medical treatment at both one and two years. Following these
results, use of LVADs as destination therapy is now approved for some patients in-
eligible for transplantation. However, problems such as infection, stroke, bleeding,
and device failure remain areas requiring further progress.
Although there have been many advances in the medical management of heart fai-
lure over the last 50 years, transplantation is the only available treatment of the un-
derlying cause. Despite its success, however, transplantation carries disadvantages
including operative mortality and those relating to immunosuppression. Further-
more, the number of patients who can be helped with transplantation worldwide
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remains extremely small, and continues to decrease. There is therefore, an urgent
need for additional alternative forms of therapy, especially those aiming to correct
the underlying defect.
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1.2 Cardiac excitation-contraction (EC) coupling
‘The physiological process of converting an electrical stimulus to a me-
chanical response.’ – Sandow (1952)
The process of excitation-contraction (EC) coupling occurs in individual cells, and
is fundamental to the physiology of muscle including myocardium. The electrical
stimulus is an action potential and the mechanical response is contraction during
systole, followed by relaxation during diastole. Although EC coupling has been
known for over fifty years, it continues to be an active area of research (Bers 2002,
Bers 2003). The Ca2+ ion has been identified as the ubiquitous second messenger
in EC coupling. Of the various ions involved in cardiac EC coupling the dynamics
of Ca2+ is considered perhaps the most important. In this chapter the details of
processes involved in EC coupling in cardiomyocytes will be discussed.
1.2.1 The importance of single cell studies
Cardiomyocytes are the sole generators of contractile force in the myocardium. Their
main role is to contract during systole and relax during diastole in a coordinated
manner. Although they constitute only 30 ∼ 35% of the cells in the heart by
number, cardiomyocytes are the dominant cell type in the normal heart with respect
to volume, making up approximately 75% (Nag 1980, Vliegen et al. 1991).
In the myocardium cardiomyocytes are strongly bound to each other by the ex-
istence of intercalated discs. The intercalating discs contain membrane junctions
(desmosomes and fascia adherens) which form anchoring sites to the cytoskeletal
elements within cardiomyocytes (Green & Jones 1996). The arrangement of car-
diomyocytes attached via intercalated discs leads to the formation of a mechanical
syncytium out of unitary contractile elements. The intercalating discs also contain
gap junctions, which enable efficient electrical conduction between cardiomyocytes
(Davis et al. 1995). This feature, together with the ability of cardiomyocytes to
transmit action potentials along their membranes, allows the formation of an electri-
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cal syncytium. The fact that cardiac muscle functions as a mechanical and electrical
syncytium is in contrast to skeletal muscle, where a variable number of fibres can be
recruited to meet mechanical load. In addition, cardiac muscle must relax regularly
with each heart beat and is therefore unable to utilize tetany. Thus, in cardiac
muscle adaptation to dynamic mechanical loads occurs within individual myocytes,
in large part by changes in the dynamics of Ca2+ handling and the arrangements of
myofilaments.
The isolation of contracting, morphologically intact cardiomyocytes from adult
rat hearts became available in 1970. Initial preparations involved incubation of
minced muscle in digestive enzyme solutions (Kono 1969), but have been replaced
by methods whereby low-Ca2+ solutions containing digestive enzymes are perfused
through the coronary arteries (Berry et al. 1970). Today, it is possible to isolate
cardiomyocytes which can be used for physiological experiments from many other
animal species including mouse, human, bovine, and guinea-pig (for a review see
Tytgat 1994).
The availability of intact isolated cardiomyocytes enabled detailed studies of
physiological mechanisms underlying the contraction of the heart. The effects of
various ionic and physical conditions as well as pharmacological agents could be
examined without the need for consideration of their effects on other non-cardio-
myocyte elements that are normally present in the myocardium. As described in the
following sections, sophisticated methods are available for detailed characterization
of cellular processes underlying EC coupling in isolated normal cardiomyocytes.
Furthermore, characterizing the properties of isolated cardiomyocytes of diseased
hearts have provided much valuable insight into pathological mechanisms.
1.2.2 EC coupling in the normal cardiomyocyte
During the cardiac action potential (see below), Ca2+ enters the cardiomyocyte
through voltage-gated Ca2+ channels as inward Ca2+ current (I Ca). The Ca
2+ that
has entered the cardiomyocyte triggers the release of additional Ca2+ from the sar-
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Fig. 1.5: Simplified schematic illustration of EC coupling in a cardiomyocyte. Abbrevia-
tions: AP, action potential; I ca, Ca
2+ current; Na/K, Na+/K+ ATPase; NCX, Na+/Ca2+
exchanger;RyR, ryanodine receptor; SERCA, sarcoplasmic and endoplasmic reticulum Ca2+
ATPase; SR, sarcoplasmic reticulum.
coplasmic reticulum (SR) via the ryanodine receptors (RyR). The combination of
Ca2+ influx and release causes a rapid rise in the free intracellular Ca2+ concentra-
tion ([Ca2+]i), allowing Ca
2+ to bind to the myofilament protein troponin-C. The
binding of Ca2+ to troponin-C leads to the activation of the myofilaments (Fig.1.5).
The waveform describing the rise and fall of [Ca2+]i with each heartbeat is termed
the Ca2+ transient.
For relaxation of the cardiomyocyte to occur the entry and release of Ca2+ must
be terminated and [Ca2+]i must decline, allowing Ca
2+ to dissociate from troponin.
Ca2+ is removed from the cytosol by four pathways: i)sarcoplasmic and endoplas-
mic reticulum Ca2+ ATPase (SERCA), ii)sarcolemmal Na+/Ca2+ exchange (NCX),
iii)sarcolemmal Ca2+-ATPase, and iv)mitochondrial Ca2+ uniport. These mecha-
nisms are discussed in further detail in later sections.
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The action potential
The action potential, originally described in the giant squid axon by Hodgkin &
Huxley (1952), is an event consisting of a series of membrane potential changes. It is
the result of a complex interplay of many ion channels and transporters (DiFrancesco
& Noble 1985, Luo & Rudy 1994), and forms a waveform of electrical activity that
travels along the membranes of electrically excitable cells. In cardiomyocytes the
action potential is the initiating event in EC coupling, and also forms the driving
membrane potential that eventually generates the Ca2+ transient. Cardiomyocytes
within the heart are well-connected electrically via gap junctions and the action
potential of one cardiomyocyte causes depolarization of its adjacent cardiomyocytes
above its threshold for action potential generation. Thus, the action potential is the
electrical signal that is transmitted between cardiomyocytes within the heart.
The waveform of the action potential varies considerably not only between ani-
mal species, but also between different parts of the heart (Nerbonne 2000). These
various waveforms within the heart (Fig.1.7) underlie phenomena such as the ini-
tiating pacemaker activity in the sino-atrial node and also explain why T-waves in
a normal human electrocardiogram are in the same direction as the QRS complex.
The ventricular action potential in many animal species, including human, demon-
strates a long plateau at a positive potential before the late repolarization phase.
The formation of the plateau is the result of a delicate balance between inward
currents such as the L-type Ca2+ current (I Ca,L) and outward currents such as the
delayed rectifier K+ currents (IKr, see Luo & Rudy 1994). The presence of a long
plateau at a positive Em increases the inward flow of Ca
2+ via the L-type Ca2+
channel.
The L-type Ca2+ current
The importance of extracellular Ca2+ in cardiac contraction was first demonstrated
by Ringer (1883), but it was only in 1967 when the inward current carried by Ca2+
was described (Reuter 1967). Cardiomyocytes express two types of voltage-gated
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Fig. 1.6: An example action potential in a guinea-pig ventricular myocyte (A). The fast
kinetics and large amplitude of the fast Na+ current (I Na, B) result in the upstroke of the
AP. The I Ca,L (C) is also activated quickly to support the action potential plateau against
the repolarizing K+ current (I K , D) and the total time-independent current (I V , E). Finally,
the large increase of I K and the late peak of I V during its negative slope phase repolarize
the membrane to the resting potential. During the late repolarization and early postrepo-
larization phases, the Na+-Ca2+ exchanger current (I NaCa, F) is activated to extrude Ca
2+
and contributes an additional component of inward current. Currents shown are for 1 µF of
membrane capacitance. Original figure taken from Luo & Rudy (1994).
Ca2+ channels on their surface membranes, L-type (‘Long lasting’, also known as
the dihydropyridine receptor (DHPR)) and T-type (‘Transient’ ) (Hagiwara et al.
1975, Bean 1985). Of these, the T-type Ca2+ channel is present in low density in
normal ventricular myocytes, and it is the L-type that are functionally dominant.
Cardiomyocyte L-type Ca2+ currents (I Ca,L) are rapidly opened by depolariza-
tion of the membrane. Although the opening threshold potential depends on physical
parameters such as temperature and [Ca2+]o, under most physiological conditions it
is approximately −40 mV (Rosenberg et al. 1988, Hess 1988). This is notably higher
than that for sodium currents. Although I Ca,L was initially termed “slow inward
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Fig. 1.7: Regional action potential waveform variation within the heart. The membrane
potential at the sino-atrial node gradually depolarizes until an action potential is generated.
Within the myocardium, the action potential is shortest at the epicardium, then endocardium,
and longest at the mid-myocardium. Figure taken from Nerbonne, The Journal of Physiology,
2000.
current” (Reuter 1967) subsequent single-cell studies in isolated cardiomyocytes have
revealed that peak I Ca,L is reached in 2 ∼ 3 ms (Bean 1985).
Inactivation of Ca2+ channels is dependent on time, Em, and [Ca
2+]i (Lee et al.
1985). The dependence on [Ca2+]i can be demonstrated by experiments in which
Ca2+-free extracellular solutions are used, with alternative divalent cations being the
charge carriers: when Ca2+ is substituted with Ba2+ or Sr2+ I Ca,L is prolonged. The
inactivation of Ca2+ channels by a rise in [Ca2+]i limits the amount of Ca
2+ influx
during the action potential. One notable feature of the Ca2+-dependent inactivation
of I Ca,L is that it can be observed even when the intracellular Ca
2+ is heavily buffered
using a Ca2+ chelator such as ethylene glycol bis(2-aminoethyl ether)-N,N,N´N´ -
tetraacetic acid (EGTA). This suggests that Ca2+ entering via I Ca,L can exert an
inactivating effect locally (Ho¨fer et al. 1997). On the other hand, increasing the
amount of Ca2+ released from the SR during a normal twitch results in faster inhi-
bition of I Ca,L (Sipido et al. 1995), indicating that Ca
2+ released from the SR also
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Fig. 1.8: The relationship between L-type Ca2+ current and membrane voltage. The upper
panel illustrates the dependence of the Ca2+ transient amplitude on the membrane voltage.
The lower panel illustrates the peak L-type Ca2+ current on the membrane voltage. Figure
taken from Beuckelmann & Wier (1988).
contributes to this inactivation process. It is thought that I Ca,L inhibition by Ca
2+
released from the SR can occur because the Ca2+ channels are located near the SR
Ca2+ release channels, the RyRs (Scriven et al. 2000).
One of the hallmarks of Ca2+ channels is their sensitivity to dihydropyridines
(DHP), and this property has been key to understanding their function and in identi-
fying the existence of multiple subtypes (Fleckenstein 1983). DHPs bind specifically
to the α1C subunit of the L-type Ca
2+ channel to stabilize their closed state, and
for this reason are often called “Ca2+ antagonists”. The various classes of Ca2+
antagonists were found to block I Ca,L with differential selectivity in cardiac and
smooth muscle, and this forms the basis of their therapeutic roles in the treatment
of conditions such as hypertension and angina.
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Ca2+-induced Ca2+ release
The Ca2+ that enters the cardiomyocyte via the L-type Ca2+ channels is not suffi-
cient to constitute a Ca2+ transient and activate myofilaments. Instead, the release
of a larger amount of Ca2+ from the SR is triggered. The mechanisms by which
the Ca2+ is released from the SR continues to be an area of active research but
there is much evidence to support the “Ca2+-induced Ca2+ release” (CICR) model,
described by Fabiato (1983) following a series of experiments using mechanically
skinned canine Purkinje fibres. Ca2+ entry via I Ca,L was simulated by rapid ap-
plication of Ca2+, which induced the release of Ca2+ from the SR. Although one
may anticipate such a mechanism to result in the formation of a positive feedback
loop, always proceeding to complete emptying of the SR, Fabiato described a graded
response: the amount of Ca2+ released from the SR is graded towards i)the level
of Ca2+ preloading of the SR, ii)level of [Ca2+]i, and also
iii)the rate of change of
[Ca2+]i (Fig.1.9).
Based on his experimental observations, Fabiato proposed that the SR Ca2+
release channel has two Ca2+ binding sites: an activating site with modest affinity,
and also an inactivating site with a higher affinity but a slower rate of association. At
low [Ca2+]i, rapid application leads to channel opening by the preferential binding
on the activation sites. When the same [Ca2+]i is applied slowly, the inactivation
sites can compete for the available Ca2+, and the channels do not open. When the
SR channels are subjected to very high [Ca2+]i even rapid application does not result
in channel opening because the very high [Ca2+]i can overcome the limitation of the
slow association with inactivating sites.
CICR also exhibits a refractory period, during which further CICR events do
not occur. However, this is not due to the SR being empty, since Ca2+ can still be
released during this period by the acute application of caffeine (Fabiato 1985).
Further support for Fabiato’s model of CICR comes from experiments using
intact cardiomyocytes where the extracellular Ca2+ is substituted with other divalent
cations such as Ba2+. In such cases, release of Ca2+ from the SR does not occur,
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Fig. 1.9: Relationship between trigger [Ca2+]i and SR Ca
2+ release. The amplitude of the
Ca2+ transient and developed tension depends on the trigger [Ca2+]i, and also the time taken
to reach that [Ca2+]i. With high trigger [Ca
2+]i inhibition is seen. Figure taken from Fabiato
(1985).
despite a substantial flow of charge through the L-type Ca2+ channel (Na¨bauer et al.
1989). This experiment showed that EC coupling does not occur by the exposure of
the SR Ca2+ release channels to positive charge or current, but that the presence of
Ca2+ ions is an absolute requirement. This interpretation is offered further support
from the experiments in which CICR is triggered by I Ca,L tail currents (Cannell
et al. 1987): when the Em of a cardiomyocyte is voltage-clamped (see section 2.12.2
on page 107 for a more detailed description of voltage-clamping experiments) and
acutely increased from resting levels to +100 mV (which is more positive than the
equilibrium potential of Ca2+) the L-type Ca2+ channels open but no CICR occurs
because there is no flow of Ca2+. When the cardiomyocyte is subsequently allowed
to repolarize, a brief tail current is elicited which triggers CICR leading to a full
Ca2+ transient and contraction.
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Termination of Ca2+ release
For the cardiomyocyte to relax SR Ca2+ release must be terminated, and the cy-
tosolic Ca2+ extruded. So although CICR is inherently a positive-feedback process
additional mechanisms are in place for Ca2+ release termination in a controlled
manner, whilst maintaining a graded, and highly amplifying release of SR Ca2+.
Until the late 1980s all mathematical models of cardiac EC coupling assumed
the cytosol of a cardiomyocyte to be a uniform space wherein the trigger Ca2+
reaches the SR via the same cytosolic calcium pool into which SR calcium is released:
the “common pool” model (e.g. Hilgemann & Noble 1987). However, Stern (1992)
reasoned, following extensive mathematical analysis of numerous models of CICR,
that “common pool” models are incompatible with graded high amplification. He
proposed that the SR Ca2+ release channels are arranged in clusters, in close proximi-
ty to the L-type Ca2+ channels, where they have initial exposure to the Ca2+: “local
control theory; cluster-bomb model”. Evidence for the existence of such clusters of
SR Ca2+ release channels has subsequently become available with the introduction
of line-scan confocal microscopy. Cheng et al. (1993) visualized focal Ca2+ release
events in rat cardiomyocytes using this tool, and named them “Ca2+ sparks”. Ca2+
sparks are elementary Ca2+ release events that are restricted in space (see Fig.2.19
and Fig.2.20 for illustrative examples of visualized Ca2+ sparks). They raise the
local [Ca2+] to a peak of ∼ 200 nM, have a time-to-peak of ∼ 10 ms, and decline
with a decay time constant (τ) of ∼ 25 ms (Cheng et al. 1993).
With the local-control model arrangement of L-type Ca2+ channels and RyRs it is
possible to suggest three mechanisms, which are not necessarily mutually exclusive,
to explain the termination of Ca2+ release: stochastic attrition, local depletion of
SR Ca2+, and inactivation of the RyR. Stochastic attrition describes simultaneous
closure of all L-type Ca2+ channels and RyRs in a junction occurring as a random
event at a given time. On its own, with the numbers of L-type Ca2+ channels
and RyRs involved, the stochastic attrition model can not adequately explain the
effective, consistent termination of Ca2+ release that occurs with every heartbeat.
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Local depletion of SR Ca2+ also does not offer an adequate model of termination
of Ca2+ release, because it is known that diffusion of Ca2+ can occur within the SR
lumen that enables Ca2+ sparks that last > 200 ms (Cheng et al. 1993).
It is also conceivable that the RyR, after opening for a period of time, closes au-
tomatically and becomes inactivated for reopening, in a manner similar to that seen
with Na+ channels: the absorbing inactivation model (Sitsapesan et al. 1995, Sham
et al. 1998). RyRs, instead of becoming inactivated, could alternatively become
desensitized to Ca2+, so that their probability of opening upon exposure to Ca2+
decreases: (Gyo¨rke & Fill 1993, Valdivia et al. 1995). While the opening of RyRs
shows a refractory period, the precise molecular mechanisms underlying the refrac-
tory period continue to be an interesting area of research.
Na+/Ca2+ exchange
Na+/Ca2+ exchange (NCX) is the sarcolemmal ion transport process by which three
Na+ ions are exchanged for one Ca2+ ion in opposite directions (Philipson & Nicoll
2000). NCX is a reversible secondary active transport process - no ATP is utilized,
but the electrochemical gradients of the ions involved drive the transport process.
The stoicheiometry of NCX implies electrogenicity: the direction and size of the
NCX current (INCX) depend not only on the concentration gradients of Na
+ and
Ca2+, but also on Em. Therefore, NCX provides a mechanism by which Ca
2+ is
transported through the sarcolemma in a manner dependant on Em. INCX exhibits
a reversal potential, ENCX , where ENCX = 3 · ENa+ − 2 · ECa2+ .
Entry of Ca2+ through the L-type Ca2+ channel that occurs with each contraction
requires an equal amount of sarcolemmal Ca2+ extrusion within a single heartbeat
to maintain steady-state Ca2+ homeostasis. NCX provides the principal pathway for
Ca2+ removal through the sarcolemma during diastole. In the presence of caffeine
(the rapid application of which empties the SR of Ca2+ and prevents Ca2+ re-
accumulation), a ventricular cardiomyocyte would not relax if Ca2+ extrusion via
NCX is also disabled by the removal of external Na+ (Bridge et al. 1990).
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The direction of NCX can be reversed: Na+ out, and Ca2+ in. LeBlanc & Hume
(1990) provided evidence that Na+ entering myocytes through Na+ channels dur-
ing the action potential could accumulate and drive reverse-mode exchange. The
amount of Ca2+ entering the cardiomyocyte by reverse-mode NCX could elicit SR
Ca2+ release in a manner dependent on [Ca2+]o. Since Em during the plateau of
the cardiac action potential is far higher than the normal physiological ENCX of
approximately −40 mV, it might also add a substantial driving force for reverse
mode NCX. However, the importance of such reverse mode NCX in vivo, both in
normal and pathological conditions, remains a topic of ongoing discussion. Matters
are complicated by i)the dynamically changing [Ca2+]i (and hence ECa2+) with the
Ca2+ transient, and ii)the difficulty in accurately measuring local [Na+] and [Ca2+]
near the internal surface of the exchanger, which are likely to be affected by re-
stricted diffusion given the complex internal architecture of cardiomyocytes. Under
experimental conditions, reverse mode NCX can be of sufficient magnitude even to
trigger CICR (Wasserstrom & Vites 1996, Litwin et al. 1996), but the physiological
significance of such events remain controversial (Sipido et al. 1997).
The removal of Ca2+ following release
During diastole Ca2+ is removed from the cytosol by i)SERCA, ii)NCX, iii)sarcolem-
mal Ca2+-ATPase, and iv)mitochondrial Ca2+ uniport. The last two of these are
often collectively called ‘slow systems’, and contribute only 1 ∼ 2% towards Ca2+
removal (Bassani et al. 1994). SERCA and NCX compete effectively for removal of
the majority of the Ca2+, and their relative quantitative importance varies between
animal species (Bassani et al. 1994). For example, NCX removes approximately
30% of the Ca2+ in guinea-pig (Terracciano & MacLeod 1994), and 28% in rabbit
(Bassani et al. 1994), but only 7% in rat (Bassani et al. 1994). In humans, this
figure is reported to be approximately 37% (Pieske et al. 1999).
NCX is influenced by Em, and more Ca
2+ extrusion occurs by NCX at lower
Em (Bridge et al. 1988). Thus, the fraction of Ca
2+ removal by NCX depends on
48
SERCA
SERCA
Fig. 1.10: Relative contributions of various processes towards Ca2+ removal from the cell.
Integrated Ca2+ fluxes during twitch relaxation in rabbit and rat ventricular myocytes. Curves
are based on [Ca2+]i and the [Ca
2+]i dependence of transport rates measured for each system.
Percentages are relative contributions to Ca2+ removal. Figure adapted from Bassani et al.
(1994).
the profile of the action potential: a long action potential will result in more of the
Ca2+ being removed by SERCA rather than NCX. Other variables that affect the
relative contributions of SERCA vs NCX include [Na+]i and resting [Ca
2+]i, and the
states of the SR and Na+-Ca2+ exchanger. The importance of [Na+]i was studied
by Armoundas et al. (2003) who demonstrated shortening of APD with increasing
[Na+]i in canine ventricular myocytes. In failing cardiomyocytes with [Na
+]i ≥
10 mM outward INCX during the action potential plateau facilitated repolarization,
whereas when [Na+]i = 5 mM INCX had a depolarizing effect.
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Role of the released Ca2+ in activating myofilament activity
The intracellular myofilaments are the contractile machinery of the cell, responsible
for transducing chemical energy into mechanical force. The myofilaments are com-
posed of myosin, actin, the troponins, and titin. In the mammalian ventricle, they
occupy 45 ∼ 60% of the intracellular volume, although this fraction is smaller in
atrial cardiomyocytes and Purkinje fibres.
Ca2+ is the direct activator of the myofilaments, which effect cardiomyocyte con-
traction (Fig.1.11). Contractile force develops in a graded but non-linear manner
with increasing [Ca2+]i, mainly because of strong myofilament cooperativity with
respect to [Ca2+]i (Solaro 1999). The sensitivity of the myofilaments to [Ca
2+]i is
also enhanced by stretching the myocardium (Allen & Kentish 1985), because the
number of cross bridges formed depend on the sarcomere length3. Other factors that
affect the sensitivity of myofilament to Ca2+ include the intracellular concentrations
of H+ (Fabiato & Fabiato 1978) , PO3−4 , and Mg
2+ (Fabiato & Fabiato 1975). Drugs
such as β-adrenergic agonists, caffeine, and other phosphodiesterase inhibitors (such
as milrinone, a cardiac inotrope) can also alter the sensitivity of myofilament to
Ca2+. Thus, factors that influence the dynamics of intracellular Ca2+ have direct
consequences on cardiomyocyte contraction, but how the myofilaments sense the
intracellular Ca2+ are important additional considerations.
3This is the dominant theory for the cellular basis of Frank-Starling’s Law, which states that
the more the ventricle is filled with blood during diastole, the greater the volume of ejected blood
will be during systolic contraction.
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Fig. 1.11: Activation of contractile myofilaments by intracellular Ca2+. A.) The organization
of the sarcomere. B.) During systole Ca2+ binds to and activates troponin-C. The binding
signal is transmitted to tropomyosin through troponin-T (the tropomyosin-binding unit of
the troponin complex) and also to troponin-I. Troponin-I is then released from its tether on
actin, and the tropomyosin becomes free of steric hindrance of the actin-cross bridge reaction.
Strong binding of a cross bridge promotes the reaction of a near neighbour cross bridge by
actively pushing tropomyosin away from its blocking position. This mechanism results in
strong cooperative activation. Figure adapted from Solaro (1999).
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1.3 Excitation-contraction coupling in the failing
heart
In section 1.1 the ætiology and clinical features of heart failure were discussed, and
in section 1.2 the cellular mechanisms underlying EC coupling in a normal cardio-
myocyte were described. During the last 20 years there has been an accumulation
of substantial evidence that altered cardiomyocyte EC coupling is of significant rel-
evance for the pathophysiology of heart failure (Hasenfuss & Pieske 2002, Tomaselli
& Marban 1999). Studies of the properties of cardiomyocytes isolated from human
patients (Beuckelmann et al. 1992) as well as numerous animal models of heart
failure (Hasenfuss 1998) have been performed.
A number of experimental animal models of chronic heart failure have consis-
tently demonstrated depressed cardiomyocyte function (Capasso & Anversa 1992,
Spinale et al. 1997). Studies that employed tissue strips (Pieske et al. 1996) or
isolated cardiomyocytes (Davies et al. 1995, del Monte et al. 1995) from failing
human myocardium obtained in the setting of cardiac transplantation have also
demonstrated depressed contractility. Impairment of Ca2+ handling are also more
apparent with increasing frequencies (Pieske et al. 1996). Accordingly, an altered
force-frequency relationship of myocardial function is considered as one of the most
characteristic alterations related to pathological Ca2+ homeostasis in the failing
heart.
1.3.1 Changes to the action potential profile in heart failure
A common finding in failing hearts, regardless of species or mode of failure is prolon-
gation of the action potential (Beuckelmann et al. (1992), Na¨bauer & Ka¨a¨b (1998).
See Fig.1.13A). The prolongation is usually most apparent at low frequencies and
becomes smaller with increasing frequency, as the action potential duration shortens.
The delay in repolarization is due to alterations in several currents that contribute
towards the action potential profile. When measured directly, reductions in the tran-
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Fig. 1.12: Cardiomyocytes isolated from heart failure patients have impaired contractions.
Figure taken from Davies et al. (1995).
sient outward current (I to) has been commonly seen (Na¨bauer et al. 1993). Another
K+ current that has been closely studied is the inward rectifier K+ current (IK1),
which sets the resting membrane potential and contributes to the terminal phase of
repolarization. Reduced IK1 has been reported in heart failure, including patients
with dilated cardiomyopathy, but not with the same consistency as with I to (for a
general review of K+ current changes in heart failure see Tomaselli & Marban 1999).
1.3.2 Ca2+ handling in heart failure
The impairment of mechanical properties of cardiomyocytes in heart failure is re-
flected in changes in Ca2+ transients (Gwathmey et al. 1987, Beuckelmann et al.
1992). Where changes have been detected, the Ca2+ transients of failing cardiomyo-
cytes show increased diastolic baseline levels, reduced amplitudes, prolonged times-
to-peak, and slower decay rates compared to normal counterparts (Fig.1.13B).
There are several mechanisms that could underlie the reduced Ca2+ transient,
which are not necessarily mutually exclusive. Defects in EC coupling can occur, for
example, in i)the I Ca,L,
ii)the storage of Ca2+ in the SR, or iii)the release of Ca2+
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Fig. 1.13: Action potential (A) and Ca2+ transient (B) traces from cardiomyocytes from
human hearts with dilated cardiomyopathy. The action potential duration is longer in cardio-
myocytes from failing hearts compared to control. The Ca2+ transients of cardiomyocytes from
failing hearts show higher baseline, smaller amplitude, and a slower rate of decline. Figure
adapted from Beuckelmann et al. (1992).
stored in the SR via RyRs. There have been some studies reporting reduced peak
I Ca,L density in heart failure patients (Ouadid et al. 1995) as well as in animal models
of heart failure (Santos et al. 1995). On the other hand, a number of other studies
have reported no significant change (Beuckelmann et al. 1992, Gomez et al. 1997).
The discrepancy may be due to differences in animal species, mode of heart fai-
lure induction, and duration and severity of disease. In any case, since numerous
models of heart failure show clearly reduced Ca2+ transients without reduced I Ca,L,
it appears that other EC coupling defects are important.
The SR Ca2+ load in failing human myocardium has been assessed using rapid
cooling contractures in muscle strips (Pieske et al. 1999) or rapid application of
caffeine onto isolated cardiomyocytes (Lindner et al. 1998). These reveal that SR
Ca2+ load in failing human hearts is decreased. This reduction may, at least in part,
54
be due to reduced SERCA activity, since an additional characteristic feature of
failing cardiomyocytes is slower relaxation and Ca2+ transient decay. The SERCA
activity measured in crude membrane preparations of SR is lower in failing car-
diomyocytes compared to normal cardiomyocytes (Schwinger et al. 1995). Further
evidence for the involvement of SERCA in heart failure comes from experiments
where SERCA2 is overexpressed in cardiomyocytes from failing human hearts by
adenoviral gene transfer: this not only increases the rate of Ca2+ transient decay,
but also increases the amplitude of the transient and improves overall myocyte
contractility (del Monte et al. 1999).
The RyR is a 600 kDa protein which forms a homotetrameric complex through
which Ca2+ is released from the SR during CICR (Nakai et al. 1990). Studies
comparing expression levels of RyR in failing hearts with normal hearts have re-
ported mixed results. Subsequently, the modulation of the RyR function through
its phosphorylation state and association with other proteins such as FK506-binding
protein 12.6 (FKBP12.6) has been a focus of much research. In particular, Marx
et al. (2000) showed that the RyR can become hyperphosphorylated by protein ki-
nase A (PKA) and become dissociated with FKBP12.6. This dissociation increases
the open probability of the channel and disturbs the functional coupling of the RyRs
with each other, resulting in increased leak of Ca2+ during diastole and a reduced
SR Ca2+ load. Consistent with this theory, overexpression of FKBP12.6 in rabbit
cardiomyocytes reduces spontaneous SR Ca2+ leak with increased SR Ca2+ content
and myocyte contractility (Prestle et al. 2001).
As well as decreasing the amount of Ca2+ in the SR available for release, it has
been proposed that abnormal regulation of the RyR by FKBP12.6 may decrease the
RyR threshold for spontaneous Ca2+ release (Jiang et al. 2004). It is conceivable
that Ca2+ released in such manner, if it becomes substantial, may cause acute de-
polarization of the cardiomyocyte by reverse-mode NCX - a plausible explanation
for the arrhythmias seen in failing hearts.
In addition to the maladapative changes occurring in the RyRs, it has been
55
suggested that disruptions in the spatial relationships between the L-type Ca2+
channels and RyRs might impair CICR (Gomez et al. 1997). As reasoned by Stern
(1992) the activation of a RyR is sensitive to its geometric relation to the L-type
Ca2+ channel. In cardiomyocytes isolated from rats with spontaneously hypertensive
heart failure, the Ca2+ transient is reduced despite a normal I Ca,L, normal SR
Ca2+ content, RyR open probability, and Ca2+ spark morphology. Following these
observations Gomez et al. (1997) reasoned that the reduced ability of the I Ca,L to
trigger SR Ca2+ release comes from its further physical separation from the RyRs.
The importance of SR Ca2+ regulation has been further highlighted by experi-
ments in which the SERCA2A gene was over-expressed in cultured isolated failing
cardiomyocytes (del Monte et al. 1999). Compared to control failing cardiomyo-
cytes, those which were virally transfected with the SERCA2A gene showed lower
diastolic [Ca2+]i and higher peak systolic [Ca
2+]i. In addition, contractility was
improved and a positive force-frequency response was maintained. In corresponding
in vivo experiments, viral delivery of the SERCA2A gene in rat hearts subjected
to aortic banding resulted in maintenance of smaller ventricular volumes, superior
myocardial contractility, and improved survival (del Monte et al. 2001). These
studies not only confirm the importance of the identified Ca2+ handling mechanisms
in cardiac function, but also suggest that correction of Ca2+ handling defects can
reverse the adverse remodeling process.
1.3.3 Na+/Ca2+ exchange in heart failure
The expression of the Na+/Ca2+ exchanger protein is increased in heart failure
(Studer et al. 1994, Quinn et al. 2003). However, the net effect of such an increase
on cytoplasmic [Ca2+] is difficult to predict because of the bidirectional nature of
exchange and its dependence on multiple dynamic factors including Em and [Na
+]i.
An increase in forward mode exchange would remove more Ca2+ during diastole
over SERCA and this might contribute towards the reduction of the SR Ca2+ load
that is seen (Pogwizd et al. 1999). On the other hand, an increase in reverse mode
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exchange might increase Ca2+ influx during systole, especially given the background
of the prolonged action potentials and increased [Na+]i that are characteristic of
heart failure. Sipido et al. (2002) summarized the published studies of NCX in
heart failure and found that, out of 29 animal studies of heart failure, 14 reported
an increase in NCX expression and/or function, 10 a decrease, and 5 no change.
The heterogeneity of results appears to be due to a variety of factors, such as mode,
severity, and duration of pressure overload to the heart as well as animal species.
The cellular changes that occur in failing cardiomyocytes are complex, depend on
many variables, and continue to be an active area of study. Some cellular features,
such as depressed contractility and relaxation, decreased amplitude and slower de-
cay of the Ca2+ transients, and prolongation of the action potential are common
findings. Other important aspects of EC coupling, for example the regulation of
the RyR, continue to be debated, whilst mixed results have also been reported for
I Ca,L and INCX . The seemingly inconsistent and sometimes contradictory findings
highlight the important species differences in EC coupling and, more importantly,
the complexity of the pathological process. Increasingly, it is becoming apparent
that EC coupling in failing cardiomyocytes are characterized by a number of com-
pensatory processes superimposed on central defects.
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1.4 Cell transplantation for heart failure
The understanding that a common mechanism of development of heart failure is the
loss of ventricular cardiomyocytes (Narula et al. 1996) naturally leads to the notion
of supplementing those losses by delivering cells directly into the diseased ventricle
as a mode of treatment. During the last 10 years there have been numerous studies
performed in the field of cardiac cell transplantation involving a wide range of animal
models and also in large clinical trials. Some of the reported data have stimulated
much interest, and the field continues to be a highly active area of ongoing research.
On the other hand, there has also been considerable controversy over some of the key
points, and some important questions remain unanswered. In this section the major
recent developments will be summarized, and the outstanding issues discussed.
1.4.1 Animal studies of cardiac cell transplantation
The majority of the animal studies of cardiac cell transplantation have employed
the strategy of directly injecting cells which were labeled using genetic or fluorescent
markers into normal or diseased hearts (for comprehensive reviews see Dowell et al.
2003, Laflamme et al. 2007). Such a study model enabled tracking of the phenotypic
fate of the transplanted cells along with monitoring of the function of the diseased
recipient ventricle.
Fœtal & neonatal cardiomyocytes
Cardiomyocytes would constitute the ideal donor cell for transplantation into dis-
eased hearts, as they already possess the necessary structural and physiological
attributes to integrate with the recipient myocardium. Some of the early animal
studies injected committed cardiomyocytes from fœtal and neonatal sources into
rat hearts which had previously undergone myocardial infarction. The implanted
myocytes formed stable grafts within the myocardium and resulted in improved
left ventricular function (Li et al. 1996, Scorsin et al. 2000, Rubart et al. 2003).
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As expected for differentiated cardiomyocytes, the implanted cells retained their
contractile phenotype and even expressed the necessary gap junction connexins for
intercellular electrical communication. Further direct evidence of electrical integra-
tion of injected fœtal cardiomyocytes were reported by Rubart et al. (2003). They
injected cardiomyocytes from transgenic mice overexpressing enhanced green fluores-
cent protein (eGFP) into recipients, and used two-photon laser scanning microscopy
for simultaneous visualization of Ca2+ transients in the transplanted cells and the
recipient cells within intact myocardium. These studies demonstrated synchronous
Ca2+ transients in adjacent cardiomyocytes of different origin, indicating that the
grafted cells had integrated and were capable of appropriate activation. Clearly,
delivery of committed cardiomyocytes can form nascent myocardium in the normal
heart, with appropriate electrical integration.
The studies utilizing committed cardiomyocytes can only be considered proof-
of-principle studies, since there is no accessible source of fœtal or neonatal cardio-
myocytes for transplantation into patients. The other major potential obstacle that
needs to be overcome with fœtal and neonatal cardiomyocytes is the likely immune
rejection. For these reasons, the majority of animal studies of cardiac cell trans-
plantation utilized types of cells which are available from autologous sources, as
discussed below.
Skeletal myoblasts
The first cardiac cell transplantation experiments utilized skeletal myoblasts derived
from skeletal muscle satellite cells (Chiu et al. 1995, Murry et al. 1996, Taylor
et al. 1998). The advantages of skeletal myoblasts that lead to their selection include
their i)availability from autologous sources (which bypasses the immunological and
ethical considerations associated with some of the other cell types that become
prohibitive when applied to humans), ii)ability to proliferate and be expanded ex
vivo, and iii)superior resistance to ischæmia compared to cardiomyocytes. Skeletal
myoblasts are also well-known to be committed to a contractile tissue phenotype.
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Initially, it was hoped that these cells might transdifferentiate into cardiomyo-
cytes following injection, or at least be genetically manipulated into acquiring more
of the features of cardiomyocytes. However, it has become apparent that skele-
tal myoblasts remain committed to forming mature skeletal myotubes in the heart.
Furthermore, mature myotubes as well as skeletal myoblasts that remain unfused
appear to remain mechanically and electrically isolated from the recipient myocar-
dium (Leobon et al. 2003, Rubart et al. 2004). Another important consideration is
the limited survival of the skeletal myoblasts following injection. Labeling the in-
jected skeletal myoblasts with 14C-thymidine and monitoring 14C radioactivity after
injection revealed that only ∼ 7.4% of the injected cells survived at 72 hours (Suzuki
et al. 2004). Clearly, the small numbers of surviving cells cannot contribute a sub-
stantial contractile force to the myocardium. However, despite these disappointing
findings from characterization of the injected cells, there appears to be a modest im-
provement in ventricular performance (Scorsin et al. 2000, Taylor et al. 1998). This
important paradox remains unexplained. A variety of interpretations have been put
forward, some of which are discussed later.
Bone marrow-derived cells
In 2001, Orlic et al. reported that widespread myocardial regeneration could be in-
duced in mice that had undergone myocardial infarction by injecting the Lin−, c-kit+
subset of bone marrow cells. The authors described developing tissue consisting of
proliferating myocytes and vascular structures, and suggested that locally delivered
bone marrow-derived cells could generate new myocardium through transdifferentia-
tion. Their report sparked tremendous interest not only amongst scientists, but also
in the clinical community since methods for obtaining and sorting large numbers
of bone marrow-derived cells from autologous sources were already well established
and there was a good degree of clinical familiarity of transplanting such cells into
patients for treating hæmatopoietic disorders.
Unfortunately, despite exhaustive attempts by several research groups the results
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of Orlic et al. could not be reproduced (Murry et al. 2004, Deten et al. 2005).
Instead, the subsequent studies concluded that bone marrow-derived cells adopt
mature hæmatopoietic fates (Balsam et al. 2004, Nygren et al. 2004). The studies
identified only very small numbers of cardiomyocytes from the recipient myocardium
that also expressed the genetic markers of cells that were injected. These cells, as well
as occurring only in extremely low frequency, invariably contained genetic material
from both injected and recipient cells, suggesting that they were the result of cell
fusion rather than transdifferentiation. Further evidence that bone marrow-derived
cells fuse with recipient cardiomyocytes came from experiments utilizing Cre/lox
recombination technology (for a description of this DNA manipulation tool see Sauer
1998). Bone marrow-derived cells harvested from mice constitutively expressing Cre
recombinase in addition to eGFP were injected into the hearts of R26R reporter
mice (Alvarez-Dolado et al. 2003). The R26R reporter cardiomyocytes expressed
the LacZ reporter gene only after a loxP-flanked stop cassette was excised by Cre
recombinase, supplied by the donor bone marrow-derived cells. β-galactosidase+
cardiomyocytes were morphologically indistinguishable from other recipient cardio-
myocytes, and expressed troponin-I and gap junction connexins. Their karyotypes
were either tetraploid or hexaploid. On the other hand, eGFP+/β-galactosidase−
cells had appearances of small mononuclear cells.
A subset of bone marrow-derived cells, termed mesenchymal stem cells (MSC)
have attracted special interest. MSCs compose the stromal compartment of bone
marrow, and are not hæmatopoietic. In culture they adhere to polystyrene surfaces
and proliferate indefinitely. They express CD29 and CD90, and are negative for
the surface markers found on other bone marrow-derived cells, including CD31,
CD34, and CD45, which enables their separation using fluorescence-activated cell
sorting (FACS). MSCs have been shown to be able to differentiate into a variety
of tissue cell types in vitro, including adipocytes, chondrocytes, osteoblasts, and
skeletal myoblasts. In 1999 Makino et al. demonstrated that exposure of MSCs
to 5-azacytidine, which methylates DNA and can alter the expression of genes that
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regulate differentiation, can yield proliferating cells similar to those of fœtal cardio-
myocytes. Their described cells beat spontaneously, fused into tube-like structures
that exhibited sarcomeres, stained positive for myocardial proteins such as myosin,
desmin, and actinin, and also had measurable action potentials.
Despite these special properties of MSCs, the results of their injection into hearts
appear to be no different from that of other bone marrow-derived cells. The overall
survival of cells after injection is low, and those few that do survive do not form ma-
ture cardiomyocytes which integrate with their native neighbours (Dai et al. 2005).
Mangi et al. (2003), Toma et al. (2002), and Nagaya et al. (2005) all demonstrated
cells which exhibited the markers of donor cells along with some of the proteins
which are only expressed in cardiomyocytes, but none specifically addressed the
possibility of cell fusion. It is interesting however, that all three groups measured
improvement in whole heart function.
To summarize, the large number of animal model studies involving various types of
cells have not succeeded in generating large numbers of new cardiomyocytes. Al-
though injected fœtal cardiomyocytes can provide additional myocardium, the for-
mation of new cardiomyocytes by transdifferentiation of skeletal myoblasts or bone
marrow-derived cells has not been convincingly demonstrated. However, several
studies have surprisingly reported moderate improvements in whole heart function
in post-infarct rat or mice hearts following transplantation of skeletal myoblasts or
bone marrow-derived cells. This paradox remains unaccounted for.
1.4.2 Clinical trials of cardiac cell transplantation
Skeletal myoblasts
After approximately ten years of pre-clinical testing resulting in more than 40 studies
skeletal myoblasts were the first to enter the clinical arena (Menasche´ et al. 2001).
Because autologous skeletal myoblasts need to be expanded ex vivo over several
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weeks these trials were performed in patients with chronic ischæmic heart disease
with severe heart failure, rather than acute myocardial infarction. Autologous skele-
tal myoblasts were prepared from muscle biopsies, and expanded using fœtal bovine
serum. Four of the trials that have been published are summarized in Table 1.2.
Additional feasibility studies are ongoing. As can be seen, all of these studies entailed
coronary artery bypass graft (CABG) surgery. Further trials in which skeletal myo-
blasts are administered via percutaneous catheters are in progress.
These trials have demonstrated that hundreds of millions of skeletal myoblasts
can be grown from muscle biopsies and subsequently injected into the heart with-
out early procedural complications. Long-term engraftment of skeletal myoblasts,
featuring clusters of myotubes aligned parallel to host cardiomyocytes, has been vi-
sualized by microscopy of explanted hearts up to 18 months after transplantation
(Pagani et al. 2003, Hage`ge et al. 2003, Dib et al. 2005). However, the myotube
grafts were only very small compared to the left ventricles, and given the large num-
bers of cells injected this implies that the vast majority of cells were lost, either to
inefficient seeding or high rates of cell death after injection.
No meaningful conclusions can be drawn regarding the efficacy in augmenta-
tion of function in the injected areas from these phase I clinical trials. The large
randomized controlled trial by Menasche´ et al. (2008) found no improvement in
ejection fraction, but measured decreased ventricular chamber dimensions 6 months
after skeletal myoblast transplantation. Other studies, such as that by Gavira et al.
(2006) and Dib et al. (2005) found clear improvements in ejection fraction. The
main limitation of these trials is that their interpretation has been made difficult
by concomitant coronary artery bypass surgery, which sometimes included the re-
gion receiving myoblast injections. Furthermore, there are differences among studies
that make direct comparisons difficult, including differences in cell culture processes
(which may influence myoblast viability and differentiation), the variable end points
used to judge efficacy (including tool of cardiac function assessment), and the vari-
able baseline function of the engrafted regions.
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Patient safety has been a major concern, especially following observations of
ventricular tachycardia in 4 out of 10 patients in the early study carried out by
Menasche´ et al. (2001). As a safety precaution and also to assess the incidence
and timing of graft related arrhythmias, this group has implanted internal cardiac
defibrillators in all subsequent study patients. In the study published in 2008,
Menasche´ et al. detected ventricular arrhythmias in 12 ∼ 17% of patients who
received skeletal myoblast transplantation, compared to 6% in control patients (p =
ns).
64
Table 1.2: Clinical trials of skeletal myoblast transplantation in chronic ischæmic disease
Study n Control Cell dose CABG Outcome
Menasche´ et al. (2008) 97 placebo injection 4 ∼ 8× 108 yes • No change in EF at 6 months
• EDV and ESV ↓ at 6 months
Hage`ge et al. (2006) 10 none 8.7× 108 yes (remote) • Improved symptoms
• EF ↑ by 6.7% at 4 years.
• VT arrhythmias in 3 patients
Gavira et al. (2006) 12 none 2.2× 108 yes • EF ↑ by 20% at 1 year
• Improved viability of injected segments
Dib et al. (2005) 30 none 5× 107 yes • EF ↑ by 8% at 2 years
• VT arrhythmias in 2 patients
• Skeletal myotubes were visualized in hearts
which were explanted later.
Siminiak et al. (2004) 10 none 1.1× 107 yes • EF ↑ by 6.8% at 1 year
Abbreviations: CABG: coronary artery bypass graft. EF: ejection fraction. EDV: end-diastolic volume. ESV: end-systolic
volume. VT: ventricular tachycardia.
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Bone marrow cells
In marked contrast to the ten years of preparation which preceded initiation of
the skeletal myoblast transplantation clinical trials phase I, non-randomized clinical
trials of bone marrow-derived cell transplantation were reported within only six
months of the publication by Orlic et al. (2001). Subsequently, there have been
many randomized clinical trials published.
Unlike skeletal myoblasts, hundreds of millions of autologous bone marrow-de-
rived cells can be obtained without the need for ex vivo expansion. This has allowed
most of the clinical studies to be aimed towards treatment of patients who suffered
recent acute myocardial infarction (summarized in Table 1.3), although others
have performed bone marrow-derived cell transplantation in patients with chronic
ischæmic heart failure (Table 1.4). Another difference between the trials using
bone marrow-derived cells compared to skeletal myoblasts is that most of those
injecting bone marrow-derived cells have done so using percutaneous approaches.
The commonest method has been intracoronary perfusion, where pressures up to ten
times atmosphere have been applied. All of these studies have been carried out on
patients who received coronary revascularization. There has been one study of direct
intramuscular cell injection during coronary artery bypass surgery (Hendrikx et al.
2006). Other trials have employed percutaneous endocardial injection (Perin et al.
2004), which enables electromechanical mapping to help identify viable myocardium
for appropriate delivery.
As can be seen in Tables 1.3 and 1.4 the results for both acute myocardial
infarction and chronic disease have been mixed. This is despite careful performance
of prospectively randomized trials using controls with well-matched baseline charac-
teristics. Although only the studies by Ge et al. (2006), Janssens et al. (2006), and
Scha¨chinger et al. (2006) have carried out blinded sham-infusions (placebo treat-
ment) into their recruited controls, most of the studies outlined in Tables 1.3 and
1.4 were at least appropriately blinded during follow-up. The inconsistency of re-
sults, together with the modest improvements measured, has prompted a variety of
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interpretations. Some have commented that variables such as different i)protocols
of cell preparation, ii)timing (relative to onset of myocardial infarction) of injec-
tion, iii)baseline patient characteristics, and iv)method of evaluation of cardiac func-
tion might account for the variation on the results seen (Rosenzweig 2006). For
example, Chen et al. (2004) used purified MSCs whereas most others injected un-
fractionated bone marrow mononuclear cells. Several investigators, including Kang
et al. (2006) mobilized bone marrow-derived cells by administering systemic gran-
ulocyte colony-stimulating factor (G–CSF) prior to cell harvest, which may have
had additional effects. Subgroup analysis of the data obtained by Scha¨chinger et al.
(2006) suggested that bone marrow-derived cell transplantation is more beneficial
when performed more than five days after the onset of myocardial infarction. Fi-
nally, Penicka et al. (2007) commented that the negative finding from their trial
(which was terminated early) may be related to the fact that they recruited only
patients with severe heart failure (those with ejection fraction < 40%).
With increasing skepticism over the collective results, two systematic meta-
analyses of bone marrow-derived cell transplantation trials have been published
(Abdel-Latif et al. 2007, Lipinski et al. 2007). Both have concluded that mod-
est yet statistically significant benefits exist compared to control, in terms of left
ventricular dimensions, ejection fraction and infarct size. However, no new insight
into the underlying physiological mechanisms of action were revealed. The meta-
analysis of 18 studies including 999 patients by Abdel-Latif et al. found no correla-
tion between the number of cells injected and beneficial effect. Many researchers in
the field, including the authors of these meta-analyses, have expressed doubt over
the clinical significance of the small benefit (Lipinski et al. 2007, Nadal-Ginard &
Fuster 2007, Laflamme et al. 2007). With regard to future directions, opinions vary
widely. Some have suggested that larger randomized, double-blind, controlled trials,
perhaps even with repeated treatment, are warranted for further sub-group analysis
(The task force of the European Society of Cardiology concerning the clinical inves-
tigation of the use of autologous adult stem cells for repair of the heart: Bartunek
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et al. (2006)). On the other hand, others (Nadal-Ginard & Fuster 2007, Arnesen
et al. 2007) have proposed a moratorium on new clinical trials until additional insight
is gained from further animal studies on key points such as optimum cell type, tim-
ing and method of delivery, and perhaps most crucially, the underlying mechanisms
of action.
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Table 1.3: Randomized controlled trials of bone marrow cell transplantation following acute myocardial infarction
Study n Follow up Cell dose Assessment method Outcome
Chen et al. (2004) 69 6 months 6× 1010 Echo EF ↑ 18%.
Ge et al. (2006) (TCT-STAMI) 20 6 months 4× 107 SPECT/Echo EF ↑ 6.7%.
Janssens et al. (2006) 67 4 months 1.7× 108 MRI No effect.
Kang et al. (2006) (MAGIC Cell-3-DES) 56 6 months 1.4× 108 MRI EF ↑ 5.2%.
Lunde et al. (2006) (ASTAMI) 100 6 months 8.7× 107 SPECT/Echo/MRI No effect.
Meyer et al. (2006) (BOOST) 60 18 months 2.5× 109 MRI EF ↑ 6.7% at 6 mo. ns at 18 mo†.
Scha¨chinger et al. (2006) (REPAIR-AMI) 204 4 months 2.4× 108 LV Angiography EF ↑ 2.5%.
Meluzin et al. (2006) 66 3 months 108 SPECT/Echo EF ↑ 3%. ns when 107 cells injected.
Li et al. (2007) 70 6 months 7.3× 107 Echo EF ↑ 5.5%.
Penicka et al. (2007) 24 4 months 2.6× 109 SPECT/Echo No effect.‡
All studies used the intracoronary injection route. All studies demonstrated satisfactory patient matching.
†EF at 18 months was higher than at baseline, but showed no statistically significant difference compared to control.
‡Patients with severe heart failure recruited. Trial terminated early because of adverse events and no significant benefit.
Abbreviations: SPECT: single-photon-emission computed tomography. MRI: magnetic resonance imaging. ns: not significant.
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Table 1.4: RCTs of bone marrow cell transplantation in chronic heart disease
Study n Follow up Cell dose Function assessment Outcome
Erbs et al. (2005) 26 3 months 6.9× 106 MRI EF ↑ 7.2%.
Assmus et al. (2006) (TOPCARE-CHD) 75 3 months 2.1× 108 LV Angiography EF ↑ 2.9%.
Hendrikx et al. (2006) 20 4 months 6× 107† MRI No effect
Kang et al. (2006) (MAGIC Cell-3-DES) 40 6 months 1.4× 108 MRI No effect
All studies demonstrated satisfactory patient matching.
† In this trial cells were injected intramuscularly during CABG.
Abbreviations: SPECT: single-photon-emission computed tomography. MRI: magnetic resonance imaging.
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1.4.3 Putative mechanisms mediating the benefits of cell
transplantation
“Do these distinctions matter? . . . patients benefited from many established thera-
pies, including aspirin, before we understood the underlying mechanisms. There is
no doubt that the ultimate success or failure of cell therapy will rest on its ability to
show clinical efficacy rather than on the imputed mechanism.”
– Rosenzweig (2006). The New England Journal of Medicine.
“The results reported so far are modest at best, inconsistent and unconvincing. . .
. . . Even if the reported improvements are real, their clinical significance is highly
doubtful. This messy situation has been caused, at least partly, by the lack of mea-
ningful pre-clinical data.”
– Nadal-Ginard & Fuster (2007). Nature Clinical Practice.
Although therapies did not always need to be fully understood before gaining clinical
acceptance, elucidation of their underlying cellular mechanisms provide the most
promising path towards their optimization, whilst maintaining safety. It remains
impossible to predict the ideal cell type, number, and delivery protocol for cardiac
cell therapy in the absence of knowledge of their physiological mechanisms of action.
To obtain such information by trial and error would not only take many years and
valuable resources, but also expose patients to substantial avoidable risk.
The clinical trials outlined in the previous pages and the pre-clinical experiments
using animal models of heart failure were originally undertaken with the aims of
true cardiac regeneration. It was hypothesized that supplementation of the diseased
heart with the correct type of cells would correct the deficiency in numbers (Orlic
et al. 2001). However, as discussed in section 1.4.1 the animal studies, whilst often
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demonstrating clear functional improvements, have shown that substantial primary
remuscularization does not happen. Apart from fœtal cardiomyocytes, no type of cell
has formed adequately integrated, additional myocardial tissue following injection.
The numerous clinical trials have suggested between them that a modest functional
benefit might exist, but the lack of human cardiac tissue for histological analysis has
meant that, apart from some exceptions (e.g. Dib et al. 2005), clinical studies have
not been able to follow the phenotypic fate of the cells injected into human hearts.
The demonstration that the function of a diseased myocardium can be enhanced by
cell therapy without any remuscularization has resulted in a search for alternative
mechanisms of action. Some of these mechanisms, which are not mutually exclusive,
are discussed below.
Neoangiogenesis
This hypothesis relates to both acute myocardial infarction and chronic ischæmia,
and states that injected cells contribute towards increased development of collateral
blood vessels. In the case of acute myocardial infarction, there is ongoing loss of cells
at the border region (Abbate et al. 2003). It is proposed that cell transplantation
attenuates the ongoing cell loss by increasing perfusion to these tenuously supplied
areas (Kinnaird et al. 2004, Kocher et al. 2001).
Direct evidence that cell transplantation might benefit the recipient myocar-
dium in such manner is provided by the study by Reffelmann et al. (2003). Using
radioactive microspheres they demonstrated an increase in regional myocardial blood
flow after transplantation of neonatal cardiomyocytes. In addition, the capillary
densities were higher when histological ventricular sections were examined.
In the case of bone marrow-derived cell transplantation it has been suggested
that the endothelial progenitor cells (EPC) might play a central role in neoangio-
genesis. EPCs are CD34+ and were originally described by Asahara et al. (1997).
As their name implies they are thought to be the bone marrow cells in the circu-
lation with a chief role in formation of new collateral vessels. Kocher et al. (2001)
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carried out intravenous injections of human EPCs into athymic rats which had un-
dergone myocardial infarction and later found them incorporated in newly formed
coronary vessels. Controls which had received injections of other types of human
bone marrow cells did not show this effect. The injection of EPCs also reduced
the extent of myocardial infarction, resulting in relatively preserved LV function.
Interestingly, it has subsequently been demonstrated that injection of MSCs into
animal models of ischæmic hearts and hindlimbs might also increase collateral per-
fusion, albeit without direct integration into the newly formed vessels (Kinnaird
et al. 2004). This suggested that transplantation of bone marrow-derived cells may
augment neoangiogenesis via indirect as well as direct mechanisms.
Modulation of the extracellular matrix
In body tissues extracellular matrix (ECM) formation and digestion, and main-
tenance of optimal tissue structure, are related to the fine balance between the
activities of matrix metalloproteinases (MMPs) and tissue inhibitors of metallopro-
teinase (TIMPs). Pathological ventricular remodeling involves maladaptive changes
in the ECM, which leads to further myocardial deterioration (Lindsey et al. 2003).
A net increase in ECM leads to interstitial fibrosis. Although this can be useful in
limiting ventricular enlargement, it also decreases tissue compliance and adversely
affects systolic and diastolic performance.
Murtuza et al. (2004) first showed that transplantation of skeletal myoblasts
results in decreased levels of collagen in the ECM, correlating with attenuated up-
regulation of MMP. Xu et al. (2005) injected MSCs into infarcted rat hearts and
found that the increases in cardiac expression of collagen and TIMP–1 were atten-
uated, whilst there was no effect on the levels of MMP–1. Correspondingly, the
left ventricular enlargement was reduced and whole ventricular function improved.
Thus, there is limited, but interesting experimental data to support the hypothesis
that cell transplantation might modulate the ECM to augment mechanical perfor-
mance of the myocardium.
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Paracrine effects on the recipient myocardium
As briefly mentioned above, Kinnaird et al. (2004) demonstrated that MSCs im-
prove the collateral circulation without directly integrating into new vessels. This
effect was demonstrated in a rat model of hindlimb ischæmia. In the same study
the authors found that growth media that were conditioned by 24 hour exposure to
MSCs enhanced the proliferation of cultured endothelial cells and smooth muscle
cells in a dose-dependent manner. Analysis of the growth media revealed increased
levels of various cytokines including vascular endothelial growth factor (VEGF), ba-
sic fibroblast growth factor (bFGF), placental growth factor (PlGF), and monocyte
chemoattractant protein-1 (MCP–1). Inhibition of VEGF and bFGF using antibod-
ies only partly attenuated these effects, implying that multiple cytokines had exerted
their influence in combination. From these experiments the authors concluded that
MSCs increased collateral circulation through paracrine mechanisms.
A similar study supporting the presence of a paracrine effect was performed
by Takahashi et al. (2006), but using unfractionated bone marrow mononuclear
cells rather than only MSCs. The growth media that were conditioned by 24
hour exposure to bone marrow mononuclear cells contained higher concentrations
of interleukin-1α (IL–1α), platelet-derived growth factor (PDGF), and insulin-like
growth factor-1 (IGF–1), and protected cardiomyocytes isolated from normal rat
hearts from hypoxia. When injected into rat hearts undergoing acute myocardial
infarction the conditioned media decreased the sizes of infarcts and increased blood
vessel densities, with corresponding improvements in cardiac function.
The long-term in vivo benefit demonstrated by Takahashi et al. is unexpected,
considering that soluble factors remain in body tissues for only minutes to hours.
However, similar effects were demonstrated when the same experiments were per-
formed using MSCs overexpressing the pro-survival gene Akt1 (Gnecchi et al. 2006).
Growth media conditioned by 12 hour exposure to AKT-overexpressing MSCs pro-
tected normal isolated rat cardiomyocytes exposed to hypoxia in vitro. When in-
jected into rat hearts undergoing myocardial infarction, the resulting infarct sizes
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were reduced and ventricular function relatively preserved.
Following the demonstrations of cardioprotective effects of cell-free conditioned
media the paracrine theory of cell transplantation has increasingly become the
subject of discussion amongst scientists and also those performing clinical trials
(Dimmeler et al. 2005, Srivastava & Ivey 2006, Rosenzweig 2006, Laflamme et al.
2007). However, although commonly invoked the paracrine theory remains unde-
fined. At its minimum, it postulates that locally secreted substances from the in-
jected cells benefit their surrounding myocardium, but the cellular targets and the
precise physiological effects resulting in the potential benefit have not been de-
scribed. Furthermore, there is only a vague consensus on the disease process that is
targeted by cell transplantation. The few published studies mentioned above that
have led to the paracrine theory have all focussed on protection of cardiomyocytes
from death during an acute myocardial infarction, but the vast majority of reports
in the field have put their main emphases on the function of the whole heart in the
long term. Therefore, studies in cardiac cell transplantation attempting to elucidate
their underlying mechanisms need to clarify their goal as an initial step – limita-
tion of cardiomyocyte death, or attenuation of the ensuing maladaptation of the
surviving cardiomyocytes?
As discussed in section 1.3 individual cardiomyocytes that have survived a myo-
cardial infarction subsequently undergo substantial long-term maladaptive changes
as the ventricle becomes remodeled. These changes contribute directly to further
deterioration of whole heart performance. Whilst the potential effects of any type
of transplanted cell on these chronically failing cardiomyocytes would be of major
interest, they have never been studied.
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1.5 Hypotheses
The collective evidence suggests that the beneficial effects of adult progenitor cell
transplantation to the heart do not result from myocardial regeneration. It has been
suggested that transplanted cells might improve performance by exerting indirect
effects on the diseased recipient myocardium, possibly involving paracrine secretions
(Dai et al. 2005, Kinnaird et al. 2004, Murry et al. 2005). The aim of this study was
to address this hypothesis using a rat model of post-infarct chronic heart failure. In
particular, the following hypotheses were tested.
1. The properties of individual failing recipient cardiomyocytes are af-
fected by adult progenitor cell transplantation.
2. Paracrine mechanisms can improve the function of failing cardio-
myocytes.
In Chapter 3 the first hypothesis is tested by studying the morphological and func-
tional changes in the recipient ventricular cardiomyocyte population of a chronically
failing rat heart following skeletal myoblast or bone marrow-derived cell transplan-
tation. In Chapters 4 and 5 explanations for those observations made in Chapter 3
are sought by experiments utilizing cell co-culture systems.
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Chapter 2
General Methods
The choice of animal model of heart failure to use for this study took many con-
siderations into account. Animals in which heart failure could be induced reliably
and in a consistent, reproducible manner were considered to be useful candidates.
The availability of a transgenic model constitutively expressing green fluorescent
protein in all organs (GFP+) was a necessity for distinguishing transplanted cells
from native cardiomyocytes. The technical feasibility with which GFP+ cells could
be transplanted into failing hearts several weeks after an initial operation was im-
portant. Taken together, these three main factors led to the decision to use adult
rats. Other considerations included the availability of robust methods to monitor in
vivo heart function and isolate single ventricular cardiomyocytes. The rat was also
a good candidate from practical points such as cost and the need for a significant
number of housed animals over many weeks.
The adult rat has been the subject of the largest number of previous studies
of cell transplantation into the heart (Dowell et al. 2003). Such familiarity gave
reassurance that measurable physiological effects would be induced following cell
transplantation, allowing the hypotheses of this study to be tested. Furthermore,
it was also felt that it would be technically feasible to inject cells with sufficient
consistency to allow subsequent comparison between control and various treatment
groups.
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The features of cardiac EC coupling in normal hearts of many different animal
species has been described by others previously (for reviews, see Hasenfuss 1998,
Bers 2002). Various parameters of cardiomyocyte function and electrophysiological
properties are known to differ between animal species, which is perhaps unsurprising
considering differences in functional demand, whole organ size, and normal beating
rate (Bers 2003). The action potential profile and gain of CICR, for example, differ
significantly between mouse, rat, guinea-pig, and human (Wettwer et al. 1993, Bas-
sani et al. 1994, Terracciano & MacLeod 1994, Pieske et al. 1999). In the rat
heart the force of contraction shows a negative correlation with increasing frequency
(Banijamali et al. 1991), which is a relationship opposite to that seen in guinea-pigs
(Kurihara & Sakai 1985) and humans (Pieske et al. 1999). That this study was per-
formed ultimately to increase an understanding of cell transplantation in patients
with heart failure meant it would have been most useful if an animal with cardiac
EC coupling similar to that of human were available for study. However, the various
considerations laid out above led to the decision to use adult rats. The relevance of
experiment data obtained in this study for humans is discussed later.
Previous studies of animal models of heart failure have employed various meth-
ods to apply chronic wall stress to the ventricle in several animal species (Sipido
et al. 2002). Myocardial infarction caused by permanent left coronary artery ligation
(Dixon et al. 1992) was the preferred mode of heart failure induction in this study,
rather than alternative methods employed by others previously such as rapid elec-
trical pacing (O’Rourke et al. 1999), chronic administration of cardiotoxic drugs, or
constrictive banding of the ascending aorta (Weinberg et al. 1999). This was because
coronary ligation would mimic the commonest clinical scenario (i.e. patients devel-
oping chronic heart failure following myocardial infarction and ventricular remod-
eling). Animal models of heart failure resulting from genetic manipulation (Gomez
et al. 1997) or chronic cardiotoxic drug administration (Siveski-Iliskovic et al. 1995)
were not considered appropriate, due to the possibility of interference of any physi-
ological effects of cell transplantation. Other advantages of coronary artery ligation
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included the high rate of development of heart failure as well as technical simplicity
and low cost.
To date many different types of cells have been injected into failing hearts, both
in animal studies (Dowell et al. 2003) and in clinical trials (Abdel-Latif et al. 2007,
Lipinski et al. 2007). This study focused on the two types of cell most widely
employed by others previously: skeletal myoblasts and bone marrow mononuclear
cells. These two cell types are also the subjects of the most active ongoing research,
probably due to their large availabilities from autologous sources. Bone marrow
mononuclear cells comprise of a complex assortment of cells, including HSCs, MSCs,
and the so-called side-population (SP) cells. To date no study has identified a
sub-population of bone marrow mononuclear cells which exert a greater effect on
whole myocardial function following injection (Laflamme et al. 2007). The majority
of studies demonstrating beneficial effects of bone marrow mononuclear cells have
utilized freshly prepared cells without further purification or ex vivo expansion,
and this study sought to reproduce such findings and elucidate the physiological
mechanisms accounting for the observations.
2.1 Induction of myocardial infarction and heart
failure
All animal procedures were carried out in accordance with the United Kingdom
Animals (Scientific Procedures) Act 1986. Appropriate project and personal licenses
were acquired from the United Kingdom Home Office for the duration of the study.
Myocardial infarction was induced by ligation of the left coronary artery using
standard surgical methods previously described by Johns & Olson (1954) and later
modified by Selye et al. (1960). Adult female Sprague-Dawley rats weighing 200 g
(Harlan, UK) were anæsthetized with 1∼2% isoflurane (Schering-Plough Animal
Health, UK) in 100% oxygen and intubated with a 16G plastic cannula. They were
then ventilated using a volume-controlled mechanical ventilator (Harvard Appara-
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tus, Kent, UK) at 2.5 ml tidal volume and 70 breaths per minute. Operations were
performed using aseptic conditions and autoclave-sterilized instruments to prevent
infections. The skin was shaved using an electric shaver. Povidone-iodine antisep-
tic solution (Videner) was applied on the operation site. After incising the skin
with a scalpel, the left pectoralis major and latissimus dorsi muscles were parted
using blunt dissection and retracted to reveal the ribs and intercostal muscles. Tho-
racotomy at the fourth intercostal space was performed using pointed-tip scissors,
taking care to avoid injury to the left lung, intercostal neurovascular bundle and
left internal mammary artery. Pericardiectomy then provided direct access to the
heart. The left coronary artery was identified and permanently ligated at the level
of the left atrial appendage using a round-needle 6–0 polypropylene suture to cause
myocardial infarction and heart failure (Fig.2.1). Left coronary artery occlusion
was confirmed by observing discolouration of the left ventricle (LV), including the
apex, which occurred within a few seconds.
After re-inflating the lungs by positive-pressure ventilation, the chest wall was
closed using a continuous 4–0 polypropylene intercostal suture. Antiseptic solu-
tion was applied again to the inner operation site and the skin was closed using a
continuous 3–0 silk suture.
Once established, it became possible to complete the entire operation from skin
incision to skin closure within 20 minutes. Bleeding was minimal. The 24 hour
mortality following coronary artery ligation was 26/132 (∼ 20%).
Sham operated animals were also generated for use as normal heart controls.
These were subjected to thoracotomy and pericardiectomy in an identical manner,
but received no LAD ligation. Mortality in these animals was 0%.
2.2 Preparation of bone marrow mononuclear cells
Bone marrow mononuclear cells were freshly prepared on the day of use. They were
harvested from adult male Sprague-Dawley transgenic rats constitutively expressing
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Fig. 2.1: A) The left coronary artery was identified and permanently ligated at the level of
the left atrial appendage. B) Discolouration of the left ventricle, including the apex, confirmed
acute myocardial ischæmia and the onset of infarction.
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green fluorescent protein (GFP+) in all tissues (from Rat Resource and Research
Centre, MO, USA).
GFP is a fluorescent chromophore originally discovered in the jellyfish species
Aequorea victoria (Johnson et al. 1962, Morise et al. 1974). GFP consists of 238
amino-acids and is a stable protein within cells. Its formation from its encoding gene
is species independent, and does not require other factors. Its maximum emission
is at wavelength 509 nm (green) following maximum excitation at 395 nm without
the need for additional substrates (Chalfie et al. 1994). Together, these properties
of GFP make it a useful in vivo reporter system, and it has been used in many
studies of gene expression patterns and tracking of transplanted cells (for reviews,
see Prasher 1995, Tsien 1998).
Rats were anæsthetized and then sacrificed by cervical dislocation. The femurs
and tibiæ were removed and all soft tissue excised. The marrow cavity of each
bone was flushed using 5 ml of Hank’s balanced salt solution (HBSS, Sigma-Aldrich,
Poole, UK) containing 10% fœtal bovine serum (FBS, Gibco, Paisley, UK) to obtain
whole bone marrow aspirate. The 20 ml of whole marrow aspirate was then spun at
1200 rpm for 10 minutes, and the supernatant layer was removed, leaving only 3 ml.
After trituration 1 ml of this concentrated whole marrow aspirate was then spun
through a Percoll™ gradient formed by 5 ml of 55% Percoll™ (Density 1.130 g/ml,
Amersham, Little Chalfont, UK), diluted with HBSS, layered above 5 ml of 70%
Percoll™ (also diluted with HBSS) in a 15 ml test tube at ×1600 g for 25 minutes
(Fig.2.2). Using a glass Pasteur pipette, the mononuclear cell fraction was then
extracted from the border between the two layers, washed twice, and stored in HBSS
containing 10% FBS.
Before use, the viability of these cells was checked using 0.4% trypan blue so-
lution. Using this method, it was possible to obtain bone marrow mononuclear
cells with > 99% viability consistently. Cells prepared for injection into hearts were
washed once again using PBS and stored on ice.
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Fig. 2.2: Separation of the mononuclear fraction of bone marrow cells from whole cell aspirate
was done using a Percoll™ gradient. Whole cell aspirate was placed on top of 55% Percoll™.
After centrifugation, the mononuclear cell fraction was extracted from the border between the
55% and 70% layers.
2.3 Preparation of primary skeletal myoblasts
2.3.1 Harvest and passage of primary skeletal myoblasts
Primary skeletal myoblasts were cultured using the single fibre method, as described
by Rosenblatt et al. (1995). This is a well-established method of obtaining large
numbers of expanding primary skeletal myoblasts whilst avoiding contamination by
other cell types such as fibroblasts.
GFP+ male Sprague-Dawley rats were anæsthetized and then sacrificed by cer-
vical dislocation. The skin of the lower limbs and abdomen was shaved and prepped
with antiseptic solution. Using aseptic technique, the extensor digitorum longus
muscles were removed from the hindlimbs. Care was taken to include the tendons
at both ends, and also to minimize trauma to the muscles. The excised muscles
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were then shaken for 90 minutes at 35 ℃ in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco, UK) with 2 mg/ml added collagenase (type I, Sigma-Aldrich, UK).
The partially digested muscle tissue was triturated in DMEM in Petri dishes using
a wide-bore (4 mm) glass Pasteur pipette to separate the single myofibres. Intact
individual myofibres with healthy appearance were identified under light microscopy
using a ×4 objective and plated in individual droplets of 20% Matrigel™ (Becton
Dickinson, Oxford, UK) in DMEM in standard 6-well polystyrene culture plates.
They were then bathed in plating medium, consisting of DMEM with 10% added
horse serum (Gibco, UK), 0.5% chick embryo extract (Sera Labs, Bolney, UK),
and 1% penicillin/streptomycin (Sigma-Aldrich) and incubated at 37 ℃. At 37 ℃
20% Matrigel™ sets from liquid into gel, mechanically supporting the myofibre. By
24 ∼ 48 hours after plating, the proliferating satellite cells had started to migrate
away from myofibres and adhered onto the culture plate floor. The myofibres were
then removed and the bathing medium changed to proliferation medium, which was
similar to that above, but also with 20% FBS and 5 ng/ml basic fibroblast growth
factor (bFGF, Invitrogen, Paisley, UK) added. Thereafter, primary skeletal my-
oblasts were passaged in 75 ml culture flasks every 2 ∼ 3 days and used within two
weeks.
Although the single fibre method has been known to yield primary skeletal my-
oblasts of high purity consistently, measures were taken to confirm that the prolifer-
ating cells were primary skeletal myoblasts rather than contaminating cell types such
as fibroblasts. Approximately 5% of the passaged cells were separated and allowed
to proliferate until a confluent layer was formed. The growth medium was then
changed to differentiation medium, consisting of DMEM with only 1% added horse
serum and 1% penicillin/streptomycin. Under such conditions skeletal myoblasts
were seen to fuse and form uniformly-aligned myotubes within 48 hours, confirming
their skeletal tissue phenotype. However, such formed myotubes were not used for
any further experimentation.
Immediately before injection skeletal myoblasts were checked using 0.4% trypan
84
blue. The average viability was > 98%. Cells prepared for injection into hearts were
washed once again using PBS and stored on ice.
2.4 Cell injection into the heart
Three weeks after coronary artery ligation rats were anæsthetized using 1 ∼ 2%
isoflurane and mechanically ventilated. Thoracotomy via the fifth intercostal space
was carried out, and blunt dissection was performed to free the heart from adhesions
and allow access. Using a 25G needle mounted on a standard 1 ml syringe, either
107 bone marrow mononuclear cells or 5 × 106 cultured skeletal myoblasts were
directly injected into the myocardium. These numbers were chosen following earlier
studies performed within our research group, and those reported by others (Pouzet
et al. 2001, Tambara et al. 2003, Nagaya et al. 2005, Dai et al. 2005), which have
demonstrated improvements in LV ejection fraction. However, it should be noted
that there has been no report establishing the optimal injection numbers in any
animal model or patients. Cells were suspended in 150 µl PBS. Half of this volume
was injected into viable myocardial tissue at the apex of the LV. The remaining half
of the cells were injected into the viable portion of the LV lateral wall. By the time
of cell injection the infarcted portion of the ventricle had formed mature scar tissue
which was distinguishable from the viable myocardium by visual inspection. This
portion of the ventricle received no cell injection. The needle was inserted obliquely,
and care was taken such that the tip would not reach the ventricular cavity (this was
considered important in order to avoid injecting cells into the circulating blood as
well as to minimize bleeding). Successful injection in such manner was confirmed by
visualization of the needle tip within the ventricle wall throughout the procedure,
blanching of the ventricle upon injection and lack of bleeding from the ventricle
cavity after withdrawal of the needle.
In control heart failure animals, and in the sham-operated group, 150 µl of PBS
only was injected in the same manner. After injection the lungs were re-inflated and
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the chest wall was closed using a 4–0 polypropylene suture. Antiseptic solution was
applied to the operation site, and the skin was closed using a 3–0 silk suture.
2.5 Monitoring heart function using echocardiog-
raphy
Animals were anæsthetized by administering 1 ∼ 1.5% isoflurane in 100% oxygen via
a nose-cone and allowed to self-ventilate whilst in a supine position. Attempts were
made to keep the level of anæsthesia minimal and constant throughout image acqui-
sition, to avoid the hæmodynamic artefacts induced by the myocardial depression
and vasodilation effects of isoflurane (Davies et al. 2000, Hanouz et al. 1998, Sprague
et al. 1974). Animals were shaved over the anterior chest wall and ultrasound gel
was applied. Using a 15 MHz probe (model “15L8”) on an Acuson Sequoia™ 256
system (Siemens Medical Systems, Germany) transthoracic echocardiography was
performed to obtain parasternal short-axis views at the level of the mid-papillary
muscle (Fig.2.3). Ejection fraction (EF) was calculated from the systolic and dias-
tolic 2-dimensional cross-sectional LV areas, using the formula below, as previously
described by Yang et al. (1999):
EF(%) =
(End Diastolic Area)− (End Systolic Area)
End Diastolic Area
× 100 (2.1)
Although it was also possible to calculate EF using data acquired from the M-
mode studies, only the EF calculated from cross-sectional LV areas was used. A
small disparity was sometimes noted between the figures obtained by the two dif-
ferent methods, and because the anterior wall of the LV was sometimes tethered to
the inner chest wall by inflammatory adhesions, the method utilizing 2-dimensional
cross-sectional LV areas was considered to be more accurate. Studies were per-
formed immediately before cell injection and also immediately before the harvesting
of hearts.
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Fig. 2.3: Example cross-sectional views of the heart acquired during diastole (above), and
systole (below). Dotted lines demarcate the endocardium.
2.6 Cell isolation
Ventricular cardiomyocytes were isolated using a modification of standard enzymatic
digestion protocols described previously (Hering et al. 1983, Tytgat 1994). The main
strategy was to perfuse the excised whole heart via its aorta and coronary arteries
with solutions containing digestive enzymes and low concentrations of Ca2+ to break
the structural bonds between the cardiomyocytes.
Rats were sacrificed and the hearts removed quickly. The excised heart was
promptly attached to a Langendorff perfusion system at the aorta via a blunted
16G needle (Fig.2.4). The heart was then perfused via its coronary arteries for
2 minutes at 37 ℃ with oxygenated normal Tyrode solution containing (in mM)
NaCl 140; KCl 6; glucose 10; MgCl 1; CaCl2 1; N -2-hydroxyethylpiperazine-N´ -2-
ethansulphonic acid (HEPES) 10; pH 7.4. Perfusion was carried out at a rate of
approximately 12 ml per minute. Care was taken to minimize myocardial hypoxia.
The perfusing solution was then changed to a low-Ca2+ solution containing (in mM)
NaCl 120; KCl 5.4; CaCl2 0.045; MgSO4 5; Na
+-pyruvate 5; glucose 20; taurine 20;
HEPES 10; nitrilotriacetic acid 5; pH 6.96. The change was made with the use
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Fig. 2.4: Heart attached on Langendorff apparatus for retrograde perfusion via the coronary
arteries
of a three-way tap, enabling continuous perfusion of the heart throughout. The
heart was perfused with low-Ca2+ solution for 5 minutes, before changing to an
enzyme solution containing (in mM) NaCl 120; KCl 5.4; CaCl2 0.2; MgSO4 5; Na
+-
pyruvate 5; glucose 20; taurine 20; HEPES 10; pH 7.4. In addition, this solution
contained 1 mg/ml collagenase (Type-2, 280 u/mg, Worthington Biochemical Corp,
Lakewood, NJ, USA) and 0.6 mg/ml hyaluronidase (999 u/mg, Sigma-Aldrich).
Perfusion with this enzyme solution continued for 9 minutes, after which the heart
was removed from the Langendorff setup, and both atria and the right ventricle
were discarded. The infarcted scar tissue was visually assessed and removed from
the LV. The viable LV tissue was cut into smaller pieces and shaken in the solution
containing enzymes for a further 5 minutes before gentle trituration to yield a single-
cell suspension. This was then filtered through a 300 µm nylon mesh and stored in
enzyme-free buffer at room temperature until use.
Using this method it was possible to reliably obtain sufficient amounts of Ca2+-
tolerant left ventricular cardiomyocytes for physiological experiments. Approxi-
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mately 70% of the resulting cardiomyocytes were rod-shaped, and there was no
noticeable difference in yield between the different heart groups. Isolated cardiomy-
ocytes were used within 6 hours.
2.7 Cell area planimetry
The dimensions of individual isolated cardiomyocytes were measured and compared
between groups for assessment of degrees of hypertrophy. Cardiomyocytes were
examined using an Olympus IX-71™ inverted microscope with a ×60 oil-immersion
objective. Digital images of rod-shaped cardiomyocytes of healthy appearance were
acquired using an IonOptix Myocam™ camera (IonOptix Corp, Milton, MA, USA)
attached to the microscope light path, and a standard personal computer (PC)
running Wisepixel Handysnapr software (Wisepixel Multimedia, freeware). The
magnification scale was calibrated by the use of a standard stage micrometer, and
the projected 2-dimensional area for each cell was measured oﬄine using ImageJ
software (Rasband 1997, Abramoff et al. 2004).
Fig. 2.5: An example photograph of an isolated cardiomyocyte (left). A line was drawn
around the cardiomyocyte (right) to measure the 2-dimensional area for each cell. Scale bar
represents 10 µm.
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Bright Field Fluorescence Bright Field Fluorescence
Fig. 2.6: Example photographs of cardiomyocytes isolated from wild-type rats (left) and
also from GFP+ rats (right). For both examples, normal bright-field photomicrographs and
fluorescence micrographs are shown. Scale bar represents 10 µm.
2.8 Examination for GFP fluorescence
To determine whether the isolated cardiomyocytes studied had originated from host
or injected cells their level of green fluorescence was assessed. Cardiomyocytes were
placed in a bath on the stage of a Nikon TE2000-U™ inverted microscope and initially
studied by light microscopy via a ×40 oil-immersion objective. Using a DeltaRAM–
V™ Monochromator (Photon Technology International, NJ, USA) cardiomyocytes
were subjected to fluorescent excitation at 488 nm. Fluorescence emissions were
passed through a 545 nm band-pass optical filter (model XF3074, Omega optical
Inc. VT, USA) for visual assessment (Fig.2.6).
2.9 Assessment of cardiomyocyte contraction by
measurement of sarcomere shortening
Freshly isolated cardiomyocytes were initially studied for their contractile character-
istics. The main parameters analyzed for comparison between groups were magni-
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tude of contraction, speed of contraction, and speed of relaxation. These parameters
were measured in field-stimulated cardiomyocytes which were not individually me-
chanically stretched.
The dynamics of cardiomyocyte contraction were studied by measuring the aver-
age length of the sarcomere. In this method the average distance between striations
within a highlighted area of interest is calculated. A fast Fourier transform is then
performed and the peak within the power spectrum represents the average sarcomere
spacing, measured in real time. Compared to the traditional method of measuring
whole cell length changes, this method was considered to be more sensitive to length
changes, and less susceptible to artefacts from sideways movements of the cardio-
myocyte.
Cardiomyocytes were placed onto a bath held within the stage of an Olym-
pus IX-71™ inverted microscope. Approximately 3 µl of 1 mg/ml laminin solution
(Sigma-Aldrich) was applied to the bath before plating cardiomyocytes to aid their
adhesion to the bath floor. Cardiomyocytes were superfused with normal Tyrode so-
lution containing 1 mM Ca2+. The flow of normal Tyrode solution through the bath
was by gravity, and controlled to ensure laminar flow and maintain a bath depth of
approximately 1 mm. The normal Tyrode solution was heated by a custom-made
heating jacket covering the solution tubing. The temperature of the heating jacket
was controlled to maintain a bath temperature of 36 ∼ 38 ℃, and was checked
regularly.
The cardiomyocytes in the bath were electrically field-stimulated at 1 ∼ 5 Hz
using platinum electrodes connected to an IonOptix Myopacer™ bipolar field stim-
ulator (IonOptix Corp.). The stimulation pulse duration was 5 ms. The output
voltage was adjusted to stimulate over 80% of the rod-shaped cardiomyocytes and
was usually in the range of 10 ∼ 20 V. The output signal from the field-stimulator
was also connected to the IonOptix Fluorescence System Interface™ (the image data
processor, IonOptix Corp.), enabling its recording during data acquisition.
Images of contracting cardiomyocytes were acquired at a rate of 240 frames per
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Fig. 2.7: Analysis of cardiomyocyte sarcomere shortening.
second using an IonOptix Myocam™ video camera (model CCD100M, IonOptix
Corp.) attached to the microscope light-path. The signal was processed using an
IonOptix Video Power Controller™ and IonOptix Fluorescence System Interface™
connected to a standard personal computer (PC) running IonOptix IonWizard™
data acquisition software (Version 5.0. IonOptix Corp.). The captured images un-
derwent real-time Fourier analysis of the striations in a selected area of approxi-
mately 50% of the contracting cardiomyocyte under study. This yielded sarcomere
length shortening data averaged for the cardiomyocyte.
Oﬄine analysis of the acquired sarcomere shortening patterns were carried out
using IonWizard™ software (Fig.2.7). Between 10 and 20 representative steady-
state contractions were averaged with reference to the field-stimulation signal. The
baseline sarcomere length, peak contraction amplitude, and time-to-peak (Tpeak)
of the averaged contraction were calculated using the field-stimulation signal as a
reference point. The time-to-50% relaxation (T50) and time-to-90% relaxation (T90)
of the averaged contraction were calculated from Tpeak.
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2.10 Measurement of Ca2+ transients using indo-1
The dynamics of intracellular Ca2+ is a major determinant of EC coupling. Cyto-
plasmic Ca2+ concentration ([Ca2+]i) and its pattern of change with each contrac-
tion was monitored using the Ca2+-sensitive fluorescent indicator indo-1. Indo-1 is
a widely used intracellular Ca2+ indicator first introduced by Grynkiewicz et al. in
1985 and has several useful characteristics:
• High selectivity for Ca2+ than for other divalent cations
• High fluorescence quantum efficiency and low affinity for Ca2+, leading to less
buffering of cellular Ca2+ and easier observation of intracellular Ca2+ dynamics
• Ratiometry. The absorption maximum of indo-1 is in the region of 360 nm.
The maximum emission shifts from 495 nm in zero Ca2+ towards 405 nm when
indo-1 combines with Ca2+. This means the fluorescence emission at 405 nm
increases whilst that at 495 nm decreases with increasing [Ca2+] (Fig.2.8A).
Thus, the ratio of the fluorescence emissions (i.e. F405/495) allows accurate es-
timation of [Ca2+]i, changing only with alterations in [Ca
2+]i and independent
of other factors (Tsien & Poenie 1986). This ratiometric property of indo-1
is useful in that it corrects for uneven loading between cells, dye leakage, dif-
ferent cell sizes (including thickness), and photobleaching during the course of
an experiment.
Loading cardiomyocytes with indo-1: Cardiomyocytes were loaded with indo-
1 (Molecular Probes, UK) using its acetoxymethyl (AM) ester form, as ori-
ginally described by Tsien (1981). In this preparation the indo-1 is made
membrane-permeable temporarily by masking its charged groups with esteri-
fying groups. Once in the cytoplasm, the esterifying groups are hydrolyzed
and the indo-1 becomes trapped within the cell. The only alternative method
of using pure indo-1 salts necessitates direct microinjection into cells. Not only
is this cumbersome, but the membrane integrity and cytoplasmic composition
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Fig. 2.8: A. Fluorescence emission spectra of indo-1 in solutions containing various concen-
trations of free Ca2+. The fluorescence emission at 405 nm increases and that at 495 nm
decreases when indo-1 combines with Ca2+ (Taken from “Fura and Indo Ratiometric Calcium
Indicators”, Molecular Probesr Product information.). B. Schematic illustration of the micro-
scope setup for simultaneous visual assessment, cardiomyocyte sarcomere length measurement,
and indo-1 fluorescence studies.
are disturbed. The method using the AM preparation enables simultaneous
loading of many cells without disrupting their cell membranes.
Indo-1 AM was dissolved in enzyme buffer at 10 µM concentration. Car-
diomyocytes were incubated in this solution at room temperature for 20 min-
utes in a dark environment. They were then allowed to de-esterify in enzyme
buffer for at least 1 hour before study.
Hardware setup: Cardiomyocytes loaded with indo-1 were placed onto a bath
held within an inverted microscope stage and superfused, as above. They
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were then subjected to visible illumination by light of wavelength > 700 nm.
At the same time, they underwent fluorescence excitation at a wavelength
of 355 nm by means of a xenon lamp light source and a narrow band-pass
optical filter (Type 355HT15, Omega Optical Inc. VT, USA) held within an
IonOptix Microstepper™ device (IonOptix Corp.). The 355 nm illumination
was limitted to the duration of fluorescence acquisition only, minimizing the
photobleaching of indo-1.
Acquisition of fluorescence emissions: This setup enabled simultaneous visual
assessment via the microscope eyepiece, measurement of cardiomyocyte sar-
comere length dynamics, and indo-1 fluorescence detection (Fig.2.8B). A
dichroic mirror (type 585DCXR, Chroma Technologyr, VT, USA) separated
visible light within the light path of the microscope such that light of wave-
length > 585 nm was directed to the video camera whilst that < 585 nm was
directed to the photomultiplier tubes (PMTs). Fluorescence emissions from
cardiomyocytes (light < 585 nm) were split into two light paths via another
dichroic mirror (type 455DCLPO2, Omega Optical Inc.). The emissions with
wavelength < 455 nm were allowed to pass through a 405 nm narrow band-
pass optical filter and those > 455 nm through a 495 nm optical filter (Types
405DF40 and 495DF20, respectively, both from Omega Optical Inc.) before
detection by two separate PMTs (Type P30CWAD5-62, from Electron Tubes
Ltd, Ruislip, UK.).
Analogue output signals from the two photomultiplier tubes were digi-
tized at 500 Hz and recorded by the IonOptix Fluorescence System Interface™
connected to a PC running IonOptix IonWizard™ data acquisition software,
as above. The indo-1 fluorescence ratio (F405/495) was calculated and taken as
a measure of [Ca2+]i for comparison between groups.
Background subtraction: Immediately before fluorescence acquisition the field of
view was moved to a part of the bath containing no cells and the fluorescence
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Fig. 2.9: Parameters analyzed from an averaged indo-1 transient.
levels recorded. After setting the fluorescence levels at this background to zero
the field of view was moved back to the cardiomyocyte under study for the
experiment.
Protocol for field-stimulation transients: Cardiomyocytes were studied whilst
being field-stimulated at 1, 2, or 3 Hz. Once steady-state contractions were es-
tablished fluorescence emissions were acquired. Offline analysis of the acquired
indo-1 transients was carried out using Ionwizard™ software, in a manner sim-
ilar to the analysis of sarcomere shortening. Between 10 and 20 transients
were averaged with reference to the field-stimulation signal. The baseline le-
vels, peak amplitudes, and times-to-peak (Tpeak) of the averaged transient
were calculated using the field-stimulation signal as a reference point. The
times-to-50% decay (T50) and times-to-90% decay (T90) of the transients were
calculated from Tpeak (Fig.2.9).
Protocol for caffeine-induced transients Caffeine application studies were per-
formed to assess the sarcoplasmic reticulum (SR) Ca2+ content, fractional re-
lease, and the relative contribution of Na+/Ca2+ exchange (NCX) towards
Ca2+ removal during diastole (Callewaert et al. 1989). The protocol relies on
the ability of rapidly applied caffeine to release Ca2+ from the SR completely,
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Fig. 2.10: Protocol for studying SR Ca2+ handling. Following a train of 1 Hz field
stimulation in normal Tyrode solution, the stimulator was stopped, and the solution
was rapidly changed to that containing 0 Na+ and 0 Ca2+ for 100 ms. This was then
followed by a 1 s application of 20 mM caffeine diluted in 0 Na+/0 Ca2+ solution.
Finally, 20 mM caffeine in normal Tyrode was applied for 5 s to determine the rate of
Ca2+ extrusion mediated by NCX.
whilst inhibiting its re-uptake. Field-stimulation was stopped and then 20 mM
caffeine was rapidly applied for 5 seconds using a solenoid-controlled solution
switching device, as described previously by Terracciano & MacLeod (2001).
The protocol was as follows: the superfusate was switched to a 0 Na+/0 Ca2+
solution containing (in mM) LiCl 140; glucose 10; HEPES 10; EGTA 0.75;
MgCl2 1; KOH 6; pH 7.40 for 100 ms. This prevented Ca
2+ extrusion by
NCX. This was followed by a 1 second application of 20 mM caffeine dissolved
in the same 0 Na+/0 Ca2+ solution to open the ryanodine receptors, leading to
complete Ca2+ release from the SR (see Fig.2.10). Finally, 20 mM caffeine in
normal Tyrode was then applied for 5 seconds to determine the rate of Ca2+
extrusion mediated by NCX.
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The peak amplitude of the caffeine-induced transient (Amp
Caffeine
) was
taken as a measure of the total SR Ca2+ content. The amplitude of the imme-
diately preceding 1 Hz transient (Amp
Twitch
) divided by the caffeine-induced
transient was taken as the fractional release. Monoexponential curves were
fitted to the decay phases of the caffeine-induced transient and the preceding
1 Hz twitch transient. Once the decay rate constants (κ) of these monoexpo-
nential curves were calculated the relative contribution of NCX towards Ca2+
removal during diastole was calculated by dividing the decay time constant
(τ) of the caffeine-induced transient by that of the 1 Hz twitch transient, as
described by Maier et al. (2003):
Fractional release =
Amp
Twitch
Amp
Caffeine
(2.2)
Contribution of NCX =
τ
Twitch
τCaffeine
(2.3)
Oﬄine analysis of the caffeine-induced transients was also carried out
using Ionwizard™ software. Only caffeine-induced transients with complete,
singular release were analyzed.
2.11 Measurement of intracellular pH and sodium-
hydrogen exchanger activity
2.11.1 Measurement of intracellular pH
The intracellular pH (pHi) of cardiomyocytes was measured using the pH-sensitive
fluorescent indicator 5-(and-6)-Carboxy-SNARFr-1 (SNARF). Similar to the Ca2+-
sensitivity of indo-1, SNARF shows pH-dependent emission wavelength shift. This
enables the fluorescence intensities at two different wavelengths (typically 580 nm
and 640 nm) to be measured for accurate pH determination, with the ratiometric
property correcting between uneven loading, different cell sizes, and bleaching during
an experiment.
98
Fig. 2.11: Fluorescence emission spectra of 5-(and-6)-Carboxy-SNARF-1 following excitation
at 488 nm in solutions of varying pH. The fluorescence emission at 640 nm increases whilst that
at 580 nm decreases with increasing pH (Taken from “SNARFr pH Indicators”, Molecular
Probesr Product information.)
The AM form of SNARF (Molecular Probes, UK) was dissolved in enzyme so-
lution at 10 µM concentration. Cardiomyocytes were immersed in this solution at
room temperature for 8 minutes, and then allowed to de-esterify for at least 1 hour
before study. They were then plated on a perfusion bath attached to the stage of a
Nikon TE200™ inverted microscope. They were studied with a ×40 oil immersion
objective whilst being superfused with normal Tyrode solution containing 1 mM
Ca2+ at 37 ℃. Light from a Nikonr xenon lamp (Model No¯ LH-M100CB-1) pow-
ered by a Hamamatsur power supply (Model No¯ C6979, Hamamatsu Photonicsr,
Japan) was passed through a 480 nm narrow band-pass optical filter for fluorescent
excitation.
Fluorescent light emitted was split within the microscope light path by means
of a 610 nm dichroic mirror (Model No¯ 610DRLP). The light < 610 nm was then
passed through a 580 nm narrow band-pass optical filter (Model No¯ 580DF30) and
that > 610 nm was passed through a 640 nm filter (Model No¯ 640DF35; both filters
and the dichroic mirror were from Omega Optical Inc.) before detection by two
separate PMTs (Type 9789B, Electron Tubes Ltd.).
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The outputs from the two PMTs were directed to a custom-made analogue signal
ratio amplifier. Immediately before fluorescence acquisition the field of view was
moved to a part of the bath containing no cells (the background). The fluorescence
levels at this background was set to zero by the analogue signal ratio amplifier.
The field of view was then moved back to the cardiomyocyte under study for data
acquisition.
The ratio of the two background-subtracted output signals (F580/640) which was
given out by the ratio amplifier was digitized at 250 Hz by an Axon MiniDigi™
analogue-to-digital converter. The digitized signal was acquired and stored by a
standard PC running Axon pClamp™ software (version 9.2).
2.11.2 Calibration of SNARF in situ
A standard curve plotting the relationship between F580/640 and pHi was gener-
ated using calibration superfusates, as described previously (Lagadic-Gossmann
et al. 1992, Sun et al. 1996). Calibration superfusates of pH 5.5, 7.5, and 9.5,
containing 10 µM nigericin (Sigma-Aldrich, UK) were used (see Table 2.1 for com-
positions). The nigericin permeabilized the cardiomyocytes to allow intracellular
pH to equilibrate with the superfusate, but not to allow the intracellular SNARF
to diffuse away. Readings of F580/640 at pH 5.5, 7.5, and 9.5 were used to plot the
standard curve, allowing subsequent readings to be translated directly to pHi.
2.11.3 Measurement of intracellular buffering capacity and
sodium-hydrogen exchanger activity
Because the changes in pHi in response to an intracellular acid load depend on
intracellular buffering capacity (βi) as well as the ability of the cardiomyocyte to
extrude acid through the sodium-hydrogen exchanger (NHE), βi was derived from
a separate series of experiments. SNARF-loaded cardiomyocytes were superfused
in normal Tyrode solution as above, with added 5-(N -ethyl-N -isopropyl)amiloride
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Table 2.1: Calibration superfusates used for generating the standard curve plotting the
relationship between F580/640 and pHi.
5.5 7.5 9.5
KCl 140 mM 140mM 140 mM
MgCl2 1 mM 1 mM 1 mM
nigericin 10 µM 10 µM 10 µM
MES 20 mM - -
HEPES - 20 mM -
CAPSO - - 20 mM
pH (using NaOH) 5.5 7.5 9.5
Abbreviations: MES: 2-(N -morpholino)ethanesulphonic acid.
HEPES: N -2-hydroxyethylpiperazine-N´-2-ethansulphonic acid.
CAPSO: 3-cyclohexylamino-2-hydroxy-1-propane-sulphonic acid.
(EIPA, Sigma-Aldrich, UK), an inhibitor of NHE (n=3). 0, 5, 10, and 20 mM NH4Cl
was applied to exert varying loads of intracellular acid. The resulting shifts in pHi
measured allowed the deduction of βi, which was estimated to be
βi = −15.6×pHi + 85
2.11.4 Protocol for measurement of resting pHi and NHE
activity
Cardiomyocytes were studied for their resting pHi and NHE activity. For assessing
NHE activity, pHi recovery was measured after subjecting the cardiomyocyte to an
intracellular acid load using the NH4Cl removal technique (Fig.2.12B-E.). This
technique allows delivery of a consistent acid load to the cytoplasm. The acid load
can be varied by changing the extracellular NH4Cl concentrations and/or exposure
time. Furthermore, the extracellular pH remains unaffected during the experiment,
including the recovery phase. For these reasons, the NH4Cl removal technique has
been widely adopted by others in studies of acidosis (Bountra & Vaughan-Jones
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1989, Terracciano & MacLeod 1994).
The technique utilizes the difference between the permeability of cell membranes
to NH3 and NH
+
4 . When a cardiomyocyte is subjected to NH4Cl solution for a
few minutes, NH3, which is uncharged and therefore more permeable to the cell
membrane, enters the cell faster than NH+4 . Once intracellular, NH3 buffers protons
to cause pHi to rise. Subsequently, as NH
+
4 eventually also enters the cell in similar
quantities, pHi returns to normal values. Upon changing the superfusate to one
containing no NH4Cl a large intracellular acidosis is then induced because this time
NH3 leaves the cell faster, leaving NH
+
4 behind which dissociates from protons (for
a review of this mechanism, see Roos & Boron 1981).
Throughout this study cardiomyocytes were superfused with normal Tyrode so-
lution. A bath depth of less than 1 mm was maintained, and free gas exchange was
allowed between cardiomyocytes and the atmosphere. There was no added HCO−3
in the normal Tyrode solution, minimizing the effect of the CO2/HCO
−
3 buffer sys-
tem on pHi. The baseline F580/640, representing resting pHi, was measured during
the initial period of superfusion with normal Tyrode solution. The superfusate
was then changed to that containing 15 nM NH4Cl for 5 minutes (Fig.2.12B,C).
This was followed by a recovery phase in normal Tyrode solution, during which the
cardiomyocyte was allowed to extrude protons via NHE (Fig.2.12D,E). F580/640
was translated to pHi directly using the standard curve obtained using the method
above. Having identified βi it was also possible to measure NHE activity at various
pHi points.
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Fig. 2.12: A. An example trace of SNARF F580/640 ratiometric signal during the NH4Cl
removal protocol. Following measurement of the baseline value for F580/640 15 nM NH4Cl
was applied for 5 minutes. During this time pHi initially increases as NH3 enters the car-
diomyocyte and binds to the free protons (B). As NH+4 then follows the NH3 into the cell pHi
returns to baseline levels (C). During washout with normal Tyrode solution, NH3 leaves the
cardiomyocyte first. This applies an intracellular acid load as NH+4 dissociates into NH3andH
+
(D). Finally, as protons are removed by NHE, pHi recovers to baseline levels (E).
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2.12 Electrophysiological parameters
EC coupling in cardiomyocytes isolated from hearts were further studied using elec-
trophysiological measurements. Whole cell clamping was employed for direct mea-
surements of membrane potentials and currents in intact cardiomyocytes. High-
resistance microelectrodes were used for action potentials (AP) and L-type Ca2+
currents (I Ca,L). The Na
+/Ca2+ exchanger current (INCX) was measured using the
whole cell patch clamping method, employing low-resistance patch pipettes.
As part of these experiments the whole cell membrane capacitance data were
also obtained. Membrane capacitance is a useful measurement of cell surface area,
and the collated data obtained were compared to the cell surface area estimation
made using planimetry (section 2.7).
2.12.1 Measurement of action potentials
The APs of isolated cardiomyocytes were measured using the current clamping
method using high-resistance electrode micropipettes (Fig.2.13). This method en-
ables measurement of fast changes in membrane potentials in intact cells whilst
causing minimal disruption to the composition of the cytoplasm.
Hardware Setup : Cardiomyocytes were superfused with normal Tyrode solu-
tion containing 1 mM Ca2+ at 37 ℃. The bath was attached to a Nikon
Diaphot 200™ inverted microscope which was supported by an air-inflated vi-
bration isolation table (Technical Manufacturing Corpr. Peabody, MA, USA).
A Type-2 Faraday cage (Technical Manufacturing Corpr) was attached to the
table, shielding the microscope setup in order to minimize interference from
external static electrical fields.
Electrode pipettes : High-resistance electrode micropipettes were fabricated from
borosilicate glass tubes of 0.86 mm inner diameter (Harvard Apparatus, UK)
using a microprocessor-controlled Flaming/Brown pipette-pulling machine (Mo-
del P97, Sutter Instruments, CA, USA). Once filled with the pipette-filling
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Fig. 2.13: Schematic view of whole-cell clamping configuration using a high-resistance elec-
trode. The electrode pipette tip has impaled the cardiomyocyte membrane, forming a high-
resistance seal. The narrow bore of the electrode tip allows negligible dialysis between the
pipette-filling solution (coloured in grey) and the cytoplasm during the experiment, whilst
allowing voltage and current clamping. One AgCl electrode wire is placed inside the pipette.
An AgCl pellet electrode is placed in the superfusate bath to complete the circuit.
solution, the pipette resistances were 20 ∼ 30 MΩ. The pipette-filling solution
contained (in mM) KCl 2000, HEPES 5, EGTA 0.1; pH 7.2 using KOH.
Circuit : Pipettes were mounted onto an Axon HS-2A headstage (Axon Instru-
ments) which was manœvered by a Burleigh PCS-5000™ piezoelectric micro-
manipulator (EXFO Lifesciences, Ontario, Canada). An AgCl pellet ground
electrode was placed in the same bath and connected to the headstage to com-
plete the circuit. The headstage was controlled by an Axon Axoclamp 2B™
amplifier (Axon Instruments) which communicated with a standard PC via an
Axon Digidata 1200™ analogue-to-digital conversion board. The PC utilized
pClamp™ software (version 8.2) for running current-clamp protocols whilst
acquiring and recording data.
Entry into the cardiomyocyte: Once the configuration above was prepared the
micropipette tip was inserted into the bath superfusate whilst applying a
100 Hz, 10 mV square wave. The potential difference between the electrodes
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Fig. 2.14: Example trace of a rat ventricular myocyte action potential elicited from a 1 ms
pulse. APD50 and APD90 were measured from the upstroke of the stimulation pulse.
(pipette offset) was then calibrated to zero. The pipette resistance and pipette
capacitance were compensated. The pipette tip was then inserted into the car-
diomyocyte by the micromanipulator under visual guidance.
Amplifier configuration : Action potentials (AP) were measured in discontinuous
current-clamp (DCC) mode. In DCC mode the clamping current is passed
cyclically through the microelectrode. After all transient voltages due to this
current passing have decayed completely, the microelectrode tip records the
membrane voltage, which is memorized by a “sample-and-hold” circuit. A
new cycle of clamping current application is then started again (Brennecke &
Lindemann 1974a, Finkel & Redman 1984). Compared to alternative modes
of sampling DCC mode may increase the measurement noise but offers the
advantage of recording membrane potentials independently of voltage drops
across the microelectrode. Furthermore, DCC mode is also more tolerant of
small changes in pipette resistance that may occur during experiments. In or-
der to maintain the fastest dynamic response and smallest steady-state error,
the highest cycling frequency and highest open-loop gain that would allow sta-
ble maintenance of clamp were chosen. In these AP measurement experiments
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the frequency of cycling between current clamping and voltage sampling was
usually 6 ∼ 7 kHz.
Acquisition protocol and data analysis : Cardiomyocytes were stimulated at
1, 3, and 5 Hz using a 1 ms, 1.2 ∼ 1.4 nA pulse. Data were sampled at 10 kHz
for recording. The recorded APs were analyzed oﬄine using pClamp™ software
(version 9.0). Approximately 20 ∼ 30 representative traces were averaged with
reference to the stimulation pulse, and the time to 50% repolarization (APD50)
and time to 90% repolarization (APD90) from the stimulation pulse were taken
as measures of the AP duration for comparison between groups (Fig.2.14).
2.12.2 Measurement of the L-type Ca2+ current
Hardware setup and amplifier configuration : L-type Ca2+ currents (I Ca,L)
were measured using the identical hardware configuration as for AP measure-
ment, but the amplifier was set to discontinuous single electrode voltage-clamp
mode (dSEVC). In this mode the amplifier continuously cycles between pass-
ing the clamping currents and measuring voltages. The amount of pulsed
clamping current is proportional to the measured deviation of the membrane
voltage from the command voltage (Brennecke & Lindemann 1974a, Brennecke
& Lindemann 1974b). Within each cycle, the voltage drop across the electrode
is allowed to decay completely before each membrane potential measurement.
This gives dSEVC its main advantage, that actual membrane voltages are
measured rather than command voltage. As well as eliminating errors arising
due to electrode series resistance dSEVC enables accurate control of membrane
voltages when large clamping currents are required. The main disadvantage
of dSEVC is the inherently greater noise, making dSEVC only suitable for
measuring large membrane currents, such as I Ca,L. In this study the cycling
frequency was generally 6 ∼ 7 kHz.
Cell membrane capacitance measurement : The cell membrane acts like an
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electrical insulator between two conducting media, the superfusate and the
cytoplasm. This constitutes an electrical capacitor, whereby the two ionic
media are the two conducting plates and the cell membrane is the dielectric.
The capacitance of the membrane, Cm, can be approximated by the following
equation :
Cm ≃ ε ·
A
d
(2.4)
where A = Cell Membrane Area, d = Cell Membrane Thickness and
ε = permittivity of the membrane. The equation is a good approximation
when A ≫ d. Because ε and d can be assumed to be constant under most
physiological conditions, Cm is directly proportional to the membrane area.
In these experiments Cm was measured after establishing the stable
whole cell configuration by means of a capacitative surge technique (Fenwick
et al. 1982): a 10 mV step was applied at ∼ 100 Hz and a monoexponential
curve fitted to the decay phase of the resulting membrane current trace. Once
the decay time constant (τ) of this curve was determined Cm was calculated
by :
Cm =
I0 · τ
Vstep
(2.5)
where I0 is the membrane current at time = 0, and Vstep is 10 mV (Fig.2.15).
The Cm values obtained were used to normalize currents measured from
cardiomyocytes of different sizes (i.e. the densities of measured currents were
compared between heart groups). The value of Cm itself was also compared
between heart groups, as a measure of hypertrophy.
Protocol for measuring current density : Current-voltage (I–V) relationships
were built using 450 ms depolarization steps from a holding potential of
−40 mV (range −45 mV to +50 mV, in 5 mV increments, Fig. 2.16A). Hol-
ding the membrane potential at −40 mV, rather than at the normal resting
membrane potential of −75 mV enabled activation of I Ca,L without contami-
nation by the voltage-gated sodium channel current. The protocol steps were
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Fig. 2.15: Measurement of cell membrane capacitance using the capacitative surge
technique. Abbreviations: Vm membrane voltage; Vstep voltage step, which was usu-
ally 10 mV; Im membrane current; I0 initial membrane current, at t = 0; Qm charge
held by membrane, which is represented by the area under the curve; τ time constant
of the monoexponential curve fitted to the decay phase of the current trace.
applied at 1 Hz. I Ca,L was taken to be the peak current elicited following de-
polarization minus the maintained current (Fig. 2.16B), and was normalized
to the whole cell capacitance for comparison between groups.
In previous experiments conducted in the laboratory using this technique
it was possible to abolish the current measured in Fig.2.16B by acute applica-
tion of 10 mM nifedipine, a specific antagonist of the L-type Ca2+ channel. On
the other hand application of 4-aminopyridine (4–AP), an antagonist of the
K+ channel, had no effect. These observations confirmed that the measured
currents were attributable to I Ca,L.
Protocol for measuring time- and Ca2+-dependent inactivation of I Ca,L:
To study time- and Ca2+-dependent inactivation of I Ca,L a two-exponential de-
cay of the current at 0 mV was calculated (protocol step shown in Fig. 2.16C).
This particular step was used because it usually activated the largest cur-
rent. The fast and slow components of I Ca,L inactivation were then identi-
fied for calculation of their respective decay rate constants (τfast and τslow,
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(Fig. 2.16D)).
Protocol for voltage-dependent activation and inactivation of I Ca,L: The
voltage-dependent steady-state activation profile (G/G
MAX
) was derived from
the same multiple depolarization step protocol used for obtaining the I–V
relationships (Fig. 2.16A). The command voltage step which elicited the
maximum I Ca,L was initially identified. The fraction of this maximum I Ca,L
elicited by the preceding command steps was then calculated.
The steady-state inactivation (F/F
MAX
) profile of the I Ca,L was studied
using a double-pulse protocol, as previously described (Keung et al. 1991, Lee
et al. 1985). Inactivating prepulses of 200 ms duration were applied from a
holding potential of −50 mV, after which the membrane potential was held at
−40 mV for 5 ms, and then the test pulse applied (Fig. 2.16E). As the initial
pulse was gradually increased the I Ca,L elicited by the second (test) pulse was
seen to gradually decrease, until it was completely inhibited, usually at 0 or
+5 mV. Boltzmann curves were fitted to the mean data points to obtain the
profiles of G/G
MAX
and F/F
MAX
. All I Ca,L data were analyzed oﬄine using
pClamp™ software (version 9.0).
2.12.3 Measurement of the Na+/Ca2+ exchanger current den-
sity
The Na+/Ca2+ exchanger currents (INCX) of cardiomyocytes were measured with
the whole-cell patch-clamping method, originally described by Hamill et al. (1981).
Compared to the method employing high-resistance microelectrodes which was used
to measure APs and I Ca,L, this method has the advantage of lower electrical access
resistance. The signals recorded are less affected by interference noise, enabling mea-
surements of small currents (for a review on whole-cell patch-clamping see Sakmann
& Neher 1984). Unlike the high-resistance microelectrodes the large bore of the
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Fig. 2.16: A. Protocol for measurement of I Ca,L density, I Ca,L time-dependent inactivation,
and G/GMAX . Voltage steps of 450 ms duration were applied from a holding potential of
−40 mV. B. The resulting current trace from A. I Ca,L was taken to be the difference between
the peak inward current and the steady-state current at the end of the 450 ms depolarization
step. C. Command step from −40 mV to 0 mV was used to activate the maximum I Ca,L,
shown in (D). The two-exponential decay of this current was studied for identification of
τfast and τslow. E. Double-pulse protocol for measurement of F/FMAX . Variable inactivating
prepulse steps of 200 ms duration were applied from −50 mV. The membrane potential was
then held at −40 mV for 5 ms, and before applying the test pulse. F. The resulting current
trace from E.
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Fig. 2.17: Schematic view of whole-cell patch clamping configuration. The electrode pipette
is first “patched” onto the cardiomyocyte membrane, forming a high-resistance (> 1 GΩ) seal.
The portion of cell membrane enclosed within the pipette bore is then carefully ruptured by
a combination of suction and application of a brief voltage pulse to allow access. The large
bore of patch electrodes (∼ 1 µm) allows full dialysis between the pipette-filling solution and
the cytoplasm (coloured in grey). One AgCl electrode wire is placed inside the pipette and
an AgCl pellet electrode is placed in the superfusate bath to complete the circuit.
patch pipette tip (∼ 1 µm) enables the pipette-filling solution to dialyze the cy-
toplasm of the cell under study within a few minutes. Because the volume of the
pipette is many orders of magnitude larger than that of the cardiomyocyte, the
composition of the pipette-filling solution effectively determines the intracellular
environment conditions (Fig.2.17).
Hardware Setup: Cardiomyocytes were placed in a bath on the stage of a Nikon
TE2000-U™ inverted microscope. They were then superfused at 37℃ with K+-
free solution containing (in mM) NaCl 140; HEPES 10; glucose 10; MgCl2 1;
CaCl2 1; CsCl 6; pH 7.4. In addition, the solution contained 0.01 mM stro-
phanthidin (Sigma-Aldrich, UK). Together with the lack of K+ in the super-
fusate, this eliminated the current attributable to Na+/K+ ATPase. The su-
perfusate also contained 0.01 mM nifedipine (Sigma-Aldrich, UK) to eliminate
contaminating I Ca,L.
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Electrode pipettes: The low-resistance electrode pipettes were fabricated from
borosilicate glass tubes of 0.86 mm inner diameter. The same Flaming-Brown
pipette-pulling machine was used as for the high-resistance pipettes, but glass
tubes were heated less and pulled in five stages to give pipettes with much
wider, fire-polished tips. Once filled with the pipette-filling solution, the
pipette resistances were 2.3 ± 0.1 MΩ. The pipette-filling solution contained
(in mM) CsCl 45; HEPES 20; MgCl2 11; Na2ATP 10; CsOH 100; EGTA 50;
CaCO3 25; pH 7.2 with CsOH. The high concentrations of Ca
2+-EGTA were
added to buffer the [Ca2+]i during application of the protocol. [Ca
2+]i was
calculated to be ∼ 250 nM, as previously described by Quinn et al. (2003).
Circuit: Pipettes were held by an Axon pipette holder (model HL-U) which had
a side-vent connected to a 1 ml syringe via a three-way tap for application of
air suction as required during the patching process. The pipette holder was
attached to an Axon CV-7A headstage, which was manœuvered by a Burleigh
PCS-5000™ micromanipulator. A silver chloride pellet ground electrode was
placed in the same bath and connected to the headstage.
Entry into the cardiomyocyte: The patch pipette tip was inserted into the su-
perfusate and the pipette offset was nulled. A 100 Hz, 10 mV square wave
was continuously applied and the current induced was monitored continuously
on an oscilloscope. The pipette tip was manœvered onto the cardiomyocyte
membrane whilst monitoring visually and also via the oscilloscope. A small
amount of suction was applied to the side-vent of the the pipette holder to es-
tablish a high-resistance (> 1 GΩ) seal. The pipette was then voltage clamped
at −40 mV, which approximates the anticipated resting membrane potential,
before rupturing the portion of membrane within the pipette tip using a com-
bination of suction and application of a brief voltage transient (“zap”) to
allow access into the cytoplasm. After achieving the whole-cell configura-
tion, a period of at least 4 minutes was allowed for complete dialysis of the
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pipette-filling solution into the cardiomyocyte cytoplasm. Following dialysis,
the resting membrane potential was usually in the region of −35 mV, and the
access resistance was 3 ∼ 6 MΩ.
Amplifier configuration: With the low-resistance access obtained above, it was
possible to use continuous single electrode voltage-clamp (cSEVC) mode on a
Multiclamp 700A™ amplifier (Axon Instruments). Here, the membrane current
is continuously recorded whilst the voltage at the top of the patch pipette is
simply clamped to dynamically changing command voltages by means of a
feedback amplifier. Voltages acquired using this mode become meaningful only
when the current-induced voltage drop across the pipette is small (i.e. when
the pipette resistance is low). Compared to dSEVC, cSEVC of a whole-cell
patch gives superior signal-to-noise ratio, making it ideal for recording small
whole cell currents.
Acquisition protocol and data analysis: From a holding potential of −40 mV,
a 3 second descending ramp was applied from +80 mV to −120 mV (see
Fig.2.18A). The ramp was applied repeatedly once every 10 seconds until
a steady-state was reached, and then acquired 5 times to yield an average
current trace for analysis. The superfusate was then acutely changed to that
with 5 mM Ni2+ added by means of a custom made solenoid-controlled solution
switcher device. Ni2+ at this concentration is known to block all NCX activity
(Brommundt & Kavaler 1987, Kimura et al. 1987). Further current traces were
acquired once a new steady state was reached (Fig.2.18B). INCX was taken as
the 5 mM Ni2+-sensitive component of the active current (Fig.2.18C), which
was normalized to the whole cell capacitance (measured using the method
described in section 2.12.2). INCX was calculated for various command volt-
age points to obtain the current-voltage (I–V) relationship, which was subse-
quently used for cross-group comparisons. Data were analyzed oﬄine using
pClamp™ software (version 9.0).
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Fig. 2.18: An example NCX current trace. A. The 3 second descending ramp protocol, from
+80 mV to −120 mV. B. Whole-cell currents measured in the presence and absence of 5 mM
Ni2+. C. Ni2+-subtracted current, which is taken as I NCX .
2.13 Ca2+ sparks study
The Ca2+-sensitive fluorescent dye, fluo-4 (Molecular Probes, UK) was used to mon-
itor localized changes in [Ca2+]i. The most important properties of fluo-4 include
an absorption spectrum compatible with excitation at 488 nm by an argon-ion laser
source and a large fluorescence intensity increase in response to Ca2+ binding (i.e. a
wide dynamic range). For this reason, fluo-4 has been widely used in Ca2+ sparks
detection studies. On the other hand, fluo-4 is a single excitation, single emission
dye. It does not have the ratiometric property of indo-1 or fura-2, so self-correction
between cells of different sizes and uneven loading is unavailable.
fluo-4 loading: Aliquots of cardiomyocytes were incubated with the AM prepara-
tion of fluo-4 (10 µM in enzyme solution) at room temperature for 20 mins.
They were then allowed to de-esterify for at least 30 mins prior to use. Car-
diomyocytes were kept in the dark throughout to minimize photobleaching.
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Hardware setup: Cardiomyocytes were placed on a bath mounted on the stage
of a Zeiss Axiovert™ microscope with an LSM 510 confocal attachment and
superfused with normal Tyrode solution containing 1 mM Ca2+ at 37 ℃. The
bath contents were field-stimulated when required using platinum wires and
a custom-made bipolar stimulator. Cardiomyocytes were observed through
a Zeiss EC Plan-NeoFluar™ ×40 oil-immersion objective (numerical aperture
= 1.3). Fluo-4 was excited using the 488 nm line of an argon laser (Zeiss
LSM 510 Laser module) and the emitted fluorescence was collected through a
505 nm long-pass filter.
Protocol: After a period of steady-state 1 Hz field-stimulation a period of 30 s
quiescence was allowed to pass before line scans (x-t scans) were collected. Up
to 30,000 lines ranging from 50 ∼ 173 µm were scanned at speeds between
546 ∼ 964 µs. Acquired x-t scans were exported as high-resolution tagged
image file format (TIFF) digital files.
Analysis: Analysis of the collected TIFF image files was performed oﬄine using
custom scripts written by Dr. Mark A. Stagg (Laboratory of Cell Electro-
physiology, Harefield Heart Science Centre) to run in Matlabr R2006b (Math-
Works Inc. MA, USA) following the algorithm for automatic Ca2+ spark detec-
tion described by Cheng et al. (1999). Detection criteria for Ca2+ sparks were
set at 3.8 times the standard deviation above the mean background noise level
(baseline, F0). The frequency of Ca
2+ spark occurrence (CaSpF) was obtained
from the line scans. The amplitude of Ca2+ sparks was defined as the peak
fluorescence divided by the background fluorescence (F/F0). Further mor-
phometric analysis of Ca2+ sparks elucidated the full-width at half-maximal
(FWHM) and full-duration at half-maximal (FDHM) parameters (Fig.2.20).
From these parameters, the leak of Ca2+ from the SR was calculated using the
following formula, as previously described by Maier et al. (2003):
SR Ca2+ Leak = CaSpF ×Amplitude× FWHM × FDHM (2.6)
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From the same line scans it was also possible to determine the frequency of
dyssynchronous Ca2+ cycling (i.e. Ca2+ ‘waves’, Fig.2.21).
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Fig. 2.19: Example line scan image acquired from a cardiomyocyte showing Ca2+ sparks.
In some instances the analysis algorithm recognized a single spark as two or more. In this
example sparks No¯ 2 and 3 are actually one spark. Because of cases such as these, human
verification of every line scan image acquired was necessary.
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Fig. 2.20: Surface plot image (above) derived from a line scan image (below) of a typical
Ca2+ spark. A cross section of the Ca2+ spark in this surface plot was taken at half of its peak
F/F0 (represented as the ellipse). The width and duration of this cross section were taken as
the FWHM and FDHM of the Ca2+ spark, respectively.
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Fig. 2.21: Example line scan image acquired from a cardiomyocyte showing Ca2+ waves in
addition to numerous Ca2+ sparks.
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2.14 Cell culture on glass-bottom dishes
Cardiomyocytes were isolated from rat hearts using methods described in section 2.6
on page 87. They were then rinsed with Dulbecco’s modified Eagle’s medium
(DMEM) and counted using a standard hæmocytometer. Cardiomyocytes were then
plated onto sterile 35 mm glass-bottom culture dishes (Fig.2.22A, glass thickness,
No¯ 1.5. MatTek Corp, Ashland, MA, USA). The glass-bottom dishes were pre-coated
with 10 µl of 1 mg/ml laminin solution to aid cardiomyocyte adhesion. Plating
density was 5,000 rod-shaped cells per dish. This provided adequate numbers of
cardiomyocytes at the end of the culture period, but at the same time individual
cardiomyocytes were sufficiently separated from one another to enable fluorescence
measurement studies without nearby interference. The glass-bottom dishes were in-
cubated at 37 ℃, 100% humidity, 5% CO2 for 48 hours. Each glass-bottom culture
dish contained 2 ml of rat ventricular myocyte culture medium, which contained
DMEM 67%, Medium-199 16%, horse serum 10%, fœtal bovine serum 4%, 1 M
HEPES 2%, penicillin/streptomycin 1%.
In some experiments cardiomyocytes were physically separated from other cell
types by means of a porous polyester membrane (“Transwell™”, Corning Incopo-
rated, NY, USA. Pore size 0.4 µm, Fig.2.22C). This setup allowed diffusion of any
soluble substances secreted between the different cell populations whilst preventing
direct physical contact.
2.15 Analysis of co-culture supernates using the
rat cytokine antibody array
The culture media that were bathing cardiomyocytes were analyzed for active pa-
racrine substances. At the end of the 48 hour culture period, the resulting culture
media were collected and spun at 1000 rpm. The supernates were stored in 2 ml
Eppendorfr tubes at −80 ℃. At the time of analysis the samples were thawed
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Fig. 2.22: A. A 35 mm glass bottom culture dish (with lid). The bottom of the dish
consisted of a No¯ 1.5 glass cover slip, enabling light microscopy and fluorescence acquisition
from cells. B. Petri dish insert for superfusion of the contents of a glass bottom culture dish.
C. Separation of cardiomyocytes from other cell types during culture using a Transwellr.
at room temperature and gently agitated. They were then individually filtered
using syringe-filters (Pore size 0.2 µm, “Minisart plus”, Vivasciencer, Hannover,
Germany).
Supernate samples were initially analyzed using the rat cytokine antibody array
(“Type-I”, RayBiotech Inc. Norcross, GA, USA). The array provides a sensitive
method for simultaneous detection of multiple cytokine expression levels in culture
media, sera or cell lysates (Huang et al. 2001, Huang 2003). Details of the cytokines
that could be detected using the array are illustrated in Table. 2.2. The basic
working principle of the array and experimental protocol are illustrated in Fig.2.23
and can be described as follows:
1. The arrays are available with pre-determined quantities of primary antibo-
dies adhered onto nitrocellulose sheets. These were initially blocked using the
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supplied blocking buffer to prevent non-specific protein binding.
2. Blocked arrays were rinsed using the wash buffer provided and then exposed to
undiluted culture media samples for 1 hour at room temperature. The arrays
were gently rocked using a rocking table. During this period, any cytokines
present in the culture media bound onto the array via their specific primary
antibodies.
3. Arrays were rinsed again and then immersed in the supplied biotinylated sec-
ondary antibody mixture for 2 hours. During this period, the biotinylated
secondary antibodies bound onto the array via their specific cytokines.
4. Arrays were rinsed and then streptavidin conjugated to horse radish peroxidase
(HRP) was applied for 2 hours, allowing its binding onto the biotin tag.
5. Arrays were rinsed and laid out on a glass sheet. Enhanced chemiluminescence
(ECL) substrate mixture was applied onto the arrays, which were then covered
with clear polyvinylidene chloride film (SaranWrap™). ECL is a commonly
used, highly sensitive technique for a variety of detection assays in biology.
In the presence of HRP and hydrogen peroxide a luminol-based substrate is
oxidized to produce an excited (“triplet”) carbonyl. As this compound decays
to the singlet carbonyl it emits light.
Emitted chemiluminescence was detected by direct exposure to high
performance autoradiography film (Hyperfilm™, Amersham Biosciences, Little
Chalfont, UK), for variable periods of 1 ∼ 60 seconds.
6. Developed radiography film signals were analyzed using optical densitometry.
Films were scanned at 600 dots per inch resolution using an Agfa Arius-II
scanner connected to a standard PC running Quantity-One™ software (version
4.6.1. Bio-Rad Laboratories, Hercules, CA, USA.). Optical densities of the
scanned signals were measured using the same Quantity-One™ software. The
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optical density signal level of each dot was normalized to the local background
level.
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Table 2.2: RayBio rat antibody array I.
A B C D E F G H
1 Pos Pos Neg Neg CINC–2 CINC–3 CNTF Fractalkine
2 Pos Pos Neg Neg CINC–2 CINC–3 CNTF Fractalkine
3 GM–CSF IFN–γ IL–1α IL–1β IL–4 IL–6 IL–10 LIX
4 GM–CSF IFN–γ IL–1α IL–1β IL–4 IL–6 IL–10 LIX
5 Leptin MCP–1 MIP–3α β-NGF TIMP–1 TNF-α VEGF BLANK
6 Leptin MCP–1 MIP–3α β-NGF TIMP–1 TNF-α VEGF BLANK
7 BLANK BLANK BLANK BLANK BLANK BLANK BLANK Pos
8 BLANK BLANK BLANK BLANK BLANK BLANK BLANK Pos
Abbreviations: Pos: positive control. Neg: negative control. CINC: cytokine-induced neutrophil chemoattractant.
CNTF: ciliary neurotrophic factor. GM-CSF: granulocyte colony stimulating factor. IFN: interferon. IL: interleukin.
LIX: lipopolysaccharide-induced chemokine. MCP: monocyte chemoattractant protein. MIP: macrophage inflamma-
tory protein. NGF: nerve growth factor. TIMP: tissue inhibitor of metalloproteinase. TNF: tumour necrosis factor.
VEGF: vascular endothelial growth factor.
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1° Abalready on array
Supernatant
Sample (1 Hour)
2° Ab Biotinylated
Mixture (2 hours)
Labeled
Streptavidin
(2 hours)
Enhanced
chemiluminescence
detection buffers
B
A
D
C
E Chemiluminescence
detection
Fig. 2.23: Detection of cytokines in culture media using the rat cytokine antibody array.
A. The array of primary antibodies adhered on nitrocellulose sheets is blocked and then
immersed in the undiluted culture medium sample. B. The array is rinsed and the mixture
of biotinylated secondary antibodies is applied. C. Application of streptavidin conjugated to
horse radish peroxidase for 2 hours. D. Enhanced chemiluminescence (ECL) reagent mixture
is added to the array. E. Chemiluminescence is detected using autoradiography film.
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2.16 Enzyme-linked immunosorbent assay of in-
sulin-like growth factor-1 levels in co-culture
supernates
Concentrations of insulin-like growth factor-1 (IGF–1) in the culture media were
measured using enzyme-linked immunosorbent assay (ELISA). ELISA is a biochem-
ical technique where a specific antibody immobilized on a solid support is used
to detect antigen in a fluid sample (Engvall & Perlman 1971, van Weemen &
Schuurs 1971). The basic principle of ELISA and details of experiment protocol
can be described as follows:
1. Samples were prepared as for the rat cytokine antibody array (previous sec-
tion) and used without further processing or dilution. The assay was performed
using a Quantikiner ELISA kit (type “MG100”, R & D Systems, Abingdon,
UK). An IGF–1 standard was prepared by serial dilution of the provided sam-
ple. The standard concentration range was 0 ∼ 2000 pg/ml. A positive control
was also prepared from the separately provided sample. The culture media
samples were thawed and syringe-filtered, as described for the cytokine anti-
body array.
2. A monoclonal capture antibody for IGF–1 was pre-coated onto a 96-well po-
lystyrene microplate. The samples and IGF–1 standard were added into the
plate wells. The plate was then shaken using an orbital shaker for 2 hours at
room temperature. During this period any IGF–1 present in the culture media
were captured onto the well surface via the antibody in a concentration-de-
pendent manner.
3. After rinsing with the provided rinse buffer HRP-conjugated polyclonal an-
tibodies specific for IGF–1 was added to the wells and the plate was shaken
again for 2 hours. During this period the HRP conjugated to the secondary
antibody bound onto the wells via the immobilized IGF–1 to saturation.
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4. The wells were rinsed again. The substrate mixture of hydrogen peroxide
added to 3,3´,5,5´-Tetramethylbenzidine (TMB, the chromagen) was pipetted
into the wells. The plate was incubated in the dark at room temperature for
30 minutes. During this period the HRP catalyzes the oxidation of TMB from
a colourless compound into one that emits yellow light.
5. The oxidation reaction was stopped and TMB stabilized by adding 1 M hy-
drochloric acid solution. The optical density of each well was then mea-
sured using a µQuant™microplate reader (Bio-Tekr Instruments Inc. Vermont,
USA.) operated by a standard PC running KC-Junior™ software (version 1.4.1.
Bio-Tekr Instruments Inc.). The reading wavelength was 450 nm with wave-
length correction set to 570 nm. The KC-Junior™ software was able to fit
a line to the standard, against which concentrations of IGF–1 in the culture
media samples were read.
2.17 Statistical analyses
The results in the following chapters are expressed as mean ± standard error of the
mean (S.E.M.) of n observations. Statistical analyses within groups, such as before-
after comparisons of parameters within the same subject, were performed using
paired Student’s t-tests. Statistical comparisons between groups were performed
using one-way analysis of variance (ANOVA) and post hoc testing using Newman-
Keul’s multiple comparison test on Prism™ software (Version 4, Graphpad Software
Inc. CA, USA).
2.18 Solutions
0 Na+/0 Ca2+ solution : (in Milli-Q™water, in mM) LiCl 140; glucose 10; HEPES
10; EGTA 0.75; MgCl2 1; KOH 6; pH 7.40 using LiOH
55% percoll : 55% percoll (1.130 g/ml), 45% HBSS
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70% percoll : 70% percoll (1.130 g/ml), 30% HBSS
enzyme buffer : (in AnalaR water, in mM) NaCl 120; KCl 5.4; CaCl2 0.2; MgSO4 5;
Na+-pyruvate 5; glucose 20; taurine 20; HEPES 10; pH 7.4 using NaOH
enzyme solution : collagenase (Worthington, USA. 1 mg/ml of Type-I, 280 u/mg)
and hyaluronidase (Sigma-Aldrich, UK. 0.6 mg/ml of 999 u/mg) dissolved in
enzyme buffer, above
K+-free solution for measurement of I NCX : (in Milli-Q™ water,in mM) NaCl
140; HEPES 10; glucose 10; MgCl2 1; CaCl2 1; CsCl 6; strophanthidin 0.01,
nifedipine 0.01, pH 7.4 using NaOH
low-Ca2+ solution : (in AnalaR water, in mM) NaCl 120; KCl 5.4; CaCl2 0.045;
MgSO4 5; Na
+-pyruvate 5; glucose 20; taurine 20; HEPES 10; nitrilotriacetic
acid 5; pH 6.96 using NaOH
normal Tyrode solution : (in Milli-Q™ water, in mM) NaCl 140; KCl 6; glu-
cose 10; MgCl 1; CaCl2 1; HEPES 10; pH 7.4 using NaOH
pipette-filling solution for measurement of AP and I Ca,L : (in Milli-Q™ wa-
ter, in mM) KCl 2000, HEPES 5, EGTA 0.1; pH 7.2 using KOH
pipette-filling solution for measurement of I NCX : (in Milli-Q™ water,in mM)
CsCl 45; HEPES 20; MgCl2 11; Na2ATP 10; CsOH 100; EGTA 50; CaCO3
25; pH 7.2 using CsOH ([Ca2+]i calculated to be ∼ 250 nM)
rat ventricular myocyte culture medium : DMEM 67%; Medium-199 16%; horse
serum 10%; fœtal bovine serum 4%; 1 M HEPES 2%; penicillin/streptomycin 1%
skeletal myoblast differation medium : 98% DMEM, 1% horse serum, 1% pe-
nicillin/streptomycin
skeletal myoblast plating medium : 88.5% DMEM, 10% horse serum, 0.5% chick
embryo extract, 1% penicillin/streptomycin
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skeletal myoblast proliferation medium : 68.5% DMEM, 20% fœtal bovine se-
rum, 10% horse serum, 0.5% chick embryo extract, 1% penicillin/streptomycin,
5 ng/ml bFGF
2.19 Suppliers
Animals, equipment, and materials were purchased from the following suppliers.
Chemicals were of the highest grade purity commercially available.
adult female Sprague-Dawley rats : Harlan, UK
adult male GFP+ Sprague-Dawley rats : Rat Resource & Research Center, MO,
USA
bFGF : Invitrogen, UK
CGP–20712A : Sigma-Aldrich, UK
chick embryo extract : Sera Labs, UK
clenbuterol : Sigma-Aldrich, UK
collagenase (type 1) : Sigma-Aldrich, UK
collagenase (type-2) : Worthington, USA
CsCl : Sigma-Aldrich, UK
DMEM : Gibco, UK
EIPA : Sigma-Aldrich, UK
EGTA : Sigma-Aldrich, UK
fenoterol : Sigma-Aldrich, UK
fœtal bovine serum (heat inactivated) : Gibco, UK
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HBSS (×10 stock) : Sigma-Aldrich, UK
horse serum (heat inactivated) : Gibco, UK
hyaluronidase : Sigma-Aldrich, UK
isoflurane : Schering-Plough Animal Health, UK
isoproterenol : Sigma-Aldrich, UK
laminin : Sigma-Aldrich, UK
Matrigel™ : Becton-Dickinson, UK
medical oxygen (100%) : BOC, UK
NiCl2 : Sigma-Aldrich, UK
nifedipine : Sigma-Aldrich, UK
nigericin : Sigma-Aldrich, UK
nitrilotriacetic acid : Sigma-Aldrich, UK
penicillin/streptomycin : Sigma-Aldrich, UK
Percoll™ : GE Healthcare, UK
salbutamol : Sigma-Aldrich, UK
strophanthidin : Sigma-Aldrich, UK
taurine : Sigma-Aldrich, UK
all other chemicals : VWR international, UK
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Chapter 3
Effects of cell transplantation on
the properties of recipient
cardiomyocytes in vivo
In this chapter the effects of transplantation of either bone marrow mononuclear cells
or skeletal myoblasts on the properties of recipient ventricular myocytes in vivo are
described. Myocardial infarction was induced in the rat heart. Once chronic heart
failure had established, cell transplantation was performed. After the transplanted
cells were allowed a period of time to exert their effects, the whole heart function was
assessed and cardiomyocytes were isolated from the left ventricle to be characterized
in detail.
3.1 Materials & Methods
Myocardial infarction was induced by coronary artery ligation, as described in sec-
tion 2.1 on page 79. A period of three weeks was allowed to pass for ventricular
remodeling to occur and the severity of left ventricular dysfunction was assessed us-
ing echocardiography. Animals were then divided into four groups for cell injection,
as below (Fig.3.1):
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• Normal : Normal heart controls. These animals were subjected to SHAM
operation, and subsequently received PBS injection
• Heart Failure (HF): those that received coronary ligation, and subsequently
received PBS injection
• Bone marrow (BM): those that received coronary ligation, and subsequently
received bone marrow mononuclear cell injection
• Skeletal Myoblast (SK): those that received coronary ligation, and subse-
quently received skeletal myoblast injection
The animals in the bottom three groups were randomized by minimization fol-
lowing echocardiography at three weeks. This was to ensure that there was no
significant difference between the heart function of the rats in these three groups
before any injection. After randomization cell injections were performed using me-
thods described in section 2.4 on page 85.
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Normal HF BM Skeletal
PBS
5 x 106
Skeletal
Myoblasts
107 Bone 
Marrow 
Mononuclear
Cells
PBS
Coronary
Ligation
SHAM
Echocardiography 
and cell injection 
after 3 weeks
Repeat
Echocardiography
and cell isolation 
after further 4 weeks
Fig. 3.1: The main protocol for studying the effects of cell transplantation in vivo. After either SHAM operation or coronary ligation, three weeks
were allowed to pass before animals were studied using echocardiography. Animals were then randomized to receive PBS, bone marrow mononuclear
cells, or skeletal myoblasts. After a further four weeks, the animals were studied by echocardiography again and cell isolation was performed.
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3.2 Results : Development of heart failure follow-
ing coronary artery ligation
Following the protocol described in section 2.1 it was possible to induce myocardial
infarction in a consistent manner. The appearance of the LV changed within a few
seconds after ligation, confirming correct application of suture. The 24 hour mortal-
ity following ligation was 26/132 (∼ 20%). Despite the use of sterilized instruments
and aseptic techniques 2/106 animals (∼ 1.9%) developed deep infection within the
operative site. These animals were sacrificed and their hearts were discarded without
study.
During injection of either PBS or cells at three weeks, the maturation of the
infarct scars was clearly apparent. Echocardiography revealed akinetic anterior LV
segments (seen in M-Mode in Fig.3.2). The presence of full-thickness infarcts was
further confirmed at a later time, when the hearts were harvested for cell isolation:
after perfusion of the coronary arteries with enzyme solution the infarct scar was
inspected from both outside and inside the ventricle and discarded (as described on
page 88). The remaining ventricular tissue was then cut into small pieces before
shaking in enzyme solution for 5 minutes to isolate cardiomyocytes.
Echocardiography revealed that the LV end-diastolic dimensions of failing hearts
were dilated compared to normal hearts (70.1±2.2 mm2 vs 46.9±1.9 mm2, p < 0.001
by unpaired t-test). The mean ejection fraction (EF) of failing hearts, also derived
from echocardiography, was 35.3 ± 0.8%. This is in contrast to the EF of normal
hearts, which was 76.2 ± 1.2% (p < 0.001). Despite having dilated left ventricles
with low EF, the rats which had infarcted hearts showed no symptoms of heart
failure. Although 20% of the animals died during the first 24 hours, the surviving
animals showed no peripheral œdema, behavioural withdrawal, shortness of breath,
or failure to thrive. During harvest of the hearts abdominal cavities were opened and
the livers were also examined macroscopically. No significant pigmentation about
the central veins of the liver lobules (“nutmeg liver”) was noted. There was also no
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significant abnormal accumulation of ascites within the peritoneum.
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Normal Heart Heart Failure
Fig. 3.2: Echocardiography of a normal (left) and a failing (right) rat heart. In each window the short-axis cross-sectional (2D) views are in the
windows above, whilst the M-mode views are below. Anterior akinesia and LV cavity dilation is apparent in the failing heart.
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3.3 Results : Effect of cell transplantation on ven-
tricular function
Echocardiography studies were performed again four weeks after injection of either
PBS or cells to examine the effect of cell transplantation on global heart performance.
As shown in Fig.3.3 there was no significant difference between the HF, BM, and
SK groups with respect to LV end-diastolic area or EF before any injection. There
was no significant change in the EF of failing hearts in the four weeks following PBS
injection. In comparison, injection of bone marrow mononuclear cells increased the
EF from 34.3 ± 1.1% to 42.9 ± 2.2% over this same period. Injection of skeletal
myoblasts also increased EF, from 36.5 ± 1.3% to 44.4 ± 2.3%. Collectively, these
results agree with previous reports that intramuscular injection of either cell type
improves global ventricular function.
As mentioned earlier, the degree of failure in these hearts were seen as modest,
given the lack of symptoms in the animals. The improvements following cell trans-
plantation were also moderate, especially when compared to the EF of a normal,
healthy heart of ∼ 76%. The degrees of impairment pre-cell transplantation and
improvement after transplantation in these hearts are similar to those seen in the
clinical trials (Assmus et al. 2006), making them suitable subjects for the cellular
studies described in the following sections.
3.4 Results : Green fluorescence of cardiomyo-
cytes obtained from hearts following cell trans-
plantation
Following echocardiography studies cardiomyocytes were isolated from the LV for
characterization using methods described on page 87. The isolated cardiomyocytes
were initially studied for their levels of green fluorescence to determine whether they
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Fig. 3.3: Ventricular end-diastolic area (A) and ejection fraction (B) measured using echo-
cardiography before and after cell transplantation. Failing hearts were dilated and showed
reduced EF compared to Normal. There was no significant difference between the HF, BM,
and SK groups before injection. Following injection of PBS HF showed further LV dilation.
There was no effect of PBS on EF over four weeks, whereas both BM and SK increased EF
over this period. No¯ of animals : HF 18; BM 18; SK 21. ANOVA was used for comparisons
between different heart groups. Paired Student’s t -test was used within groups for before-after
comparisons.
had derived from the host (native cardiomyocytes) or from the injected cells. To
test whether epifluorescence was sufficient to detect GFP, ventricular myocytes were
isolated from the hearts of GFP+ Sprague-Dawley rats in separate experiments for
comparison. The levels of green fluorescence was examined using methods described
in section 2.8 on page 90. Cardiomyocytes isolated from wild-type Sprague-Dawley
rats emitted low levels of background green autofluorescence. Cardiomyocytes iso-
lated from GFP+ Sprague-Dawley rats showed a notably higher level of green fluo-
rescence compared to cardiomyocytes isolated from wild type rat hearts (Fig.3.4).
Cardiomyocytes isolated from hearts which had received cell transplantation showed
low levels of green fluorescence (i.e. not above the level of background autofluores-
cence, lower panels of Fig.3.4). These observations indicated that the isolated
cardiomyocytes under investigation were of recipient origin, and not derived from
the injected GFP+ bone marrow or skeletal cells.
Although the frequency of occurrence of GFP+ cardiomyocytes was not system-
atically measured, these observations are consistent with previous reports that very
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small numbers of transplanted cells, if any, survive and adopt a cardiomyocyte-like
morphology (Fukushima et al. 2007, Suzuki et al. 2004). Furthermore, recent evi-
dence suggests that the few that do had arisen from fusion of transplanted GFP+
cell with recipient cardiomyocytes (Balsam et al. 2004, Murry et al. 2004). Following
these findings, the current study focused more on characterization of cardiomyocytes
assumed to have originated from the recipient population, all of which emitted only
background levels of green fluorescence.
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Wild Type GFP+
Bright Field Fluorescence Bright Field Fluorescence
Bright Field Fluorescence Bright Field Fluorescence
BM SK
Fig. 3.4: Microscopic examination of green fluorescence emitted from cardiomyocytes. Wild
type cardiomyocytes (above left) showed a low degree of green autofluorescence. Cardiomy-
ocytes were isolated from rats constitutively expressing GFP for comparison (above right).
These emitted notably increased green fluorescence. Cardiomyocytes isolated from hearts af-
ter bone marrow mononuclear cell (below left) or skeletal myoblast transplantation (below
right) showed only background levels of green fluorescence, similar to wild type cardiomyo-
cytes.
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3.5 Results : Cardiomyocyte size
The dimensions of the freshly isolated cardiomyocytes from the four heart groups
were estimated using planimetry. The methods are described in section 2.7 on
page 89. Only cardiomyocytes of healthy, rod-shaped appearance were characterized
using this approach.
As shown in Fig.3.5 the 2-dimensional cell areas of cardiomyocytes isolated
from failing hearts were larger than of those isolated from normal (SHAM-operated)
hearts, indicating hypertrophy. Cardiomyocytes isolated from hearts which had
received bone marrow mononuclear cell transplantation were smaller than those from
failing hearts. Similarly, cardiomyocytes isolated from hearts which had received
skeletal myoblast transplantation also showed reduction in size. These data suggest
that cell transplantation caused either attenuation or possibly even regression of the
hypertrophy that developed during the seven weeks following myocardial infarction.
Cardiac hypertrophy in humans is recognized as a maladaptive process which is
associated with an unfavorable outcome, and its reduction is thought to improve
prognosis (Frey & Olson 2003).
These data agree well with results obtained from cell membrane capacitance
measurements, which represent an alternative method of assessing cell size. The cell
membrane capacitance measurement data are described later, in section 3.10.
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Fig. 3.5: Cell area measured using planimetry. A. Left ventricular myocytes isolated from
failing hearts were larger than those from normal hearts. After transplantation of either BM or
SK, this hypertrophy was reduced. B. Example photomicrographs of cardiomyocytes isolated
from normal hearts. C. Example photomicrographs of hypertrophied cardiomyocytes isolated
from failing hearts. Scale bars represent 10 µm. No¯ of animals/cells studied: Normal 6/220;
HF 5/225; BM 5/229; SK 5/328. ANOVA was used for statistical comparisons.
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3.6 Results : Contractile properties of cardiomyo-
cytes
Freshly isolated cardiomyocytes were studied for their contractile properties by
measurement of sarcomere length changes, using methods described in section 2.9
(page 90). The cardiomyocytes used for these particular studies were not loaded
with indo-1 AM. Field-stimulation frequency was varied between 1, 2, 3, 4, and
5 Hz.
Fig.3.6 illustrates the results from sarcomere length studies. There was no differ-
ence between the four heart groups in terms of baseline (diastolic) sarcomere length
(Fig.3.6B). Cardiomyocytes from failing hearts showed markedly reduced ampli-
tude of contraction. This was true both in terms of absolute sarcomere length (ex-
pressed in µm, Fig.3.6C) as well as in terms of contraction percentage (Fig.3.6D).
Transplantation of either bone marrow mononuclear cells or skeletal myoblasts lead
to full restoration of this contraction amplitude.
The duration of cardiomyocyte contraction and relaxation were also determined
from the same acquisition traces, using methods illustrated in Fig.2.7. As shown
in Fig.3.6E, there was no difference between the four heart groups in terms of their
contraction times-to-peak. Similarly, there was no difference measured between the
times-to-50% relaxation (Fig.3.6F).
Collectively, these results demonstrate that the contractile performance of indi-
vidual cardiomyocytes from the model of heart failure used in this study are im-
paired. Furthermore, it is clear that injection of either bone marrow mononuclear
cells or skeletal myoblasts restore the contractile performance back towards that of
normal cardiomyocytes.
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Fig. 3.6: Contractile properties of cardiomyocytes obtained from the four heart groups.
A. Representative example sarcomere length measurement traces at 1 Hz contraction.
B. Baseline sarcomere length. C. Amplitude of cardiomyocyte contraction expressed as sar-
comere shortening, in µm. D. Amplitude of cardiomyocyte contraction expressed as short-
ening percentage. By either parameter, failing cardiomyocytes showed impaired contraction,
which was restored following transplantation of either cell type. E. Time-to-peak contraction
and F. Time-to-50% of relaxation showed no difference between groups. No¯ of animals/cells:
Normal 6/66; HF 6/60; BM 5/53; SK 6/57. *** p < 0.001 vs Normal, BM, SK.
145
3.7 Results : Indo-1 transients - twitch transients
To elucidate the physiological mechanisms responsible for the changes in contractile
properties described in the previous section, a number of the same cardiomyocytes
were studied for their Ca2+ handling properties using the Ca2+ sensitive fluorescent
indicator indo-1. Detailed methods are described in section 2.10 on page 93. The
field-stimulation frequency was 1, 2, and 3 Hz.
Representative 1 Hz indo-1 transient traces acquired from cardiomyocytes can
be seen in Fig.3.7A. There was no significant difference in the diastolic baseline
levels (Fig.3.7B). No significant difference was measured in the amplitudes of the
transients (Fig.3.7D). The time-to-peak (Tpeak) of the transient was prolonged in
cardiomyocytes from failing hearts (Fig.3.7D), indicating impaired release of Ca2+
during systole. Interestingly, this prolongation was corrected following transplanta-
tion of either cell type. The time-to-50% decay, a measure of Ca2+ re-uptake during
diastole, was also prolonged in failing cardiomyocytes when compared to normal
(Fig.3.7E). In contrast to the Tpeak, this defect in Ca
2+ handling was not corrected
by cell transplantation. Similar data were seen following 2 Hz and 3 Hz field-stimu-
lation (data not shown). No change in data pattern was seen when other parameters
were assessed, such as time-to-50% of peak, time-to-90% of peak, or time-to-90%
decay (data not shown).
The increased contraction amplitudes of cardiomyocytes, in the absence of change
in the amplitude of the Ca2+ transients suggest that the sensitivity of the myofila-
ments to intracellular Ca2+ might be altered. In the current series of experiments
this aspect of cardiomyocyte function was not formally assessed. The sensitivity
of cardiomyocyte myofilaments to Ca2+ can be estimated and compared between
cell groups by permeabilizing cardiomyocytes (by using saponin, Lukyanenko &
Gyo¨rke 1999) and measuring their contractions whilst applying varying concentra-
tions of Ca2+.
The two main aspects of Ca2+ regulation, Ca2+ entry and Ca2+ extrusion, have
both been implicated in the pathophysiology of heart failure with varying relative
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contributions that depend on the animal species, mode of stress induction, and seve-
rity (Hasenfuss 1998). The model of heart failure in this study showed impairment
in both aspects of Ca2+ handling. The speed of Ca2+ release during systole was nor-
malized by cell transplantation, which might help explain the improved mechanical
function of the cardiomyocytes. On the other hand, Ca2+ re-uptake during dias-
tole remained unaffected, implying persistent defects in some of the aspects of Ca2+
handling.
3.8 Results : Indo-1 transients - caffeine applica-
tion studies
As well as studying the twitch transients to characterize Ca2+ release and re-uptake,
the Ca2+ handling and storage properties of cardiomyocytes were further assessed
using rapid application of 20 mM caffeine. Detailed experiment protocol and meth-
ods of data analysis are described in section 2.10 on page 96.
The results obtained from these caffeine experiments are shown in Fig.3.8. The
SR Ca2+ content, measured as the amplitude of the caffeine-induced transient,
showed no significant difference seen between the four heart groups (Fig.3.8A).
From the same experiments, fractional release (Fig.3.8B), κ
Caffeine
(Fig.3.8C), and
relative contribution of NCX towards clearance of Ca2+ during diastole (Fig.3.8D)
were calculated. There were no significant differences seen for these measured pa-
rameters.
These data suggest that the amount of Ca2+ stored in the SR of these cardio-
myocytes are not different from each other. In all heart groups, NCX removed
approximately 6% of the Ca2+ that was released. This is in agreement with the
measured values from rat cardiomyocytes previously reported by others (Bassani
et al. 1994), and suggests that the impaired Ca2+ re-uptake measured in cardiomyo-
cytes from HF, BM, and SK groups is due to impairment in both NCX and SERCA
function by similar degrees.
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Fig. 3.7: A. Representative traces obtained following 1 Hz field stimulation. B. Baseline
(diastolic) levels. C. Amplitude of transient. There was no significant difference between
groups. D. Tpeak of the transient was prolonged in failing cardiomyocytes when compared
to normal cardiomyocytes. The prolongation was completely restored to normal following
transplantation of either type of cell. E. Time-to-50% decay of the indo-1 transient was
also prolonged in failing cardiomyocytes compared to normal. This prolongation remained
unaffected by cell transplantation. No¯ of animals/cells: Normal 6/53; HF 5/46; BM 5/43; SK
5/41. Similar data were seen from 2 Hz and 3 Hz field stimulation (data not shown).
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Fig. 3.8: Indo-1 traces from rapid caffeine application studies. Example twitch transients
and a caffeine transient elicited from a normal (A) and a failing (B) cardiomyocyte. C. SR
Ca2+ content, measured as the amplitude of the caffeine-induced transient. D. Fractional
release. E. NCX rate constant. F. Relative contribution of NCX to clearance of Ca2+ during
diastole. There were no significant differences between the four heart groups for any of these
measured parameters. No¯ of animals/cells: Normal 6/32; HF 5/14; BM 5/24; SK 5/13.
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3.9 Results : Intracellular pH and sodium-hydro-
gen exchanger activity
It has been suggested previously that disturbances in [Na+]i and intracellular pH
(pHi) via altered Na
+/H+ exchanger activity occur during heart failure leading to
dysfunctional intracellular Ca2+ homeostasis (Baartscheer et al. 2003). For this
reason pHi and acid-extrusion ability was compared between groups using the pH-
sensitive fluorescent indicator 5-(and-6)-Carboxy-SNARFr-1. Details of experiment
methods are described in section 2.11 on page 98.
Fig.3.9 summarizes the data obtained. There was no disturbance in resting
pHi in cardiomyocytes isolated from failing hearts (Fig.3.9A). There was no major
effect on pHi resulting from transplantation of either cell type. Acid extrusion was
measured between every 0.1 pHi unit between pHi 6.8 and 7.3. These measurements
also revealed no significant difference between groups (example data from pH 6.9
shown in Fig. 3.9B, Data for other pHi points not shown). From these data it
appears that effects on pHi are not related to the benefits to the recipient cardio-
myocytes resulting from cell transplantation.
3.10 Results : Cell capacitance
The surface electrical capacitances of isolated cardiomyocytes were measured as part
of the electrophysiological studies (i.e. AP, I Ca,L and INCX measurements, which
are described in the following sections). Cell capacitance represents an estimation
of the total surface area of the sarcolemma. Data were collated from experiments
utilizing both high-resistance and low-resistance pipettes and used for comparison
of cell size between the heart groups.
Ventricular cardiomyocytes from normal hearts had an average electrical capa-
citance of 178.4 ± 8.4 pF. This value is consistent with those measured by others
using similar methods (Keung et al. 1991, Benitah et al. 1993, Tomita et al. 1994).
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Fig. 3.9: A) Resting pHi, measured using SNARF fluorescence. B Acid eﬄux capabilities
of cardiomyocytes at pH 6.9. Similar data were seen at pHi 6.8, 7.0, 7.1, 7.2, and 7.3 (not
shown). No¯ of animals/cells studied: Normal 6/28; HF 5/25; BM 5/25; SK 5/25.
In comparison, cardiomyocytes isolated from failing hearts had larger capacitances
(Fig.3.10), suggesting hypertrophy. The increase (44.4%) was larger than that
estimated by planimetry (34.8%, Fig.3.5). Cell capacitance is a representation of
the entire cell surface area, including that in the T-tubules. On the other hand,
planimetry estimates only the 2-dimensional, projected area of the cell. The cell
area differences that may exist in the z -axis of visualization and those arising from
differences in T-tubule density are not incorporated in planimetry. These differences
may account for the discrepancy seen.
Following transplantation of either bone marrow mononuclear cells or skeletal
myoblasts, there was a reduced cell capacitance compared to heart failure. The
pattern of change was similar to that estimated by planimetry measurements. Both
data sets show the occurrence of hypertrophy in the hearts following coronary artery
ligation. Reduction of this hypertrophy was seen following cell transplantation,
suggesting two possibilities: either the development of hypertrophy was limited, or
regression of hypertrophy had occurred.
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Fig. 3.10: Electrical capacitance of cardiomyocytes isolated from HF were significantly higher
than that of Normal. This increase was significantly reduced following transplantation of either
BM or SK. No¯ of animals/cells studied: Normal 6/45; HF 5/57; BM 5/39; SK 5/45.
3.11 Results : Action potential duration (APD)
To further elucidate the physiological effects of cell transplantation on the recipi-
ent cardiomyocytes, electrophysiological measurement studies were performed. Ac-
tion potentials were measured directly in individual cardiomyocytes using whole
cell clamping methods as described in section 2.12.1 on page 104. Representative
example traces from 1 Hz stimulation and APD90 comparison data can be seen in
Fig.3.11. APD was prolonged in failing cardiomyocytes compared to normal by up
to 40% at 1, 3, and 5 Hz stimulation. The prolongation was most marked at 1 Hz.
At higher frequencies the difference between normal and failing cardiomyocytes was
smaller, but detectable nonetheless. These observations are consistent with those
made by others in previous studies of failing cardiomyocytes from various species
(Bassett & Gelband (1973), Brooksby et al. (1993), Keung et al. (1982). For a
review, see Tomaselli & Marban (1999)).
Transplantation of bone marrow mononuclear cells or skeletal myoblasts had
no significant effect on the prolonged APD. This suggests persistent impairment of
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the main components of electrophysiological remodeling contributing towards APD
prolongation. For example, reductions in outward currents such as the transient
outward current (I to), inward rectifier current (IK1), and Na
+/K+-ATPase current
(I p) are all known to contribute (Na¨bauer & Ka¨a¨b 1998). However, whether this is
the case in the current model of heart failure would require verification with further
experiments. Increases in inward currents such as I Ca,L or forward mode INCX could
also prolong the APD. These possibilities are discussed in the following sections.
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Fig. 3.11: Action potentials measured from failing cardiomyocytes were prolonged when
compared to normal. The prolonged AP was not significantly affected by transplantation
either cell type. A. Representative 1 Hz stimulation action potential traces. B. APD90
following 1 Hz stimulation. C. APD90 following 3 Hz stimulation. D. APD90 following 5 Hz
stimulation. No¯ of animals/cells: Normal 6/30; HF 5/38; BM 5/40; SK 5/40. ANOVA was
used for statistical comparisons. Similar patterns of data were observed when APD50 were
compared (data not shown).
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Fig. 3.12: I Ca,L current-voltage (I–V) relationships of cardiomyocytes isolated from the four
heart groups. No¯ of animal/cells: Normal 6/17; HF 5/22; BM 5/15; SK 5/22.
3.12 Results : L-Type Ca2+ currents
The L-type Ca2+ current (I Ca,L) represents the main route of entry of Ca
2+ into the
cardiomyocyte to trigger Ca2+-induced Ca2+ release (CICR, Fabiato 1983). I Ca,L
was studied in isolated cardiomyocytes using whole cell voltage-clamping methods.
Details of protocols are described in section 2.12.2 on page 107. The parameters mea-
sured were I Ca,L peak density, time- and Ca
2+-dependent inactivation, and voltage-
dependent activation and inactivation.
The peak I Ca,L density (Fig.3.12) was significantly reduced in failing cardio-
myocytes compared to normal (p < 0.05 for −10 to +5 mV). This reduction was nor-
malized by transplantation of skeletal myoblasts (p < 0.05 vs HF for−20 to +5 mV).
Interestingly, this was in contrast to transplantation of bone marrow mononuclear
cells, which had no effect on the reduced I Ca,L.
The fast and slow components of time-dependent inactivation of I Ca,L were iden-
tified for comparison, using methods illustrated in Fig.2.16D. Comparison of τ
fast
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Fig. 3.13: Inactivation time constants of I Ca,L. Both τfast (A) and τslow (B) were significantly
reduced in HF compared to Normal, indicating further impairment of I Ca,L. With both
parameters this prolongation was corrected following SK, but not BM, transplantation. No¯
of animal/cells: Normal 6/17; HF 5/22; BM 5/15; SK 5/22. ANOVA was used for statistical
comparisons.
can be seen in (Fig.3.13A), whilst that of τ
slow
can be seen in (Fig.3.13B). Both
time constants were prolonged in heart failure compared to normal cardiomyocytes,
indicating further impairment of I Ca,L. The delay was normalized by transplantation
of skeletal myoblasts (p < 0.05 vs HF), but not bone marrow cells.
As well as current density and inactivation time constants, voltage-dependent
activation (G/G
MAX
) and inactivation (F/F
MAX
) profiles of I Ca,L were characterized.
Boltzmann curves were fitted to mean data points of the I–V plots obtained from
application of protocols illustrated in Fig.2.16A and Fig.2.16E on page 111. There
was no difference between the groups in G/G
MAX
(Fig.3.14A). Heart failure resulted
in a leftward shift in F/F
MAX
(b p < 0.05 vs Normal for −25 to +15 mV). This
implies further limitation of I Ca,L. As with other parameters of I Ca,L, this defect
was normalized following transplantation of skeletal myoblasts (§, p < 0.05 vs HF
for −25 to +15 mV), but not bone marrow cells (Fig.3.14B).
Overall, these data show that the I Ca,L is impaired in this model of heart failure.
Previously, many groups have measured I Ca,L density in cardiomyocytes from heart
156
failure patients and animal models of heart failure, reporting varied results (for re-
views summarizing the findings, see Mukherjee & Spinale (1998) and also Richard
et al. (1998)). The general trend appears to be that, while the effects of compensated
ventricular hypertrophy range from no change to increases in I Ca,L, the effects of
heart failure range from no change to significant increases. The heterogeneity prob-
ably arises from a variety of factors, which may include animal species, age, mode
and severity of heart failure. With humans, additional variability is introduced by
co-morbidities, sex, and drug therapy.
The decreased I Ca,L density seen in heart failure is normalized by skeletal myo-
blast, but not bone marrow cell, transplantation. I Ca,L represents the main trigger
for CICR and changes in this current influence the rate of Ca2+ release from the SR
(Wier et al. 1994). Thus, the faster Ca2+ transient development seen from the indo-1
studies after skeletal myoblast transplantation may, at least in part, be explained by
improvements in I Ca,L. Nonetheless, alterations in other components of EC coupling
cannot be excluded. As mentioned earlier, a large number of studies have reported
unchanged I Ca,L density in various models of heart failure, indicating the presence
of other defects in EC coupling. Furthermore, the results from bone marrow mono-
nuclear cell transplantation in the current study show normalized indo-1 transient
Tpeak with persistently decreased I Ca,L, indicating changes in other components that
may have become defective in heart failure, most notably the RyR.
The prolongation of τ values in failing cardiomyocytes was an observation consis-
tent with those made previously by others (Gomez et al. 1997, Gomez et al. 2001).
The τ values represent speed of L-type Ca2+ channel closure in a stochastic manner
and by Ca2+ released from the neighbouring RyRs (Kass & Sanguinetti 1984, Lee
et al. 1985, Yue et al. 1990). It has been suggested that their prolongation is re-
lated to physical separation of the two type of Ca2+ channels: the increased distance
between the RyRs and L-type Ca2+ channels delays the inactivation of the L-type
Ca2+ channels by Ca2+ released from RyRs (Gomez et al. 1997). The normalization
of the τ values suggests that skeletal myoblast transplantation may restore some of
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the structural alterations between the L-type Ca2+ channels and their juxtaposed
RyRs that occur in heart failure.
In the previous section, the possible currents contributing to the prolongation of
APD were discussed (page 153). That I Ca,L was decreased in this particular model
of heart failure suggests that the prolongation of APD is not likely to be due to
alterations in I Ca,L.
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Fig. 3.14: A. Voltage-dependent activation profile of I Ca,L. B. Voltage-dependent inactivation profile. b p < 0.05 vs Normal; §, p < 0.05 vs HF. N
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of animal/cells: Normal 6/17; HF 5/22; BM 5/15; SK 5/22. ANOVA was used for statistical comparisons.
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3.13 Results : Na+/Ca2+ exchanger currents
It has been suggested previously that changes in NCX may be relevant to the abnor-
mal Ca2+ homeostasis in heart failure. For this reason, INCX density was measured
using the whole-cell patch clamping method described in section 2.12.3 on page 110.
Fig.3.15 shows the current-voltage (I–V) relationship curves for INCX from the
four groups of hearts. INCX at +80 mV was +1.6± 0.3 pA/pF. At −120 mV it was
−1.4 ± 0.4 pA/pF. These are values in agreement with those previously measured
by others using whole-cell patch clamping in rat ventricular myocytes (Chorvatova
et al. 2004, Wasserstrom et al. 2000, Zhang et al. 1999). Compared to INCX density
measured in other mammal species such as guinea-pig (Perchenet et al. 2000), rabbit
(Quinn et al. 2003) or human (Ginsburg & Bers 2005), these are relatively small
values. No significant difference was measured between failing and normal hearts
in terms of average current density. This also remained unchanged following cell
transplantation. The reversal potentials (range: −17 to −20 mV) were also not
significantly different between heart groups.
INCX has been previously studied in various animal models of heart failure by
other research groups (for a review, see Sipido et al. 2002). In the model em-
ploying coronary artery ligation in the rat some investigators reported decreased
INCX density along with decreased protein expression levels (Dixon et al. 1992,
Zhang et al. 1996), whereas others reported opposite findings (Wasserstrom et al.
2000). Although these discrepancies are not easily explained, they may be the result
of various factors such as age of animals, severity of infarcts and period over which
remodeling was allowed to take place.
The findings in the current study can be considered consistent with the data
obtained from the rapid caffeine application studies described in section 3.8, where
no difference was seen between the four heart groups in terms of SR Ca2+ content
and relative contributions of NCX towards Ca2+ removal during diastole. Since
there was neither an increase in inward INCX nor a decrease in outward INCX in
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the the current model of heart failure it appears that INCX , similar to I Ca,L, does
not contribute significantly to the prolongation of the APD discussed on page 153.
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Fig. 3.15: I NCX I–V relationships obtained using whole cell patch clamping. There were no differences between any of the four heart groups. N
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animal/cells: Normal 6/18; HF 5/22; BM 5/17; SK 5/17. ANOVA was used for statistical comparisons.
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3.14 Results : Ca2+ sparks studies
The RyR and its relationship with other components of EC coupling has become
a major subject of interest in the field of heart failure. It is suggested that the
defective Ca2+ release from the SR during systole in failing cardiomyocytes results
from alterations in the gating properties of RyRs (Xiao et al. 2005, Wehrens et al.
2003), or their physical locations with respect to their neighbouring L-type Ca2+
channels (Gomez et al. 1997). To study these possibilities, and to characterize the
unitary Ca2+ release patterns from the SR, cardiomyocytes were loaded with the
Ca2+ sensitive fluorescent indicator fluo-4 and Ca2+ sparks were studied. Detailed
methods are described in section 2.13 on page 115.
Fig.3.16 summarizes the results of these studies. In the absence of field-stimu-
lation (i.e. during quiescence) Ca2+ sparks were observed at a higher frequency in
failing cardiomyocytes (Fig.3.16A). Although there appeared to be a tendency for
this increase to become normalized following cell transplantation statistical testing
with ANOVA revealed no significant difference (p = ns).
Morphometric analysis was carried out on the Ca2+ sparks. When measured
as F/F0, there was no difference in spark amplitude between groups (Fig.3.16B).
The width of Ca2+ sparks, expressed as FWHM, was greater in failing cardiomyo-
cytes compared to normal (Fig.3.16C), suggesting wider diffusion of Ca2+. This
increase was reduced following transplantation of either cell type. There was no
difference seen in decay rate of the sparks, measured as FDHM, between normal
and failing cardiomyocytes (Fig.3.16D). Interestingly, transplantation of skeletal
myoblasts reduced the FDHM compared to both normal and failing cells, indicating
faster decay.
The overall rate of leak of Ca2+ from the SR during diastole should be related to
the product of these variables, CaSpF × Amplitude × FWHM × FDHM (Maier
et al. 2003). Using this product for comparison indicated that SR Ca2+ leak in-
creased in failing cardiomyocytes, but was normalized by skeletal myoblast trans-
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plantation (Fig.3.16E).
In a proportion of cardiomyocytes which exhibited a high frequency of Ca2+
sparks Ca2+ waves were also observed (example illustration of a Ca2+ wave in
Fig.2.21 on page 120). The frequency with which Ca2+ waves were observed are
compared in Fig.3.16F. Failing cardiomyocytes had a higher frequency of Ca2+
waves, suggesting increased aberrant leakage of Ca2+ from the SR. This increase
was significantly reduced after transplantation of either bone marrow mononuclear
cells or skeletal myoblasts.
To summarize, the Ca2+ sparks studies reveal that the gates controlling the
release of Ca2+ from the SR are defective in failing cardiomyocytes. Some parameters
studied are restored following cell transplantation whereas others, such as Ca2+
spark frequency, are not. Overall, the increased rate of Ca2+ leak was reduced back
towards normal following transplantation of skeletal myoblasts.
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Fig. 3.16: Parameters of Ca2+ sparks. A. Ca2+ sparks occurred at higher frequency in HF
compared to Normal. This increase remained unaffected following transplantation. B. The
peak amplitude of Ca2+ sparks did not differ between the heart groups. C. The width of the
Ca2+ sparks (FWHM), was larger in HF compared to Normal. This change was normalized
with transplantation of either cell type. D. There was no difference between HF and Normal
cardiomyocytes in terms of Ca2+ spark duration (FDHM). The FDHM of SK cardiomyocytes
were shortened when compared to HF. E. The total SR Ca2+ leak product was increased in
HF, and reduced back towards normal following transplantation of SK, but not BM. F. Ca2+
waves were observed at a much higher frequency in HF compared to Normal. This change was
normalized following transplantation of either BM or SK. No¯ of animal/cells: Normal 5/60;
HF 5/53; BM 4/46; SK 5/44. ANOVA was used for statistical comparisons.
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3.15 Discussion
The results presented in this chapter confirm the development of heart failure fol-
lowing coronary artery ligation, and show that some of the resulting changes in the
myocardium were further altered following cell transplantation. The main impor-
tant finding is the identification of recipient cardiomyocytes as a target of the phys-
iological effects of the transplanted cells. The recipient ventricular cardiomyocytes,
which had undergone chronic pathological changes following myocardial infarction,
showed reduced hypertrophy and superior contractile characteristics with improved
Ca2+ handling following cell transplantation. In the case of skeletal myoblast trans-
plantation, the parameters in I Ca,L in heart failure was normalized.
Validation of the animal model of heart failure. The left ventricles of the
rats that underwent myocardial infarction in this study showed markedly reduced
ejection fraction. Although the rats showed no symptoms or signs of congestive
cardiac failure the animal model was considered suitable for this study of cell trans-
plantation because ejection fraction of ∼ 40% approximates the cardiac function of
patients receiving cell transplantation in the current clinical trials (Assmus et al.
2006, Abdel-Latif et al. 2007). Characterization of isolated left ventricular cardio-
myocytes revealed marked hypertrophy, impaired contractile properties and Ca2+-
handling, prolonged action potentials, and reduced I Ca,L. The frequency of Ca
2+
sparks during quiescence was also increased.
Some of the cellular parameters measured showed no significant change. These
include amplitude of Ca2+ transients, SR Ca2+ load, and parameters relating to
NCX. NCX showed no alterations in terms of current density, or its relative con-
tribution towards Ca2+ removal during diastole. These findings do not necessarily
mean that the post-infarction hearts are not a valid model of chronic heart fai-
lure. However, it is tempting to speculate what further cellular changes, if any,
might have manifested if more severe infarcts were induced (for example, by ligating
the left coronary artery closer towards its left main stem), or if chronic heart fai-
lure was allowed to develop for longer than the three weeks given before cells were
transplanted. Further experiments may reveal novel important findings but on the
other hand operative mortality may have become unacceptably higher, imposing a
practical limitation.
Comparison of bone marrow mononuclear cells vs skeletal myoblasts.
From the results presented in this chapter, it is not possible to compare directly
the efficacy of bone marrow mononuclear cells versus skeletal myoblasts. For such
a comparison to be made, the dose-response relationships for each cell type need
to be measured, which was not feasible in this study. The number of cells that
were injected (5× 106 skeletal myoblasts or 107 bone marrow mononuclear cells per
heart) were chosen following earlier studies performed within our research group
(Fukushima et al. 2007), as well as by others (Pouzet et al. 2001). To date there
has been no report establishing the optimal injection numbers in any animal model
or patients. This remains a crucial point in tailoring cell therapy for patients not
only for treatment efficacy, but also from a safety standpoint (Nadal-Ginard &
Fuster 2007).
Given these limitations, the I Ca,L results from this study are particularly inter-
esting because they suggest that the mediated effects depend on the transplanted
cell type. The observation that a wide variety of cell types seem to benefit the
performance of failing hearts has led some researchers to suspect that the main ef-
fect of cell transplantation is simply to cause an inflammatory response triggered
by the death of the transplanted cells - the so-called “dying stem cell hypothesis”
(Thum et al. 2005). This hypothesis proposes that alterations of the activities of
macrophages and T-cells following the death of large numbers of transplanted cells
ultimately leads to attenuation of the infarction process with reduced scar formation
and a favourable outcome. Although the data from this current study do not rule
out that possibility, the clear difference between skeletal myoblasts and bone mar-
row mononuclear cells in terms of their effects of I Ca,L implies that more complex
mechanisms are likely to be involved, and that overall cardiomyocyte function might
be improved in more ways than one.
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What happens to the transplanted cells? The experiments in this chapter
focused on characterization of the recipient cardiomyocytes. There have been nu-
merous previous studies tracking the phenotypes of transplanted cells, in the antic-
ipation that they might adopt cardiomyocyte-like characteristics (Orlic et al. 2001).
Similar studies were performed and published by our research group (Fukushima
et al. 2007). In these experiments, male bone marrow mononuclear cells were in-
jected into female hearts, and real-time polymerase chain reaction (RT–PCR) assay
identifying the sex-determining region of the Y-chromosome (sry) was employed
to measure the proportion of cells that were surviving. These experiments revealed
that, after injection of 107 bone marrow mononuclear cells only 0.07% are remaining
in the entire left ventricle by 7 days. The survival of bone marrow mononuclear cells
then remained stable until 84 days after transplantation. When slice preparations
of the left ventricles were studied using immuno-labeling of GFP, the majority of
the surviving cells visualized assumed small, round morphology. A small fraction of
the cells were spindle-shaped. There were no GFP+ cells similar in appearance to
mature cardiomyocytes.
These observations, together with the results presented in this chapter suggest
the presence of a physiological effect of transplanted cells towards recipient cardio-
myocytes. One can postulate that such physiological effects may be mediated by a
variety of mechanisms (Laflamme et al. 2007, Dimmeler et al. 2005), such as neoan-
giogenesis and modulation of the extracellular matrix. The results are also consistent
with “the paracrine theory”, although they do not provide conclusive proof. The
possibility that the physiological effects of transplanted cells are mediated by me-
chanisms other than by paracrine secretions must be considered. For example direct
cell-to-cell contact or the recruitment of other circulating cell types may be neces-
sary. To narrow down the possibilities it became necessary to determine whether
bone marrow mononuclear cells or skeletal myoblasts could directly affect the prop-
erties of nearby cardiomyocytes in the absence of other factors that are present in
vivo by means of further experiments. These experiments were carried out using
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cell culture systems, and the results are discussed in the next chapter.
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Chapter 4
Effects of bone marrow
mononuclear cells and skeletal
myoblasts on the properties of
nearby cardiomyocytes in vitro
In the previous chapter, it was demonstrated that transplantation of either bone
marrow mononuclear cells or skeletal myoblasts influenced the contractile properties
and Ca2+ handling of individual cardiomyocytes of chronically failing hearts. This
may be due to the actions of paracrine substances secreted by the transplanted cells,
which then act directly on the myocardium, as previously proposed by Kinnaird
et al. (2004) and Uemura et al. (2006). Although such secretions may act upon
the cardiomyocytes, other possibilities also need to be considered. For example,
they may target the microcirculation and/or extracellular matrix rather than car-
diomyocytes. This is especially plausible given that the microcirculation and ex-
tracellular matrix are already known to undergo pathological changes in ventricular
remodeling (Fazel et al. 2006, Murtuza et al. 2004). Another consideration is that,
although the recipient cardiomyocytes may be the primary target of the effects of
the transplanted cells, additional factors or cells might be required. For example,
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soluble factors present in the serum or other types of cells in the circulation may
need to be recruited to the heart to enable the transplanted cells to exert their effect
(Dimmeler et al. 2005).
Thus, to determine whether the nearby presence of either bone marrow mo-
nonuclear cells or skeletal myoblasts is sufficient to influence the contractile and
Ca2+ handling properties of the failing cardiomyocytes, further experiments were
performed where cardiomyocytes were co-cultured with the donor cells. Failing car-
diomyocytes were isolated from remodeled hearts and then cultured for 48 hours in
the presence of either of the two types of cell. At the end of this period alterations to
the contractile performances and Ca2+ handling characteristics of cardiomyocytes
were studied. In such an environment there is no microcirculation, extracellular
matrix, or other types of cells to be affected by the addition of the bone marrow
mononuclear cells or skeletal myoblasts. There is also no “inflammatory response”
that is commonly initiated in vivo when tissue is damaged, and likely to occur
following cell transplantation (Thum et al. 2005). Therefore, any change that might
be effected onto the failing cardiomyocytes during co-culture can be said to be due
to the direct effects of the cells that were present in the vicinity.
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4.1 Materials & Methods
4.1.1 Cell culture
Cardiomyocytes were isolated and prepared for culture for 48 hours using methods
outlined in section 2.14. Cardiomyocytes were cultured at a density of 5,000 cells
per 35 mm dish -
• on their own (control) or
• together with 5,000 cultured skeletal myoblasts per dish or
• together with 50,000 freshly prepared bone marrow mononuclear cells per dish.
These plating densities were chosen after initial pilot studies. Plating 5,000 skele-
tal myoblasts per dish yielded large numbers of proliferating cells after 48 hours,
but left sufficient space between cells to enable indo-1 fluorescence measurement
studies (Fig.4.3). The bone marrow mononuclear cells were smaller than skeletal
myoblasts and did not proliferate significantly or exhibit morphological changes.
Therefore, 50,000 cells were plated in each dish for co-culture.
4.1.2 Study of contractile properties and indo-1 transients
of cultured cardiomyocytes
After 48 hours of culture, cardiomyocytes were studied for their contractile char-
acteristics using sarcomere length measurements and Ca2+ handling using indo-1.
Whereas in the previous chapter the contractions of freshly isolated cardiomyo-
cytes were studied without indo-1 loading, the cultured cardiomyocytes discussed
in this chapter were studied for their contractions and indo-1 transients simultane-
ously. The hardware configuration which enabled this is described in section 2.10
on page 93.
Loading cardiomyocytes with indo-1: Freshly isolated cardiomyocytes were loa-
ded with indo-1 AM in the standard manner, as described on page 93. In com-
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parison, the cultured cardiomyocytes were loaded with indo-1 AM whilst still
attached to the glass-bottom dishes. First, the culture media were removed
from the glass-bottom dishes using a standard 1 ml micropipette. These sam-
ples were then centrifuged at 1000 rpm for 5 minutes. The pellets were dis-
carded and supernates were immediately frozen and stored at −80 ℃ for later
analysis.
The cultured cardiomyocytes were then bathed in 2 µM indo-1 AM, di-
luted in DMEM for 10 minutes. Finally, the indo-1 solution was changed to
DMEM only to allow de-esterification for at least 1 hour.
Hardware setup: The same hardware setup used for studying cardiomyocyte con-
tractions and indo-1 transients described in section 2.9 on page 90 was em-
ployed. Cardiomyocytes were studied whilst being superfused in their glass-
bottom dishes with normal Tyrode solution containing 1 mM Ca2+. A 35 mm
Petri-dish insert (Fig.2.22B, Bioscience Tools Inc. San Diego, CA, USA)
was used to maintain laminar flow of superfusate, a constant bath depth of
approximately 1 mm, and a constant temperature of 37 ± 1 ℃ around the
superfused cardiomyocytes.
Protocol for field stimulation transients: The bath contents were field-stimu-
lated at 0.2 or 0.5 Hz using a pair of custom-made platinum wire electrodes.
These were adapted to fit within the Petri-dish insert at its periphery, min-
imizing impedance to the flow of superfusate. Sarcomere length shortening
data and indo-1 signals were simultaneously acquired. Only cardiomyocytes
contracting upon field-stimulation and showing healthy appearance with clear
striations were included in the study.
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4.2 Results : Effects of 48 hour culture on the
properties of normal and failing cardiomyo-
cytes
Cardiomyocytes cultured for 48 hours showed morphological changes which were
apparent under light microscopy. Their corners and edges became rounded and
there was some loss of striations, as described in previous reports by others (Volz
et al. 1991, Nag & Cheng 1986). Normal and failing cardiomyocytes were further
characterized by comparing their contractile properties and indo-1 transients before
and after 48 hours culture. As illustrated below, cultured cardiomyocytes loaded
with indo-1 showed markedly slower relaxation, leading to reduced contractions with
increasing rate of field-stimulation (Zhou et al. 2000). Contractions were small at
field-stimulation frequencies > 0.5 Hz. Following this observation, experiments were
performed using field-stimulation frequencies of 0.2 and 0.5 Hz only.
Fig.4.1 shows the results obtained from measuring cardiomyocyte sarcomere
length at 0.2 Hz field stimulation. Consistent with the results seen in the previous
chapter, the contractions of freshly isolated failing cardiomyocytes were smaller than
those of normal cardiomyocytes. In contrast to the results seen in the previous
chapter (section 3.6 on page 144) failing cardiomyocytes showed a prolongation of
the Tpeak and T50 in this series of experiments compared to normal cardiomyocytes.
Following culture for 48 hours normal cardiomyocytes showed reduced amplitude
of contraction, whereas failing cardiomyocytes showed no further impairment. The
degree was such that there was no measurable difference between normal and failing
cardiomyocytes. In addition, both types of cardiomyocytes showed marked further
prolongation of Tpeak and T50, such that there was no longer any significant difference
between failing and normal cardiomyocytes.
Fig.4.2 shows the results for indo-1 transients, also acquired at 0.2 Hz. There
was no change in the (diastolic) baseline level of fluorescence. The transient am-
plitudes of freshly isolated failing cardiomyocytes were slightly greater compared to
174
normal, although this difference was not seen at 0.5 Hz (data not shown). The Tpeak
and T50 were both prolonged in failing cardiomyocytes, as seen with the sarcomere
length data.
Following culture for 48 hours the transient amplitudes of failing cardiomyocytes
were reduced, such that there was no longer any difference compared with normal
(Fig.4.2C). As with sarcomere length changes, the transient Tpeak and T50 were
markedly prolonged in both cell types. After 48 hours, there was no longer any
significant difference between normal and failing cardiomyocytes.
Collectively, these results show that the contractile properties and EC coupling of
cardiomyocytes are markedly affected by culturing for 48 hours, as well as their mor-
phology. Following culture both normal and failing cardiomyocytes showed slower
contraction and relaxation, which correlated with slower Ca2+ release and re-uptake.
These changes were considered unsurprising, since cardiomyocytes were cultured in
an environment different to that in vivo: they were isolated, adhered onto a glass
surface, mechanically unloaded, and not electrically stimulated to contract. In ad-
dition, the bathing culture medium, whilst maintained at 37 ℃ and pH 7.4, was
most probably devoid of many of the substances that may have been present in the
extracellular fluid of the intact heart.
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Fig. 4.1: Sarcomere length shortening profiles of normal and failing cardiomyocytes, before
and after 48 hours culture. A. Example sarcomere length traces from failing cardiomyo-
cytes before and after 48 hours culture. B. There was no difference between freshly isolated
normal and failing cardiomyocytes in terms of sarcomere length baseline, and culture had
no effect. C. Freshly isolated failing cardiomyocytes contracted less than normal. Culture
for 48 hours reduced the contraction amplitude of normal cardiomyocytes, but had no effect
on failing cardiomyocytes. D. Freshly isolated failing cardiomyocytes had longer Tpeak than
normal. Following culture, Tpeak of both normal and failing cardiomyocytes were significantly
prolonged. E. Cardiomyocyte relaxation, measured as T50, was prolonged in freshly isolated
failing cardiomyocytes when compared to normal. Culture also caused prolongation of T50
in both normal and failing cardiomyocytes. Similar data were seen following 0.5 Hz field
stimulation. No¯ of hearts/cells : Normal Day 0 8/78; HF Day 0 7/41; Normal 48 hours 6/48;
HF 48 hours 5/24. Unpaired Student’s t -test was used for comparison between the two groups.
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Fig. 4.2: Indo-1 transients from normal and failing cardiomyocytes, before and after 48
hours culture. A. Example indo-1 traces from failing cardiomyocytes before and after 48 hours
culture. B. There was no difference between freshly isolated normal and failing cardiomyocytes
in terms of indo-1 baseline, and culture had no effect. C. Freshly isolated failing cardiomyo-
cytes had slightly larger indo-1 transient amplitudes compared to normal. Following culture,
the transient amplitude was reduced. D. Freshly isolated failing cardiomyocytes had prolonged
indo-1 Tpeak compared to normal. Following culture, Tpeak of both normal and failing car-
diomyocytes were significantly prolonged. E. Indo-1 transient decay, measured as T50, was
prolonged in freshly isolated failing cardiomyocytes when compared to normal. Culture also
caused prolongation of T50 in both normal and failing cardiomyocytes. N
o
¯ of hearts/cells :
Normal Day 0 8/78; HF Day 0 7/41; Normal 48 hours 6/48; HF 48 hours 5/24. Unpaired
Student’s t -test was used for comparison between the two groups.
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4.3 Results : Effects of bone marrow mononu-
clear cells and skeletal myoblasts on the prop-
erties of nearby failing cardiomyocytes in cul-
ture
The results outlined in the previous chapter showed that bone marrow mononu-
clear cells and skeletal myoblasts influenced the properties of failing cardiomyo-
cytes in vivo. One possible explanation for this is that they alter the properties of
neighbouring cardiomyocytes directly. This possibility was tested using a 48 hour
co-culture system.
The morphological changes of cardiomyocytes following 48 hours culture can be
seen in Fig.4.3. There were no apparent changes to the morphology or density
of bone marrow mononuclear cells (Fig.4.3A). Furthermore, bone marrow mo-
nonuclear cells did not appear to adhere to the culture dish floor, and did not
remain in the bath during superfusion with normal Tyrode solution. In contrast,
skeletal myoblasts proliferated markedly and also adhered onto the culture dish.
Their morphology, initially round upon plating, became stellate or spindle-shaped
(Fig.4.3B). When an initial plating density of 5,000 cells per dish was used, their
proliferation did not reach confluence after 48 hours, and there were still many
cardiomyocytes which were sufficiently far away from skeletal myoblasts to enable
acquisition of their indo-1 fluorescence emissions without interference.
Fig.4.4 shows the results from measuring sarcomere length changes in the car-
diomyocytes at 0.2 Hz. There were no changes in the baseline (diastolic) sarco-
mere length. The contraction amplitude was markedly increased following culture
together with skeletal myoblasts (Fig.4.4C), whereas the presence of bone mar-
row mononuclear cells had no significant effect. The Tpeak were not significantly
different between groups. The relaxation of cardiomyocytes, measured as T50, were
significantly hastened by the presence of either cell type (Fig.4.4E).
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The Ca2+ handling properties of these cardiomyocytes were studied simultane-
ously using indo-1. The baseline (diastolic) level was slightly lower when cardiomyo-
cytes were cultured in the presence of skeletal myoblasts, but remained unchanged
with bone marrow mononuclear cells (Fig.4.5B). There was no measurable effect on
the amplitude (Fig.4.5C) or Tpeak (Fig.4.5D) of the indo-1 transients with either
bone marrow mononuclear cells or skeletal myoblasts. The decay of the transient, ex-
pressed as T50, was significantly enhanced following culture with skeletal myoblasts
(Fig.4.5E). In contrast, the presence of bone marrow mononuclear cells had no
measurable effect. As with the results obtained from the in vivo model presented in
the previous chapter, the relatively large changes in myocyte contractility compared
to the Ca2+ transient point towards effects on the sensitivity of the myofilaments to
intracellular Ca2+. However, direct experimental assessment of myofilament Ca2+
sensitivity or molecular characterization of the myofilaments is required to clarify
this point.
Overall, these data illustrate that the contractile properties and Ca2+ handling of
failing cardiomyocytes are enhanced when they are cultured for 48 hours in the pres-
ence of skeletal myoblasts compared to when they are cultured alone. This effect
needs to be interpreted in the context of changes in these failing cardiomyocytes
brought about by their culture, described in the previous section. Compared to ske-
letal myoblasts, bone marrow mononuclear cells exerted much smaller effects (with
only T50 of relaxation showing a significant reduction). This was true even though
ten times more bone marrow mononuclear cells were plated compared to cardiomyo-
cytes. The results of the previous chapter raised the possibility that the physiological
effects exerted onto failing cardiomyocytes by the two transplanted cell types may
differ. The difference between skeletal myoblasts and bone marrow mononuclear
cells observed here may be considered consistent with such an interpretation.
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48 hours 48 hours
Cardiomyocytes + BM Cardiomyocytes + Skeletal
A B
Fig. 4.3: Appearances of cardiomyocytes cultured with either bone marrow mononuclear cells (A) or skeletal myoblasts (B) for 48 hours. Cardio-
myocytes became rounded in morphology, with some loss of striation. There was no change in the morphology of bone marrow mononuclear cells,
whilst skeletal myoblasts proliferated and attached to the dish to assume stellate appearances.
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Fig. 4.4: Effects of nearby bone marrow mononuclear cells or skeletal myoblasts on the
contractile properties of failing cardiomyocytes in co-culture. A. Representative example sar-
comere length traces from failing cardiomyocytes which were field stimulated at 0.2 Hz after
48 hours culture on their own (HF), or with either bone marrow mononuclear cells (BM) or
skeletal myoblasts (SK). B. Baseline sarcomere lengths were not different between groups.
C. The presence of skeletal myoblasts resulted in an increased contraction amplitude, whereas
the presence of bone marrow mononuclear cells had no effect. D. Tpeak was not different
between groups. E. Cardiomyocyte relaxation, measured as T50, was hastened by the presence
of either cell type. No¯ of hearts/cells: HF 6/29; BM 6/17; SK 6/19. Similar data were seen
at 0.5 Hz. ANOVA was used for statistical comparisons.
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Fig. 4.5: Effects of nearby bone marrow mononuclear cells or skeletal myoblasts on the indo-1
transients of failing cardiomyocytes in co-culture. A. Representative 0.2 Hz indo-1 transients
from failing cardiomyocytes which were cultured on their own (HF), or with either bone mar-
row mononuclear cells (BM) or skeletal myoblasts (SK). B. The indo-1 baseline levels was
reduced after co-culture with skeletal myoblasts but not bone marrow mononuclear cells. Indo-
1 transient amplitudes (C), and Tpeak (D) showed no difference between groups. E. Indo-1
transient decay, measured as T50, was hastened by the presence of skeletal myoblasts, but not
bone marrow mononuclear cells. No¯ of hearts/cells: HF 6/29; BM 6/17; SK 6/19. Similar
data were seen at 0.5 Hz. ANOVA was used for statistical comparisons.
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4.4 Results : Effects of skeletal myoblasts which
are physically separated from the failing car-
diomyocytes during culture
Following the observation in the previous section that the presence of skeletal myo-
blasts enhances the contractile performance of failing cardiomyocytes in co-culture,
the question arose: “Do the skeletal myoblasts require physical contact with the car-
diomyocytes to exert their influence?”. Previous studies had demonstrated that
skeletal myoblasts contacting adult rat cardiomyocytes in culture are able to form
electrical connections (Stagg et al. 2006). During image and fluorescence acquisition,
only solitary cardiomyocytes which were not in direct physical contact with other
cells were selected for functional assessment. This was in order to avoid fluorescence
interference. However, because the cardiomyocytes under study were superfused
with normal Tyrode solution, the possibility that they might have been in con-
tact with other types of cells during the culture period could not be eliminated.
The co-culture experiments using skeletal myoblasts were therefore repeated, but
with the two cell populations physically separated by means of a porous membrane
(“Transwellr”, see Fig.2.22 on page 122). This preparation prevented any direct
physical contact between the skeletal myoblasts and cardiomyocytes, whilst allowing
diffusion of any secreted substances between them. After the culture period cardio-
myocytes were studied as before, and visual inspection confirmed the presence of
cardiomyocytes and the absence of skeletal myoblasts in the glass-bottom dish.
The results from sarcomere length measurements are illustrated in Fig.4.6. The
contraction profile of failing cardiomyocytes cultured on their own were similar to
that seen in section 4.3. The contractions of these cardiomyocytes were enhanced
when skeletal myoblasts were present in the culture dish, even though they were
separated by the porous membrane. The amplitude of contraction (Fig.4.6C) and
speed of relaxation (measured as T50, Fig.4.6E) were increased, as seen before. The
indo-1 transients of these cardiomyocytes showed corresponding decreased T50, as
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before (Fig.4.7).
These results suggested that direct physical contact between skeletal myoblasts and
cardiomyocytes was not necessary for the beneficial effects to be mediated, and that
the influence of skeletal myoblasts were most likely mediated via soluble paracrine
substances secreted by the skeletal myoblasts.
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Fig. 4.6: Effects of skeletal myoblasts on the contractile properties of failing cardiomyocytes
in co-culture, physically separated by a porous membrane. A. Example sarcomere length
traces at 0.2 Hz. B. Baseline sarcomere length was not different between the two groups.
C. Amplitude of contraction was increased by co-culture with skeletal myoblasts. D. There
was no difference in Tpeak. E. The relaxation of cardiomyocytes, measured as T50, was
hastened by the presence of skeletal myoblasts. No¯ of hearts/cells: HF 6/28; SK 6/19. Similar
data were seen at 0.5 Hz (results not shown). Unpaired Student’s t -test was used for statistical
comparisons.
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Fig. 4.7: Effects of skeletal myoblasts on the contractile properties of failing cardiomyocytes
in co-culture, physically separated by a porous membrane. A. Example indo-1 transients at
at 0.2 Hz. B. Indo-1 baseline level was not different between the two groups. There was no
difference between CM and CM+SK in terms of transient amplitude (C) or Tpeak (D). The
transient decay rate, measured as T50 (E), was hastened by the presence of skeletal myoblasts.
No¯ of hearts/cells: HF 6/28; SK 6/19. Similar data were seen at 0.5 Hz (results not shown).
Unpaired Student’s t -test was used for statistical comparisons.
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4.5 Results : Effects of skeletal myoblasts on the
properties of normal cardiomyocytes in cul-
ture
The experiments described in section 4.2 showed that both normal and failing car-
diomyocytes were affected by a 48 hour period of culture. By the end of this period,
the cardiomyocyte contractions were slower and decreased in amplitude, and the
relaxations were slower. Results from the subsequent experiments (section 4.3)
demonstrated that the contractility and Ca2+ handling of hypertrophied, failing
cardiomyocytes improved in the presence of skeletal myoblasts in the same culture
dish, and that direct physical contact between the two cell populations was not
required for the mediated effect (section 4.4). Further experiments were carried out
to determine the effects on normal cardiomyocytes in similar conditions.
Left ventricular myocytes were isolated from normal adult Sprague-Dawley rat
hearts and cultured for 48 hours, as described in the previous sections. In some glass-
bottom dishes, skeletal myoblasts were also allowed to grow within a Transwellr.
Plating densities were identical to those of previous experiments (i.e. 5,000 cardio-
myocytes with or without 5,000 added skeletal myoblasts per dish). After 48 hours,
the contraction dynamics and indo-1 transients of cardiomyocytes were simultane-
ously assessed using the same protocols as in previous sections.
The results from sarcomere length measurements at 0.2 Hz are illustrated in
Fig. 4.8. Consistent with results seen in section 4.3, the contractions of normal
cardiomyocytes cultured on their own were decreased in amplitude and slower com-
pared to freshly isolated normal cardiomyocytes. There was no significant effect of
culturing with skeletal myoblasts on the contraction and relaxation of these normal
cardiomyocytes. Correspondingly, indo-1 transients showed no difference in any of
the measured parameters between the two groups (Fig. 4.9).
These observations, that the presence of skeletal myoblasts have no effect on
the properties of normal cardiomyocytes in co-culture, are in contrast to those seen
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when failing cardiomyocytes were cultured with skeletal myoblasts.
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Fig. 4.8: Effects of skeletal myoblasts on the contractile properties of normal cardiomyocytes
in co-culture, physically separated by a porous membrane. A. Example sarcomere length
trace at 0.2 Hz of a normal cardiomyocyte after 48 hours culture (left), and a normal cardio-
myocyte cultured in the presence of skeletal myoblasts (right). B. Baseline sarcomere length.
C. Amplitude of contraction. D. Tpeak. E. The relaxation of cardiomyocytes, measured as
T50. There was no significant difference between the two groups in any of these parameters.
No¯ of hearts/cells: Normal 7/27; Normal + SK 5/12. Similar data were seen at 0.5 Hz (results
not shown). Unpaired Student’s t -test was used for statistical comparisons.
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Fig. 4.9: Effects of skeletal myoblasts on the indo-1 transients of normal cardiomyocytes
in co-culture, physically separated by a porous membrane. A. Example indo-1 transient at
0.2 Hz of a normal cardiomyocyte after 48 hours culture (left), and a normal cardiomyocyte
cultured in the presence of skeletal myoblasts (right). B. Baseline indo-1 level. C. Amplitude
of transient. D. Tpeak. E. Indo-1 transient decay, measured as T50. There was no significant
difference between the two groups in any of these parameters. No¯ of hearts/cells: Normal
7/27; Normal + SK 5/12. Similar data were seen at 0.5 Hz (results not shown). Unpaired
Student’s t -test was used for statistical comparisons.
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4.6 Discussion
4.6.1 Skeletal myoblasts and bone marrow mononuclear cells
influence the Ca2+ handling and contractile properties
of nearby cardiomyocytes via paracrine secretions.
The experiments described in this chapter were performed after the observations
made in chapter 3, that transplantation of bone marrow mononuclear cells or ske-
letal myoblasts altered the properties of the recipient cardiomyocytes in a failing
heart. A number of possible explanations could be considered as to how these
changes might be mediated in vivo. Although it has been previously proposed that
transplanted cells influence the myocardium (Dimmeler et al. 2005, Dai et al. 2005),
such “paracrine theory” has not yet been supported by experimental evidence. The
cellular targets of such paracrine effects remain undefined: as well as the cardio-
myocytes, other components such as blood capillaries or the extracellular matrix
may be important. Furthermore, other indirect physiological mechanisms warrant
consideration. For example, it is conceivable that the effects of the transplanted
cells are mediated via by direct cell-to-cell contact rather than secreted substances.
Additional types of cells may need recruitment from the circulation.
To eliminate a number of these possibilities a similar experiment was performed
in a simplified environment. In the culture conditions employed in the experiments
in this chapter there were no blood vessels, extracellular matrix, or cell types other
than those plated. Although the culture media contained animal sera (for detailed
composition, see page 129), there was no active inflammatory process. The results
seen in this chapter after elimination of such factors show that skeletal myoblasts
and bone marrow mononuclear cells exert direct effects on failing, hypertrophied
cardiomyocytes in their proximity. Following co-culture the contractile properties
and Ca2+ extrusion dynamics of cardiomyocytes were enhanced. That these effects
were maintained even when the different cell populations were physically separated
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using a porous membrane showed that the effect could be mediated purely by soluble
factors, without the need for direct cell-to-cell contact.
Previously, Takahashi et al. (2006) performed similar experiments. Left ven-
tricular myocytes isolated from normal adult rat hearts were subjected to culture
medium which was conditioned by the growth of bone marrow mononuclear cells for
24 hours previously. After culture for 72 hours, cardiomyocytes exposed to growth
medium conditioned by bone marrow mononuclear cells showed increased contrac-
tion amplitudes at 1 Hz. Contraction Tpeak and relaxation times such as T50 or T90
were not reported. There was no change in the Ca2+ transients, as measured using
the Ca2+-sensitive fluorescent indicator fura-2. A number of differences exist in the
experimental details between the results of this chapter and those of Takahashi et al.
These include the use of normal vs failing cardiomyocytes; different initial composi-
tion of the culture media; different frequency of field-stimulation of cardiomyocytes;
and the use of conditioned media vs a co-culture system. The final of these points
deserves particular attention: in the studies reported by Takahashi et al. the growth
medium was conditioned by bone marrow mononuclear cells at a density of 5× 106
cells per ml. In comparison, the bone marrow mononuclear cells were plated in the
co-culture system used in this chapter at a density of 5×104 cells per dish (equal to
2.5 × 104 cells per ml). Despite these differences, both studies agree in suggesting
that co-culture with bone marrow mononuclear cells result in small improvements
in the mechanical properties of cardiomyocytes.
4.6.2 Comparison of bone marrow mononuclear cells vs ske-
letal myoblasts
In the previous chapter the results from I Ca,L measurement studies suggested that
skeletal myoblasts and bone marrow mononuclear cells influenced the recipient myo-
cardium in different ways. The results from the results in this chapter also show
differences between the two cell types. Compared to skeletal myoblasts, bone marrow
mononuclear cells exerted a smaller influence on the properties of nearby cardiomyo-
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cytes.
Given the similar degree of improvement measured after transplantation of ske-
letal myoblasts and bone marrow mononuclear cells in vivo, it appears that the
bone marrow mononuclear cells in the present co-culture experiments were unable
to exert their full effect. Given that there were ten times more bone marrow mo-
nonuclear cells than cardiomyocytes, and also considering the findings reported by
Takahashi et al (who used approximately 200 times more bone marrow mononu-
clear cells compared to this current study), the plating densitiy of bone marrow
mononuclear cells is unlikely to have been a limiting factor. It is possible that bone
marrow mononuclear cells need to be in the presence of cardiomyocytes for longer
durations. One can also speculate that further factors that were present in vivo,
but absent in the culture environment, may have also been required. These include,
for example, endothelial cells, other types of circulating cells, and mechanical or
electrical stimulation. The identification of additional factors that may enable bone
marrow mononuclear cells to influence their neighbouring cardiomyocytes requires
further investigation.
4.6.3 Why are normal cardiomyocytes not affected by ske-
letal myoblasts in a manner similar to failing cardio-
myocytes?
Having demonstrated the paracrine effects on skeletal myoblasts on failing cardio-
myocytes, the experiment was repeated using normal cardiomyocytes. The con-
tractile and Ca2+-handling characteristics of these were not enhanced by co-culture
with skeletal myoblasts. A direct retrospective comparison cannot be made between
normal cardiomyocytes cultured with skeletal myoblasts and failing cardiomyocytes
cultured with skeletal myoblasts, because the experiments were performed over dif-
ferent time periods.
The lack of an effect is perhaps not surprising, since normal cardiomyocytes did
not possess the same defects in EC coupling as the failing cardiomyocytes. Both
normal and failing cardiomyocytes were affected by culture and by 48 hours there
was no significant difference between them in terms of their contractile properties
or Ca2+ transients (section 4.2, page 174). It is plausible that different cellular
mechanisms were underlying the changes in contraction and relaxation during the
culture period for the two different cardiomyocyte populations.
4.6.4 The limitation of experiments
Although bone marrow mononuclear cells and skeletal myoblasts enhanced cardio-
myocyte contractility both in vivo and in culture, the patterns of change were dif-
ferent. For example, the main effect of skeletal myoblasts on Ca2+ cycling in vivo
was normalization of Ca2+ release, whereas following co-culture it was the rate
of Ca2+ re-uptake during diastole that was enhanced. Such differences may have
been due, at least in part, to the culture environment being non-physiological. In
other words, because cardiomyocytes were isolated, adhered onto a glass surface,
mechanically unloaded, and not electrically stimulated regularly to contract their
morphology and dynamics of contraction and Ca2+ handling had changed over 48
hours. It would be useful to see if an improved culture system could be established
that enabled i)incubation of small blocks of adult cardiomyocytes from failing hearts
which are devoid of blood vessels and other cell types, and ii)regular electrical stim-
ulation. One would anticipate that such a culture environment may mimic the in
vivo environment more closely and help minimize the alterations in cardiomyocytes
that are observed. This in turn would enable better elucidation of the influence of
neighbouring skeletal myoblasts and bone marrow mononuclear cells.
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Chapter 5
Analysis of culture media
composition
The experiments performed in the previous chapter demonstrated that skeletal myo-
blasts influenced the properties of failing cardiomyocytes via paracrine secretions.
During these experiments the culture media supernates were collected at the end
of the 48 hour culture period and frozen for storage. These samples were analyzed
in an attempt to identify the possible key mediators of the effects of skeletal myo-
blasts. Initially, the supernates resulting from co-culture of failing cardiomyocytes
and skeletal myoblasts were analyzed using the rat cytokine antibody array. This
offers a simple and effective method for simultaneously screening the presence of
several cytokines in a variety of fluid samples, including serum and culture media.
Further to this experiment, the same supernate samples were analyzed for insulin-
like growth factor-1 (IGF–1) using a separate enzyme-linked immunosorbent assay
(ELISA). Measurement of IGF–1 concentrations was of particular interest because
IGF–1 is a secretory protein that is known to have important regulatory roles in
cell metabolism and survival (Cohick & Clemmons 1993). IGF–1 has also been
shown previously to influence the contractility of perfused hearts directly (Freestone
et al. 1996, von Lewinski et al. 2003).
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5.1 Materials & Methods
Details of supernate sample processing and storage, usage of the cytokine antibody
array, and data analyses are described in section 2.15 on page 121. Four arrays
were used for analysis of supernates from culturing cardiomyocytes only, and four
arrays were used to analyze supernates from culturing cardiomyocytes with skeletal
myoblasts. Samples were syringe-filtered, but not diluted or processed further after
thawing. The standard experimental protocol as recommended by the manufacturer
was used throughout.
With the IGF–1 ELISA, a 96-well plate was provided, allowing simultaneous
analysis of up to 70 fluid aliquots. Pairs of fluid aliquots from seven samples were
used from each group. Details of the methods are described in section 2.16 on
page 127. Standard experimental protocol as recommended by the manufacturer
was used. Supernate samples were diluted using the provided diluent (1:1), as
recommended by the manufacturer.
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5.2 Results : Cytokines secreted by skeletal myo-
blasts detected using the rat cytokine anti-
body array
The results from studies using the cytokine antibody arrays are illustrated in Fig.5.1.
The culture media supernates which contained ventricular cardiomyocytes only con-
tained negligible trace amounts of cytokines. This was considered unsurprising, since
cardiomyocytes are highly differentiated and specialized cells whose primary func-
tion is mechanical. In comparison the culture media supernates which were bathing
skeletal myoblasts in addition to cardiomyocytes contained notably increased levels
of three cytokines: monocyte chemoattractant protein (MCP–1), tissue inhibitor of
metalloproteinase (TIMP–1), and vascular endothelial growth factor (VEGF).
5.3 Results : Levels of IGF–1 present in the co-
culture supernates
The rat cytokine antibody array (used in the section above) enables comparison
between fluid samples for relative levels of multiple cytokines. It does not provide
measurements of actual concentrations. In comparison, ELISA, which was used for
measurement of IGF–1, is able to yield actual concentration measurements against a
concentration standard. As shown in Fig.5.2 IGF–1 was absent in the culture media
supernates that contained ventricular cardiomyocytes only. In comparison, culture
media supernates that grew skeletal myoblasts in addition to the cardiomyocytes
contained 720± 126 pg/ml IGF–1.
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Fig. 5.1: Cytokines present in culture media supernates detected using rat cytokine antibody
arrays. Representative example rat cytokine antibody arrays developed after exposure to
media supernate obtained from culturing cardiomyocytes only (A), and from culturing car-
diomyocytes with skeletal myoblasts (B). The levels of MCP–1 (C), TIMP–1 (D), and VEGF
(E) were increased following culture with skeletal myoblasts. There was no significant change
in the levels of other cytokines detected by the array. Full details of these cytokines are
illustrated in Table 2.2. No¯ of arrays : cardiomyocytes only 4; cardiomyocytes + skeletal
myoblasts 4. Unpaired Student’s t -tests were used for comparison between these two groups.
Abbreviations: “O. D. Units” = Optical Density Units.
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Fig. 5.2: Concentrations of IGF–1 in culture media supernates measured using ELISA. A. Photograph of the developed ELISA microplate comparing
levels of IGF–1 in culture media supernates. Serial dilutions of the provided IGF–1 were used to generate a concentration standard (the two left
columns of wells) from 0 to 2000 pg/ml. B. Results of compiled unpaired Student’s t -tests between cardiomyocytes only and cardiomyocytes + skeletal
myoblasts. No¯ of supernate samples: cardiomyocytes only 7; cardiomyocytes + skeletal myoblasts 7.
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5.4 Discussion
The results described is this chapter reveal the increased presence of four cytokines :
MCP–1, TIMP–1, VEGF, and IGF–1. These findings provide further support to
the notion that skeletal myoblasts influence the function of failing cardiomyocytes
in co-culture by paracrine mechanisms.
One important consideration in the interpretation of these results is that the
growth medium already contained horse serum (10%) and fœtal bovine serum (4%).
Although animal sera are known to contain all of the above-mentioned cytokines in
abundance, they were not detected in significant levels in the control samples with
either assay. This can be interpreted in a number of ways. First, there are clearly
identified species differences in the molecular composition of these cytokines. For
example, the primary amino-acid sequence of IGF–1 are different between bovine
and rat at four residues (Humbel 1990). The IGF–1 ELISA assay used is highly spe-
cific for mouse and rat IGF–1, but not other animal species. Another consideration
is the possible consumptive depletion of the cytokines during the 48 hour culture
period. It is likely that even if the concentrations of these cytokines were high in
both groups of culture samples initially, early consumption of cytokines by cardio-
myocytes may have led to depletion in the wells that contained only cardiomyocytes,
but not in those that contained skeletal myoblasts in addition.
In section 4.5, it was observed that cultured normal cardiomyocytes were no
affected by the nearby presence of skeletal myoblasts in the same manner as failing
cardiomyocytes. One possible explanation for this is that skeletal myoblasts did
not secrete cytokine in a similar pattern in the presence of normal cardiomyocytes.
To exclude this possibility requires further direct measurement of cytokines using
identical assays.
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5.4.1 IGF–1
IGF–1, also known as somatomedin–C, is a single-chain polypeptide consisting of 70
residues, and shares structural similarities with pro-insulin. Its structure is relatively
highly conserved amongst animal species, with 100% sequence homology between
human, bovine, equine, porcine, and canine proteins (Humbel 1990). IGF–1 is a
progression factor in the cell cycle of many cell types, and has regulatory roles in the
proliferation and differentiation of a variety of tissues (Cohick & Clemmons 1993).
In the body it is produced by many tissue types and is abundant in the circulation.
However, local production is thought to be important for its regulatory roles. For
example, autocrine secretion by skeletal myoblasts stimulates their differentiation
in vitro upon serum withdrawal (Florini et al. 1991).
The identification of IGF–1 as a candidate mediator of the effects of skeletal
myoblasts on failing cardiomyocytes is of particular interest, especially since it has
been previously identified to affect EC coupling and contractility of cardiomyocytes
directly (Duerr et al. 1995, Freestone et al. 1996, von Lewinski et al. 2003). In
addition to the effects on the contractile performance of cardiomyocytes, IGF–1
may increase their rate of survival under stress. Experiments using transgenic mice
overexpressing IGF–1 within cardiomyocytes (under the control of the α-myosin
heavy chain promoter) have also shown that increased expression of IGF–1 can
limit tissue loss and remodeling after myocardial infarction (Li et al. 1997).
5.4.2 VEGF
VEGF is a highly specific mitogen for vascular endothelial cells. It exists as 5 differ-
ent isoforms, which are generated by alternative splicing. Regarding its physiological
importance in vivo, its role in the regulation of angiogenesis has been the subject
of most research (Ferrara 2001, Seko et al. 1999). VEGF is expressed in a spatially
and temporally coordinated manner during development of the normal cardiovascu-
lar system. Animals that lack either of the two VEGF alleles and animals lacking
201
VEGF receptors die in utero due to severe abnormalities in blood vessel formation
(Neufeld et al. 1999). In normal tissues, exposure to hypoxia potentiates VEGF
production and release (Shweiki et al. 1992). Furthermore, inhibition of the bind-
ing of VEGF to its receptors in solid tumours results in tumour regression. VEGF
acts via its receptors FLT–1 and FLK–1 to activate intracellular phospholipase–
Cγ1 (PLCγ1). Both FLT–1 and PLCγ1 are expressed in cardiomyocytes (Seko
et al. 1999). Interestingly, interference with the VEGF ⇒ FLT–1 ⇒ PLCγ1 sig-
naling pathway using Morpholino oligonucleotides results in significant impairment
of cardiac contractility (Rottbauer et al. 2005). Conversely, incubation of neonatal
rat cardiomyocytes with 100 ng/ml VEGF164 increases the amplitudes of their Ca
2+
transients.
5.4.3 TIMP–1
TIMPs are two-domain molecules made up of about 190 amino-acids (Brew et al.
2000). In humans four TIMPs have been recognized. Their main function in the
body is the inhibitory regulation of matrix metalloproteinases (MMPs), which in
turn are the chief proteinases that degrade the extracellular matrix. The fine balance
between MMP and TIMP activity is largely responsible for controlling extracellular
matrix formation and digestion, thus maintaining optimal tissue structure. In the
heart deletion of MMP–9 has been found to affect cardiac remodeling after myocar-
dial infarction favorably (DuCharme et al. 2000). Conversely, MMP-overexpression
or TIMP–1 deficiency result in increased LV remodeling following myocardial in-
farction in animal models (Creemers et al. 2003). There have been several studies
describing growth promoting activity of TIMP–1 affecting many cell types, which
appears to be independent of its MMP–inhibitory activity (Hayakawa et al. 1992).
When TIMP–1 was first cloned, it was found to be identical to a factor called ery-
throid potentiating activity (EPA). Other cell types which have been identified to be
affected directly by TIMP–1 include B-cells and keratinocytes. Thus, the TIMPs
appear to be multifunctional proteins, but the mechanisms underlying cellular func-
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tions remain poorly understood. Most relevant to this study the direct effects, if
any, of TIMP–1 on adult cardiomyocytes remain unclear.
5.4.4 MCP–1
MCP–1, also known as CC-motif chemokine ligand (CCL)–2, is a 76-residue profi-
brotic substance with a role in mononuclear cell recruitment and activation during
inflammation (Yoshimura et al. 1989). Its role in post-ischæmic heart injury and my-
ocardial remodeling has been studied using both knockout and overexpression mod-
els. MCP–1 knockout mice show less monocyte recruitment during myocardial is-
chæmia with reduced subsequent interstitial fibrosis and remodeling (Frangogiannis
et al. 2007). On the other hand, mice overexpressing MCP–1 in the heart (under con-
trol of the α-myosin heavy chain promoter) showed markedly increased macrophage
recruitment and progressive hypertrophic remodeling of the ventricle even in the
absence of injury (Kolattukudy et al. 1998). In these mice cardiac contractile per-
formance gradually deteriorated until death at around 6 months (Zhou et al. 2006).
In culture, exposure of human embryonic kidney (HEK)–293 cells or the H9C2
(a neonatal rat heart cell line) cells to MCP–1 increased the presence of a tran-
scription factor (MCP-induced protein, or MCPIP) and cell death. Using reverse-
transcription polymerase chain reaction (RT-PCR) the expression of the natural
receptor for MCP–1 (CCR–2) in the cardiomyocytes of 2 month-old rats has been
demonstrated (Zhou et al. 2006). However, the direct effect of MCP–1 on the sur-
vival and contractile properties of isolated adult cardiomyocytes remains untested.
Given the available data one may anticipate the overall effect to be adverse, but
direct experimental evidence is required.
To summarize, of the four substances which were found in increased concentrations
when cardiomyocytes were cultured together with skeletal myoblasts there is evi-
dence to hypothesize that IGF–1 and VEGF mediate beneficial effects directly. Less
is known about TIMP–1, the main function of which is the inhibitory regulation
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of MMP by complex formation, to suggest that it may have direct effects on car-
diomyocytes. Given that MCP–1 has adverse overall effects on myocardium further
study of its direct effects on cardiomyocytes and elucidation of intracellular path-
ways may be of equal importance as the potentially beneficial ones exerted by others.
To verify the roles of these substances future experiments involving corresponding
antagonists of these substances or skeletal myoblasts from gene knock-out animals
would be useful.
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Chapter 6
Acute effects of β-agonists on the
Na+-Ca2+ exchanger current
In Chapter 3 whole-cell patch-clamping experiments were carried out to measure
Na+-Ca2+ exchanger currents in freshly isolated cardiomyocytes (page 160). During
the development phase of these experiments additional, separate experiments were
performed. The purpose of this study was partly to validate the configuration of
the whole-cell patch-clamping system used to measure INCX densities in cardiomyo-
cytes isolated from the various rat hearts. The background to this separate study
and experimental findings are described in this chapter.
6.1 Introduction
6.1.1 Limitation of unloading-induced myocardial atrophy
by clenbuterol
As discussed in section 1.1.5 left ventricular assist devices (VADs) are primarily used
as a “bridge to transplantation”, where the failing heart of a patient is mechanically
assisted until a suitable donor organ becomes available (Clegg et al. 2006). However,
in a small number of patients VADs have served as “bridge to recovery”, since they
induced substantial functional improvement, enabling their explantation without
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the need for subsequent heart transplantation (Muller et al. 1997). Clearly, this is
an ideal outcome for the patient, but such “bridge to recovery” episodes have only
been observed to occur at low rates of 5 ∼ 10% (Mancini et al. 1998, Maybaum et al.
2007). The main reasons for this low frequency include the extremely severe disease
of the hearts receiving VAD support, and also the limited regenerating capacity
of the heart. Another important reason for the low frequency of recovery is that
complete mechanical unloading of a heart ventricle leads to functional, structural,
and molecular changes in its own right (Wohlschlaeger et al. 2005). Unloading
results in myocardial atrophy, often with adverse consequences. Animal studies
of ventricular unloading have demonstrated time-dependent changes in cardiomyo-
cyte contractile function and Ca2+ handling, which correlate with impaired cardiac
performance (Ito et al. 2003).
Clenbuterol is a substance classified as a β2-AR agonist, based on its molecular
structure (MacLennan & Edwards 1989). It shares structural similarities with salbu-
tamol and was previously used to treat patients with asthma (Salorinne et al. 1975).
However, in addition to its bronchodilator effects clenbuterol has been found to in-
duce hypertrophy in skeletal muscle (George et al. 2006) and myocardium (Petrou
et al. 1995). In normal rat hearts its chronic administration induces cardiomyocyte
hypertrophy (Wong et al. 1997) and increases oxidative carbohydrate utilization.
The SR Ca2+ content and the amplitude of the Ca2+ transient are increased (Soppa
et al. 2005). In a recent study, Soppa et al. (2008) tested the chronic effect of
clenbuterol on mechanically unloaded failing hearts. Rats underwent myocardial
infarction and were allowed to developed chronic heart failure. The hearts were
then mechanically unloaded for one week by means of heterotopic transplantation.
Administration of clenbuterol during this period limited the unloading-induced at-
rophy. The Ca2+ handling and contractile performance of individual cardiomyocytes
isolated from these hearts were superior compared to cardiomyocytes from control
unloaded hearts, which received only saline during the same period.
The results from these animal model experiments, which suggest that clenbu-
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terol limits the atropy induced by mechanical unloading, are consistent with data
from clinical studies performed at Harefield Hospital (Birks et al. 2006). Patients
with severe dilated cardiomyopathy were treated with a combination of mechanical
unloading and pharmacological therapy. Clenbuterol was included in the treatment
protocol after VAD implantation with the specific aim of preventing unloading-
induced atrophy and dysfunction of the myocardium. Out of 15 patients sufficient
myocardial recovery had occurred in 11 cases, enabling VAD explantation. The
cumulative rate of freedom from recurrent heart failure among the surviving pa-
tients was 88.9% at four years after explantation, with near-normal quality of life.
6.1.2 β-adrenergic signaling in the heart
The stimulation of β-adrenoreceptors by the sympathetic nervous system and cir-
culating catecholamines plays a pivotal role in regulating heart function. The phy-
siological properties which are affected include pacemaker activity (and heart rate)
and myocardial contractility. Since the classification of β-receptors into β1 and β2
subtypes by Lands et al. (1967), there has been a substantial amount of research on
β-adrenoreceptors, the pharmacological properties of various agonists and antago-
nists, and the intracellular signaling pathways activated by the receptors.
The differences between the β1- and β2-adrenoreceptors were mostly revealed
by studies using selective agonists and antagonists, in particular CGP–20712A (a
β1-antagonist, Dooley et al. 1986) and ICI–118,551 (a β2-antagonist, O’Donnell &
Wanstall 1980). In the human ventricle, the β1-subtype constitutes 70 ∼ 80% of the
total β-adrenoreceptor complement, while the β2-subtype constitutes the remaining
20 ∼ 30% (Brodde 1991). The two subtypes of receptor initially appear to have
similar functions. For example, administration of either a β1- or a β2-agonist acutely
increases myocardial contractility. However, more detailed studies reveal different,
sometimes even opposite, physiological roles between the two receptors, involving
diverging intra-cellular signaling pathways. Cardiac-specific overexpression of the
β2-adrenoreceptors in mice results in enhanced myocardial contractility, even in the
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absence of an agonist, without obvious pathology (Milano et al. 1994). In contrast,
β1-adrenoreceptor overexpression increases cardiomyocyte apoptosis and leads to
severe dilated cardiomyopathy and premature death (Engelhardt et al. 1999). Mice
in which the β1-adrenoreceptor gene has been deleted show no inotropic response to
acute stimulation by catecholamines (Rohrer et al. 1996), whereas β2-adrenoreceptor
knock-out mice show full responses (Chruscinski et al. 1999).
Valuable insight into the long-term effects of β-adrenoreceptor stimulation is
also provided by clinical data. In heart failure patients β1-agonists are useful in
the acute phase as cardiac inotropes, but their long-term administration increases
mortality (and conversely, β-blockers are well known to improve heart function and
prognosis, as discussed on page 30). However, in β1-adrenoreceptor knock-out mice,
the chronic administration of isoproterenol yields the opposite: a protective effect
(Zhu et al. 2001).
That β1- and β2-adrenoreceptors mediate different physiological effects by ac-
tivating different intracellular pathways is further supported by the subtle differ-
ences that can be seen in the Ca2+ handling and mechanical properties of cardio-
myocytes following acute exposure to selective agonists. For example, the posi-
tive inotropic effect induced via β2-adrenoreceptor activation is generally less than
that via β1 (Kaumann et al. 1996). Also, whereas β1-stimulation increases heart
rate (chronotropy), myocardial contractility (inotropy), and speed of relaxation
(lusitropy), in some animal species the lusitropic effect is not seen (Borea et al. 1992).
The differences in the cellular effects of β1- and β2-activation can be explained by
their coupling to guanosine triphosphate binding proteins (G proteins). Stimula-
tion of β2-, but not β1-adrenoreceptors, activates an inhibitory G protein (Gi) in
adult rat cardiomyocytes, while both adrenoreceptor subtypes are able to stimu-
late the classic adenylyl cyclase (AC) ⇒ 3´,5´-adenosine monophosphate (cAMP)
⇒ protein kinase-A (PKA) pathway via the stimulatory G protein (Gs, Fig.6.1).
The modulatory effect of Gi ⇒ phosphoinositide 3-kinase (PI3K) pathway can be re-
vealed using pertussis toxin (PTX), which disables Gi through ribosylation (Brechler
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Fig. 6.1: Subtype-specific signaling pathways of cardiac β-adrenoreceptors. β1-adreno-
receptors activate PKA and CaMKII via Gs. β2-adrenoreceptors, in addition to Gs, activate
the PI3K ⇒ Akt pathway via Gi. Abbreviations: PKA protein kinase A; AC adenylyl
cyclase; cAMP (cyclic) 3´,5´-adenosine monophosphate; CaMKII calmodulin-dependent
protein kinase II; PI3K phosphoinositide 3-kinase; PTX pertussis toxin; NO nitric oxide;
NOS nitric oxide synthase. Figure taken from Zheng et al. (2005).
et al. 1992). Cardiomyocytes with disrupted Gi signaling after exposure to PTX
exhibit markedly enhanced β2-mediated positive inotropy, whilst the β1-mediated
effects show no change (Xiao et al. 1995, Xiao 2001).
6.1.3 Pharmacological properties of various β-agonists
A variety of β-agonists and antagonists have been identified, with varying degrees
of selectivity for the subtypes of receptor, and even different profiles of Gi and Gs
activation (for reviews of β-adrenoreceptors and agonists, see Brodde (1991) and
also Brodde & Michel (1999)). For example, isoproterenol is a well-characterized
non-selective β-agonist. It acutely increases cardiomyocyte contractility and Ca2+
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transient amplitude, as well as speed of relaxation (Endoh & Blinks 1988, Spurgeon
et al. 1990). Salbutamol is a well-characterized β-agonist, which is commonly used
as an inhaled drug to treat patients with asthma (Xiao et al. 2003). Compared to
isoproterenol, it is relatively selective for the stimulation of β2 subtype of receptors.
Fenoterol is also a well-studied agonist which causes positive inotropy following
acute exposure. Compared to isoproterenol, it is more selective for the stimulation of
β2 subtype (Xiao et al. 2003, Harding & Gong 2004). It has attracted some interest,
with the hope that selective β2-stimulation using fenoterol might be beneficial in
the treatment of heart failure. Indeed, β2-stimulation by fenoterol restores the con-
tractility of cardiomyocytes isolated from the hearts of spontaneous hypertensive rat
(SHR, Xiao et al. 2003) and markedly protects myocardium from ischæmia-induced
hypertrophy and apoptosis (Ahmet et al. 2004, Ahmet et al. 2008). However, the
effects of fenoterol are mediated in a manner insensitive to PTX, and are there-
fore thought to be independent of the Gi pathway. Unlike other β2-agonists such
as salbutamol, fenoterol might be considered to be a selective agonist of the β2-Gs
pathway (Xiao et al. 2003), but the precise mechanisms underlying its effects require
elucidation in further detail.
Despite the interesting observations made regarding clenbuterol (described on
page 205) and potentially important clinical implications, its direct on cardiomyo-
cytes has not been extensively studied. How clenbuterol compares to other well-
established β-agonists, such as those above, in terms of β1-and β2-adrenoreceptor
stimulation, and its profile of Gs and Gi activation has not been elucidated. Previous
experimental work carried out in our laboratory showed that acute application of
30 µM clenbuterol onto normal rat cardiomyocytes reversibly reduced their I Ca,L,
Ca2+ transients, and contractions (Dr. Urszula Siedlecka, personal communication).
The effects of clenbuterol on other parameters of EC coupling, such as the action
potential profile or INCX , have not been described.
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6.1.4 Experiment design
In this chapter the acute effect of clenbuterol on the INCX density of normal rat
cardiomyocytes was assessed, and compared to other β-active compounds, including
the following:
• Isoproterenol
• Fenoterol
• Salbutamol
• Isoproterenol plus CGP–20712A: The possible effect of selective β2-sti-
mulation was investigated more extensively by using a mixture of isoproterenol
plus the selective β1-antagonist, CGP–20712A.
As mentioned earlier, these studies were performed during the preparation phase for
the experiments outlined in earlier chapters, partly to test the configuration of the
whole-cell patch-clamping system used to measure INCX densities in cardiomyocytes
isolated from the various rat hearts.
6.2 Methods
Cardiomyocytes were isolated from normal adult Sprague-Dawley rats using the
standard enzymatic digestion protocol, outlined in section 2.12.3. Isolated cardio-
myocytes were used within six hours. The INCX densities of cardiomyocytes were
measured using the whole cell patch-clamping method, as described in section 2.12.3.
Initially, steady state currents were recorded during application of the ramp pro-
tocol in K+-free superfusate (see Fig.6.2). The effects of acute administration of
various β-active substances were tested by rapidly switching the K+-free Tyrode su-
perfusate to one containing the added compound by means of a solenoid controlled
solution switcher device. Membrane currents were recorded once steady state was
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established. The superfusate was then switched to one containing the β-active com-
pound plus 5 mM Ni2+. Finally, the active current measured during superfusion
with 5 mM Ni2+ only added was recorded. The baseline INCX was taken to be
the Ni2+-sensitive component of the baseline current (i.e. current 4 subtracted from
current 1, from Fig.6.2), whilst the INCX during superfusion of the β-active sub-
stance was taken to be the Ni2+-sensitive component of the corresponding currents
(i.e. current 3 subtracted from current 2).
The concentrations of the various β-active compounds tested using this setup
were as follows.
• 1 µM clenbuterol
• 2 µM isoproterenol
• 10 µM fenoterol
• 50 µM salbutamol
• 300 nM isoproterenol + 300 nM CGP–20712A
All of these β-active compounds were purchased from Sigma-Aldrich, UK. They
were diluted in K+-free Tyrode superfusate on the day of use, either from fresh
powder or from frozen concentrated aliquots which were stored at −20 ℃. Manufac-
turer’s recommendations for preparation and storage were followed.
Statistical analyses were performed using paired Student’s t-tests to compare the
current densities measured at various membrane voltages from the same cardiomyo-
cyte before and after application of the β-agonist. Results are expressed as mean ±
S.E.M. and were considered statistically significant when p < 0.05.
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Fig. 6.2: Protocol for measuring the effect of acute application of a β-agonist on I NCX .
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6.3 Results
In K+-free Tyrode solution the INCX density measured 2.17±0.20 pA/pF at +80 mV
and−0.85±0.32 pA/pF at−120 mV (Fig.6.3, closed circles). The reversal potential
was approximately −32 mV. These values are similar to those previously measured
by others using whole-cell patch clamping in normal adult rat ventricular myocytes
(Chorvatova et al. 2004, Wasserstrom et al. 2000, Zhang et al. 1999).
The acute application of 1 µM clenbuterol decreased the INCX density by ap-
proximately 37% (Fig.6.3). The change in INCX magnitude was acute, with steady
state currents in clenbuterol being established within 1 ∼ 2 minutes. The INCX den-
sity at −120 mV was not significantly affected. The reversal potential also remained
unchanged.
The effect of clenbuterol was compared to that of other β-active compounds.
The application of isoproterenol causes substantial increases in cardiomyocyte con-
traction and Ca2+ transient amplitude at concentrations above 0.5 µM (Spurgeon
et al. (1990). Similar results were also observed in our laboratory, data not shown).
However, as can be seen on Fig.6.4 application of 2 µM isoproterenol had no mea-
surable effect on INCX . Previous studies by others reported variation in the response
of INCX to isoproterenol, depending on animal species. For example, Ginsburg &
Bers (2005) measured no effect of 1 µM isoproterenol on INCX in rabbit cardio-
myocytes, which agrees with the current results seen in rat. On the other hand,
Perchenet et al. (2000) found that 1 µM isoproterenol increased INCX density in
guinea-pig cardiomyocytes at 37℃.
The possibility that clenbuterol affects INCX via β-receptors was investigated
further by comparing against the effects of additional β-agonists. The effect of
acute application of 10 µM fenoterol, a β-agonist relatively more selective for the β2
subtype of receptors, was assessed. As illustrated in Fig.6.5 there was no significant
effect.
Fig.6.6 shows the effect on INCX density observed following application of 50 µM
salbutamol, another β2-selective agonist. In contrast to fenoterol, the INCX density
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Fig. 6.3: Acute effect of clenbuterol on I NCX density. 1 µM clenbuterol reduced I NCX
density in normal rat cardiomyocytes by up to 37%. No¯ of cells = 18. ∗ p < 0.05. Paired
Student’s t=test was used for the statistical comparison.
at +80 mV was reduced by approximately 17%. This effect took place within 1 ∼ 2
minutes. The INCX density at −120 mV and the reversal potential were not signi-
ficantly affected.
The effect of selective β2 stimulation was also investigated by applying a solution
mixture of 300 nM isoproterenol plus 300 nM CGP–20712A. CGP–20712A is a se-
lective inhibitor of β1 receptors (Dooley et al. 1986). Although a lower concentration
of isoproterenol was present in this mixture than in the previous experiment shown
in Fig.6.4, there was a decrease of INCX density, by up to 37%.
These results from testing various β-active compounds are collectively summa-
rized in Table 6.1 on page 218.
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Fig. 6.4: Acute effect of isoproterenol on I NCX density. 2 µM isoproterenol had no signifi-
cant effect on I NCX density in normal rat cardiomyocytes. N
o
¯ of cells = 11. Paired Student’s
t=test was used for the statistical comparison.
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Fig. 6.5: Acute effect of fenoterol on I NCX density. 10 µM fenoterol had no significant effect
on I NCX density in normal rat cardiomyocytes. N
o
¯ of cells = 15. Paired Student’s t=test
was used for the statistical comparison.
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Fig. 6.6: Acute effect of salbutamol on I NCX density. 50 µM salbutamol reduced I NCX
density in normal rat cardiomyocytes by up to 17%. No¯ of cells = 8. ∗∗ p < 0.01. ∗ p < 0.05.
Paired Student’s t=test was used for the statistical comparison.
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Fig. 6.7: Acute effect of isoproterenol plus CGP–20712A on I NCX density. 300 nM isopro-
terenol + 300 nM CGP reduced I NCX density in normal rat cardiomyocytes by up to 37%.
No¯ of cells = 15. ∗∗ p < 0.01. ∗ p < 0.05. Paired Student’s t=test was used for the statistical
comparison.
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Table 6.1: The effects of various β-agonists on I NCX density
Agonist Concentration Effect Receptor G-Protein
Clenbuterol 1 µM ↓ β2 Gi
†
Isoproterenol 2 µM ↔ β1 and β2 Gi and Gs
Fenoterol 10 µM ↔ β2 Gs only
Salbutamol 50 µM ↓ β2 Gi and Gs
Iso plus CGP–20712A 300 + 300 nM ↓ β2 Gi and Gs
† The contribution of Gs remains unassessed.
Abbreviations: Iso: isoproterenol. ↓ decreased. ↔ no change.
6.4 Discussion
The acute application of clenbuterol resulted in a decrease in INCX density. Similar
effects were seen following application of selective β2 stimulation by salbutamol, and
also by the mixture of isoproterenol plus CGP–20712A. In comparison, simultaneous
stimulation of both β1 and β2 receptors by application of isoproterenol had no overall
effect. Application of an alternative β2-agonist, fenoterol, also had no significant
effect on INCX.
These results can be interpreted in the context of differential coupling of the
β-receptors to intracellular signaling pathways. β-receptors are members of the G
protein-coupled receptor superfamily, and their main effect on ventricular cardio-
myocytes is to increase the amplitudes of I Ca,L, Ca
2+ transient, and contraction.
However, whereas both β1 and β2 stimulation result in these changes, only β1 stim-
ulation accelerates the decay of the Ca2+ transient and cardiomyocyte relaxation
(Borea et al. 1992, Xiao & Lakatta 1993). In addition, it has been demonstrated
that selective inhibition of the Gi pathway by pre-treatment of the cardiomyocytes
by PTX potentiates the effects of β2, but not β1 stimulation (Xiao et al. 1995).
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These observations suggest that activation of the Gi pathway following β2 receptor
stimulation may partially antagonize the Gs-mediated effects on cardiomyocyte EC
coupling (for a review on functional coupling of the β-receptor to Gs and Gi proteins
see Xiao 2001).
With the background of this understanding, it appears that simultaneous stim-
ulation of both Gi and Gs via β2 receptors causes a decrease in rat INCX density.
These are seen following application of salbutamol and also the mixture of isopro-
terenol plus CGP–20712A. β2 receptor stimulation by fenoterol has no effect on
INCX, which is most likely because it selectively activates Gs only. This interpreta-
tion is consistent with previous assessment of its effect on contractility, where the
effect of fenoterol was not further augmented after disrupting the Gi pathway by
pre-incubating cardiomyocytes in PTX (Xiao et al. 2003).
Compared with these agonists, the effect of clenbuterol suggests that it may
activate the β2-Gi pathway. This interpretation would be supported by future expe-
riments measuring the effect of clenbuterol on INCX in cardiomyocytes pre-treated
with PTX. Abolishment of the inhibitory effect would support the conclusion above.
Additional experiments are required to help understand the potential effects of
β1-stimulation on INCX . Whereas activation of both Gs and Gi pathways following
β2 receptor stimulation causes a decrease in INCX , simultaneous β1 activation, as
when isoproterenol only was applied, appears to negate this effect. Assessment of
the effect of a selective β1-agonist, such as dobutamine, or studying the effect of
isoproterenol in the presence of ICI–118,551, which is a selective β2 inhibitor, would
be interesting experiments that might provide further insight into this phenomenon.
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Chapter 7
Concluding remarks
Injection of skeletal myoblasts or bone marrow mononuclear cells into chronically
failing rat hearts improved ejection fraction at 4 weeks. Characterization of the re-
cipient cardiomyocytes isolated from these hearts revealed changes in their morphol-
ogy and EC coupling, and enhanced contractile properties. To test the hypothesis
that these effects observed in vivo are mediated by paracrine substances secreted
from the transplanted cells further experiments were performed. Cardiomyocytes
isolated from failing rat hearts were cultured for 48 hours. Co-culturing with skeletal
myoblasts or bone marrow mononuclear cells affected Ca2+ handling and improved
the contractility of nearby failing cardiomyocytes. The effect was maintained when
the different cell populations were physically separated using a porous membrane,
indicating that paracrine secretions can mediate the inter-cellular effects. The su-
pernate samples from these co-culture experiments were analyzed using ELISA and
cytokine antibody arrays. These assays detected increased levels of IGF–1, VEGF,
MCP–1 and TIMP–1, identifying them as secreted substances that might mediate
the paracrine effects.
Together, these results provide the first direct evidence to support the hypothesis
that cells transplanted into a failing heart affects recipient cardiomyocyte EC coup-
ling through paracrine mechanisms, thereby enhancing myocardial performance.
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What are the main limitations of the thesis? Although the results from
Chapter 3 are supported by those described in Chapters 4 and 5, the necessity of
performing the latter experiments in vitro has meant that the exact contribution of
the demonstrated paracrine effects towards the functional benefit in vivo remains to
be assessed. In other words, following the demonstration of a particular effect in vitro
one can not safely assume that the same effect is the only mechanism responsible for
the physiological changes occurring in vivo. However, as discussed in section 1.4 of
Chapter 1, the paracrine theory has been proposed by other researchers in the field
as an explanation following the exclusion of other possibilities, most notably the de
novo regeneration of a substantial volume of myocardium. Other mechanisms have
also been proposed by others to explain the functional benefits resulting from cell
transplantation, such as neoangiogenesis and modulation of the extracellular matrix.
These were discussed on page 72. Whilst they are potentially also important, they
have not been the main subject of this thesis.
What are the future experiments that might be useful? It is possible to
design further experiments that might yield data to support the findings currently
presented. The identification of IGF–1, VEGF, TIMP–1 and MCP–1 as candidate
paracrine mediators of the effects exerted by skeletal myoblasts leads to further study
of the effects of skeletal myoblasts and bone marrow mononuclear cells obtained
from animals which are deficient in these genes. Such cells, which were not available
during the presented study, would be most useful for confirming the physiological
involvement of these substances, as they could be studied in vivo as well as in co-
culture systems. An alternative approach, at least for assessment using co-culture
systems, would be to utilize selective inhibitors of these signaling molecules.
Should cell transplantation for heart failure be performed in humans?
Large-scale clinical trials are already being performed world-wide, although cell
transplantation is far from being established treatment for heart failure. The large
volume of animal model studies published by numerous research groups, and also
the work presented in this thesis, demonstrate that cell transplantation is capable
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of delivering a clear functional benefit. Thus, it appears that cell transplantation
holds considerable promise for the treatment of heart failure, and further research
is warranted. However, clinical trials have shown mixed results and meta-analyses
have demonstrated only small benefits. Subsequently, many researchers in the field
of cardiac cell transplantation are increasingly promoting a “return from bedside to
bench” (Arnesen et al. 2007, Nadal-Ginard & Fuster 2007). In this regard, it appears
that current research should aim to identify the similarities between the animal and
human studies and address the disparities between animal and human studies as a
priority. Substantial differences in cardiomyocyte EC coupling are known to exist
between different animal species, including human, under both normal and patho-
logical conditions. Furthermore, cardiomyocytes isolated from different models of
heart failure vary substantially in their properties depending on mode of induction
and disease duration and severity. Thus, further characterization of the pathophys-
iology of heart failure and elucidation of the physiological mechanisms responsible
for the beneficial effects mediated by transplanted cells under specific disease states
would hold the best promise towards optimizing the future results of cell therapy.
222
Bibliography
Abbate, A., Biondi-Zoccai, G. G., Bussani, R., Dobrina, A., Camilot, D., Feroce,
F., Rossiello, R., Baldi, F., Silvestri, F., Biasucci, L. M. & Baldi, A. (2003),
‘Increased myocardial apoptosis in patients with unfavorable left ventricular
remodeling and early symptomatic post-infarction heart failure’, Journal of the
American College of Cardiology 41(5), 753–760.
Abdel-Latif, A., Bolli, R., Tleyjeh, I. M., Montori, V. M., Perin, E. C., Hornung,
C. A., Zuba-Surma, E. K., Al Mallah, M. & Dawn, B. (2007), ‘Adult bone
marrow-derived cells for cardiac repair: a systematic review and meta-analysis’,
Archives of Internal Medicine 167(10), 989–997.
Abramoff, M. D., Magelhaes, P. J. & Ram, S. J. (2004), ‘Image Processing with
ImageJ’, Biophotonics International 11(7), 36–42.
Ahmet, I., Krawczyk, M., Heller, P., Moon, C., Lakatta, E. G. & Talan, M. I. (2004),
‘Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor
subtype signaling in rodent dilated ischemic cardiomyopathy’, Circulation
110(9), 1083–1090.
Ahmet, I., Krawczyk, M., Zhu, W., Woo, A. Y., Morrell, C., Poosala, S., Xiao, R. P.,
Lakatta, E. G. & Talan, M. I. (2008), ‘Cardioprotective and Survival Benefits
of Long-term Combined Therapy with β2-AR Agonist and β1-AR Blocker in
Dilated Cardiomyopathy Post-Myocardial Infarction’, The Journal of Pharma-
cology and Experimental Therapeutics (In press).
223
Al Khaldi, A. & Robbins, R. C. (2006), ‘New directions in cardiac transplantation’,
Annual Review of Medicine 57, 455–471.
Allen, D. G. & Kentish, J. C. (1985), ‘The cellular basis of the length-tension relation
in cardiac muscle’, Journal of Molecular and Cellular Cardiology 17(9), 821–
840.
Alvarez-Dolado, M., Pardal, R., Garcia-Verdugo, J. M., Fike, J. R., Lee, H. O.,
Pfeffer, K., Lois, C., Morrison, S. J. & Alvarez-Buylla, A. (2003), ‘Fusion of
bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepato-
cytes’, Nature 425(6961), 968–973.
Amoah, A. G. & Kallen, C. (2000), ‘Aetiology of heart failure as seen from a National
Cardiac Referral Centre in Africa’, Cardiology 93(1-2), 11–18.
Armoundas, A. A., Hobai, I. A., Tomaselli, G. F., Winslow, R. L. & O’Rourke, B.
(2003), ‘Role of sodium-calcium exchanger in modulating the action potential
of ventricular myocytes from normal and failing hearts’, Circulation Research
93(1), 46–53.
Arnesen, H., Lunde, K., Aakhus, S. & Forfang, K. (2007), ‘Cell therapy in myocardial
infarction’, The Lancet 369(9580), 2142–2143.
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzen-
bichler, B., Schatteman, G. & Isner, J. M. (1997), ‘Isolation of putative pro-
genitor endothelial cells for angiogenesis’, Science 275(5302), 964–967.
Assmus, B., Ho¨nold, J., Scha¨chinger, V., Britten, M. B., Fischer-Rasokat, U.,
Lehmann, R., Teupe, C., Pistorius, K., Martin, H., Abolmaali, N. D., Tonn, T.,
Dimmeler, S. & Zeiher, A. M. (2006), ‘Transcoronary transplantation of pro-
genitor cells after myocardial infarction’, The New England Journal of Medicine
355(12), 1222–1232.
224
Baartscheer, A., Schumacher, C. A., van Borren, M. M., Belterman, C. N., Coronel,
R. & Fiolet, J. W. (2003), ‘Increased Na+/H+-exchange activity is the cause of
increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure
and volume overload heart failure model’, Cardiovascular Research 57(4), 1015–
1024.
Balsam, L. B., Wagers, A. J., Christensen, J. L., Kofidis, T., Weissman, I. L. &
Robbins, R. C. (2004), ‘Hæmatopoietic stem cells adopt mature hæmatopoietic
fates in ischæmic myocardium’, Nature 428(6983), 668–673.
Banijamali, H. S., Gao, W. D., MacIntosh, B. R. & ter Keurs, H. E. (1991), ‘Force-
interval relations of twitches and cold contractures in rat cardiac trabeculae.
Effect of ryanodine’, Circulation Research 69(4), 937–948.
Barnard, C. N. (1967), ‘The operation. A human cardiac transplant: an interim
report of a successful operation performed at Groote Schuur Hospital, Cape
Town’, The South African Medical Journal 41(48), 1271–1274.
Bartunek, J., Dimmeler, S., Drexler, H., Fernandez-Aviles, F., Galinanes, M.,
Janssens, S., Martin, J., Mathur, A., Menasche´, P., Priori, S., Strauer, B.,
Tendera, M., Wijns, W. & Zeiher, A. (2006), ‘The consensus of the task force
of the European Society of Cardiology concerning the clinical investigation of
the use of autologous adult stem cells for repair of the heart’, European Heart
Journal 27(11), 1338–1340.
Bassani, J. W., Bassani, R. A. & Bers, D. M. (1994), ‘Relaxation in rabbit and
rat cardiac cells: species-dependent differences in cellular mechanisms’, The
Journal of Physiology 476(2), 279–293.
Bassett, A. L. & Gelband, H. (1973), ‘Chronic partial occlusion of the pulmonary
artery in cats. Change in ventricular action potential configuration during early
hypertrophy’, Circulation Research 32(1), 15–26.
225
Batista, R. J., Santos, J. L., Takeshita, N., Bocchino, L., Lima, P. N. & Cunha,
M. A. (1996), ‘Partial left ventriculectomy to improve left ventricular function
in end-stage heart disease’, Journal of Cardiac Surgery 11(2), 96–97.
Bean, B. P. (1985), ‘Two kinds of calcium channels in canine atrial cells. Differences
in kinetics, selectivity, and pharmacology’, The Journal of General Physiology
86(1), 1–30.
Benitah, J. P., Gomez, A. M., Bailly, P., Da Ponte, J. P., Berson, G., Delgado, C.
& Lorente, P. (1993), ‘Heterogeneity of the early outward current in ventric-
ular cells isolated from normal and hypertrophied rat hearts’, The Journal of
Physiology 469, 111–138.
Berry, M. N., Friend, D. S. & Scheuer, J. (1970), ‘Morphology and metabolism of in-
tact muscle cells isolated from adult rat heart’, Circulation Research 26(6), 679–
687.
Bers, D. M. (2002), ‘Cardiac excitation-contraction coupling’, Nature
415(6868), 198–205.
Bers, D. M., ed. (2003), Excitation-Contraction Coupling and Cardiac Contractile
Force, second edn, Kluwer Academic.
Beuckelmann, D. J., Na¨bauer, M. & Erdmann, E. (1992), ‘Intracellular calcium
handling in isolated ventricular myocytes from patients with terminal heart
failure’, Circulation 85(3), 1046–1055.
Beuckelmann, D. J. & Wier, W. G. (1988), ‘Mechanism of release of calcium from
sarcoplasmic reticulum of guinea-pig cardiac cells’, The Journal of Physiology
405, 233–255.
Bing, O. H. (1994), ‘Hypothesis: apoptosis may be a mechanism for the transition to
heart failure with chronic pressure overload’, Journal of Molecular and Cellular
Cardiology 26(8), 943–948.
226
Birks, E. J., Tansley, P. D., Hardy, J., George, R. S., Bowles, C. T., Burke, M.,
Banner, N. R., Khaghani, A. & Yacoub, M. H. (2006), ‘Left ventricular assist
device and drug therapy for the reversal of heart failure’, The New England
Journal of Medicine 355(18), 1873–1884.
Bolling, S. F., Pagani, F. D., Deeb, G. M. & Bach, D. S. (1998), ‘Intermediate-term
outcome of mitral reconstruction in cardiomyopathy’, The Journal of Thoracic
and Cardiovascular Surgery 115(2), 381–386.
Borea, P. A., Amerini, S., Masini, I., Cerbai, E., Ledda, F., Mantelli, L., Varani, K.
& Mugelli, A. (1992), ‘β1- and β2-adrenoceptors in sheep cardiac ventricular
muscle’, Journal of Molecular and Cellular Cardiology 24(7), 753–763.
Bountra, C. & Vaughan-Jones, R. D. (1989), ‘Effect of intracellular and extracellular
pH on contraction in isolated, mammalian cardiac muscle’, The Journal of
Physiology 418, 163–187.
Brater, D. C. (1998), ‘Diuretic therapy’, The New England Journal of Medicine
339(6), 387–395.
Braunwald, E. (1997), ‘Shattuck lecture – Cardiovascular medicine at the turn of the
millennium: triumphs, concerns, and opportunities’, The New England Journal
of Medicine 337(19), 1360–1369.
Braunwald, E., ed. (2007), Braunwald’s heart disease: A Textbook of cardiovascular
medicine, eighth edn, Saunders.
Braunwald, E. & Pfeffer, M. A. (1991), ‘Ventricular enlargement and remodeling fol-
lowing acute myocardial infarction: mechanisms and management’, American
Journal of Cardiology 68(14), 1D–6D.
Brechler, V., Pavoine, C., Hanf, R., Garbarz, E., Fischmeister, R. & Pecker, F.
(1992), ‘Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phos-
227
phodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein’,
Journal of Biological Chemistry 267(22), 15496–15501.
Brennecke, R. & Lindemann, B. (1974a), ‘Design of a fast voltage clamp for biologi-
cal membranes, using discontinuous feedback’, Review of Scientific Instruments
45(5), 656–661.
Brennecke, R. & Lindemann, B. (1974b), ‘Theory of a membrane-voltage clamp with
discontinuous feedback through a pulsed current clamp’, Review of Scientific
Instruments 45(a), 184–188.
Brew, K., Dinakarpandian, D. & Nagase, H. (2000), ‘Tissue inhibitors of metallo-
proteinases: evolution, structure and function’, Biochimica et Biophysica Acta
1477(1-2), 267–283.
Bridge, J. H., Smolley, J. R. & Spitzer, K. W. (1990), ‘The relationship between
charge movements associated with I Ca,L and INa/Ca in cardiac myocytes’, Sci-
ence 248(4953), 376–378.
Bridge, J. H., Spitzer, K. W. & Ershler, P. R. (1988), ‘Relaxation of isolated ventric-
ular cardiomyocytes by a voltage-dependent process’, Science 241(4867), 823–
825.
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., Marco, T. D.,
Carson, P., DiCarlo, L., DeMets, D., White, B. G., DeVries, D. W. & Feld-
man, A. M. (2004), ‘Cardiac-resynchronization therapy with or without an
implantable defibrillator in advanced chronic heart failure’, The New England
Journal of Medicine 350(21), 2140–2150.
Brodde, O. E. (1991), ‘β1 and β2-adrenoceptors in the human heart: properties,
function, and alterations in chronic heart failure’, Pharmacological Reviews
43(2), 203–242.
228
Brodde, O. E. & Michel, M. C. (1999), ‘Adrenergic and muscarinic receptors in the
human heart’, Pharmacological Reviews 51(4), 651–690.
Brommundt, G. & Kavaler, F. (1987), ‘La3+, Mn2+, and Ni2+ effects on Ca2+ pump
and on Na+/Ca2+ exchange in bullfrog ventricle’, American Journal of Physi-
ology 253(1 Pt 1), C45–C51.
Brooksby, P., Levi, A. J. & Jones, J. V. (1993), ‘The electrophysiological characteris-
tics of hypertrophied ventricular myocytes from the spontaneously hypertensive
rat’, Journal of Hypertension 11(6), 611–622.
Callewaert, G., Cleemann, L. & Morad, M. (1989), ‘Caffeine-induced Ca2+ release
activates Ca2+ extrusion via Na+/Ca2+ exchanger in cardiac myocytes’, Amer-
ican Journal of Physiology 257(1 Pt 1), C147–C152.
Cannell, M. B., Berlin, J. R. & Lederer, W. J. (1987), ‘Effect of membrane potential
changes on the calcium transient in single rat cardiac muscle cells’, Science
238(4832), 1419–1423.
Capasso, J. M. & Anversa, P. (1992), ‘Mechanical performance of spared myocytes
after myocardial infarction in rats: effects of captopril treatment’, American
Journal of Physiology 263(3 Pt 2), H841–H849.
Caves, P. K., Stinson, E. B., Billingham, M. E. & Shumway, N. E. (1974), ‘Serial
transvenous biopsy of the transplanted human heart. Improved management of
acute rejection episodes’, The Lancet 1(7862), 821–826.
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W. & Prasher, D. C. (1994), ‘Green
fluorescent protein as a marker for gene expression’, Science 263(5148), 802–
805.
Chen, S. L., Fang, W. W., Ye, F., Liu, Y. H., Qian, J., Shan, S. J., Zhang, J. J.,
Chunhua, R. Z., Liao, L. M., Lin, S. & Sun, J. P. (2004), ‘Effect on left ven-
tricular function of intracoronary transplantation of autologous bone marrow
229
mesenchymal stem cell in patients with acute myocardial infarction’, American
Journal of Cardiology 94(1), 92–95.
Cheng, H., Lederer, W. J. & Cannell, M. B. (1993), ‘Calcium sparks: elemen-
tary events underlying excitation-contraction coupling in heart muscle’, Science
262(5134), 740–744.
Cheng, H., Song, L. S., Shirokova, N., Gonzalez, A., Lakatta, E. G., Rios, E. &
Stern, M. D. (1999), ‘Amplitude distribution of calcium sparks in confocal
images: theory and studies with an automatic detection method’, Biophysical
Journal 76(2), 606–617.
Chiu, R. C., Zibaitis, A. & Kao, R. L. (1995), ‘Cellular cardiomyoplasty: myocardial
regeneration with satellite cell implantation’, The Annals of Thoracic Surgery
60(1), 12–18.
Chorvatova, A., Hart, G. & Hussain, M. (2004), ‘Na+/Ca2+ exchange current
(INa+/Ca2+) and sarcoplasmic reticulum Ca
2+ release in catecholamine-induced
cardiac hypertrophy’, Cardiovascular Research 61(2), 278–287.
Chruscinski, A. J., Rohrer, D. K., Schauble, E., Desai, K. H., Bernstein, D. &
Kobilka, B. K. (1999), ‘Targeted disruption of the β2-adrenergic receptor gene’,
Journal of Biological Chemistry 274(24), 16694–16700.
Clegg, A. J., Scott, D. A., Loveman, E., Colquitt, J. L., Royle, P. & Bryant,
J. (2006), ‘Clinical and cost-effectiveness of left ventricular assist devices
as a bridge to heart transplantation for people with end-stage heart fail-
ure: a systematic review and economic evaluation’, European Heart Journal
27(24), 2929–2938.
Cleland, J. G., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., Kappen-
berger, L. & Tavazzi, L. (2005), ‘The effect of cardiac resynchronization on mor-
bidity and mortality in heart failure’, The New England Journal of Medicine
352(15), 1539–1549.
230
Cohick, W. S. & Clemmons, D. R. (1993), ‘The insulin-like growth factors’, Annual
Review of Physiology 55, 131–153.
Cohn, J. N. (1995), ‘Structural basis for heart failure. Ventricular remodeling and
its pharmacological inhibition’, Circulation 91(10), 2504–2507.
Cohn, J. N., Ferrari, R. & Sharpe, N. (2000), ‘Cardiac remodeling–concepts and
clinical implications: a consensus paper from an international forum on cardiac
remodeling. Behalf of an International Forum on Cardiac Remodeling’, Journal
of the American College of Cardiology 35(3), 569–582.
Cohn, J. N. & Tognoni, G. (2001), ‘A randomized trial of the angiotensin-receptor
blocker valsartan in chronic heart failure’, The New England Journal of
Medicine 345(23), 1667–1675.
Cowie, M. R., Wood, D. A., Coats, A. J., Thompson, S. G., Poole-Wilson, P. A.,
Suresh, V. & Sutton, G. C. (1999), ‘Incidence and ætiology of heart failure; a
population-based study’, European Heart Journal 20(6), 421–428.
Creemers, E. E., Davis, J. N., Parkhurst, A. M., Leenders, P., Dowdy, K. B., Hapke,
E., Hauet, A. M., Escobar, P. G., Cleutjens, J. P., Smits, J. F., Daemen, M. J.,
Zile, M. R. & Spinale, F. G. (2003), ‘Deficiency of TIMP–1 exacerbates LV re-
modeling after myocardial infarction in mice’, American Journal of Physiology
- Heart and Circulatory Physiology 284(1), H364–H371.
Dai, W., Hale, S. L., Martin, B. J., Kuang, J. Q., Dow, J. S., Wold, L. E. & Kloner,
R. A. (2005), ‘Allogeneic mesenchymal stem cell transplantation in postin-
farcted rat myocardium: short- and long-term effects’, Circulation 112(2), 214–
223.
Davies, C. H., Davia, K., Bennett, J. G., Pepper, J. R., Poole-Wilson, P. A. &
Harding, S. E. (1995), ‘Reduced contraction and altered frequency response
of isolated ventricular myocytes from patients with heart failure’, Circulation
92(9), 2540–2549.
231
Davies, L. A., Gibson, C. N., Boyett, M. R., Hopkins, P. M. & Harrison, S. M.
(2000), ‘Effects of isoflurane, sevoflurane, and halothane on myofilament Ca2+
sensitivity and sarcoplasmic reticulum Ca2+ release in rat ventricular myocytes’,
Anesthesiology 93(4), 1034–1044.
Davis, L. M., Rodefeld, M. E., Green, K., Beyer, E. C. & Saffitz, J. E. (1995),
‘Gap junction protein phenotypes of the human heart and conduction system’,
Journal of Cardiovascular Electrophysiology 6(10 Pt 1), 813–822.
Davis, R. C., Hobbs, F. D. & Lip, G. Y. (2000), ‘ABC of heart failure. History and
epidemiology’, BMJ 320(7226), 39–42.
del Monte, F., Harding, S. E., Schmidt, U., Matsui, T., Kang, Z. B., Dec, G. W.,
Gwathmey, J. K., Rosenzweig, A. & Hajjar, R. J. (1999), ‘Restoration of con-
tractile function in isolated cardiomyocytes from failing human hearts by gene
transfer of SERCA2a’, Circulation 100(23), 2308–2311.
del Monte, F., O’Gara, P., Poole-Wilson, P. A., Yacoub, M. & Harding, S. E. (1995),
‘Cell geometry and contractile abnormalities of myocytes from failing human
left ventricle’, Cardiovascular Research 30(2), 281–290.
del Monte, F., Williams, E., Lebeche, D., Schmidt, U., Rosenzweig, A., Gwathmey,
J. K., Lewandowski, E. D. & Hajjar, R. J. (2001), ‘Improvement in survival and
cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase
in a rat model of heart failure’, Circulation 104(12), 1424–1429.
Deten, A., Volz, H. C., Clamors, S., Leiblein, S., Briest, W., Marx, G. & Zimmer,
H. G. (2005), ‘Hematopoietic stem cells do not repair the infarcted mouse
heart’, Cardiovascular Research 65(1), 52–63.
Dib, N., Michler, R. E., Pagani, F. D., Wright, S., Kereiakes, D. J., Lengerich, R.,
Binkley, P., Buchele, D., Anand, I., Swingen, C., Carli, M. F. D., Thomas,
J. D., Jaber, W. A., Opie, S. R., Campbell, A., McCarthy, P., Yeager, M.,
232
Dilsizian, V., Griffith, B. P., Korn, R., Kreuger, S. K., Ghazoul, M., MacLellan,
W. R., Fonarow, G., Eisen, H. J., Dinsmore, J. & Diethrich, E. (2005), ‘Safety
and feasibility of autologous myoblast transplantation in patients with ischemic
cardiomyopathy: four-year follow-up’, Circulation 112(12), 1748–1755.
DiFrancesco, D. & Noble, D. (1985), ‘A model of cardiac electrical activity incorpo-
rating ionic pumps and concentration changes’, Philosophical Transactions of
the Royal Society of London B: Biological Sciences 307(1133), 353–398.
Dimmeler, S., Zeiher, A. M. & Schneider, M. D. (2005), ‘Unchain my heart: the
scientific foundations of cardiac repair’, The Journal of Clinical Investigation
115(3), 572–583.
Dixon, I. M., Hata, T. & Dhalla, N. S. (1992), ‘Sarcolemmal calcium transport in
congestive heart failure due to myocardial infarction in rats’, American Journal
of Physiology 262(5 Pt 2), H1387–H1394.
Dooley, D. J., Bittiger, H. & Reymann, N. C. (1986), ‘CGP–20712A: a useful tool for
quantitating β1- and β2-adrenoceptors’, The European Journal of Pharmacology
130(1-2), 137–139.
Dor, V., Sabatier, M., Di Donato, M., Montiglio, F., Toso, A. & Maioli, M. (1998),
‘Efficacy of endoventricular patch plasty in large postinfarction akinetic scar
and severe left ventricular dysfunction: comparison with a series of large dysk-
inetic scars’, The Journal of Thoracic and Cardiovascular Surgery 116(1), 50–
59.
Dowell, J. D., Rubart, M., Pasumarthi, K. B., Soonpaa, M. H. & Field, L. J. (2003),
‘Myocyte and myogenic stem cell transplantation in the heart’, Cardiovascular
Research 58(2), 336–350.
Dreyfus, G. D., Duboc, D., Blasco, A., Vigoni, F., Dubois, C., Brodaty, D., de Lent-
decker, P., Bachet, J., Goudot, B. & Guilmet, D. (1994), ‘Myocardial viability
233
assessment in ischemic cardiomyopathy: benefits of coronary revascularization’,
The Annals of Thoracic Surgery 57(6), 1402–1407.
Dries, D. L., Exner, D. V., Gersh, B. J., Cooper, H. A., Carson, P. E. & Domanski,
M. J. (1999), ‘Racial differences in the outcome of left ventricular dysfunction’,
The New England Journal of Medicine 340(8), 609–616.
DuCharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E.,
Schoen, F. J., Kelly, R. A., Werb, Z., Libby, P. & Lee, R. T. (2000), ‘Targeted
deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement
and collagen accumulation after experimental myocardial infarction’, The Jour-
nal of Clinical Investigation 106(1), 55–62.
Duerr, R. L., Huang, S., Miraliakbar, H. R., Clark, R., Chien, K. R. & Ross, J.
(1995), ‘Insulin-like growth factor-1 enhances ventricular hypertrophy and func-
tion during the onset of experimental cardiac failure’, The Journal of Clinical
Investigation 95(2), 619–627.
Endoh, M. & Blinks, J. R. (1988), ‘Actions of sympathomimetic amines on the
Ca2+ transients and contractions of rabbit myocardium: reciprocal changes in
myofibrillar responsiveness to Ca2+ mediated through α- and β-adrenoceptors’,
Circulation Research 62(2), 247–265.
Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M. J. (1999), ‘Progressive hy-
pertrophy and heart failure in β1-adrenergic receptor transgenic mice’, Pro-
ceedings of the National Academy of Sciences of the United States of America
96(12), 7059–7064.
Engvall, E. & Perlman, P. (1971), ‘Enzyme-linked immunosorbent assay (ELISA).
Quantitative assay of immunoglobulin G’, Immunochemistry. 8(9), 871–874.
Erbs, S., Linke, A., Adams, V., Lenk, K., Thiele, H., Diederich, K. W., Emm-
rich, F., Kluge, R., Kendziorra, K., Sabri, O., Schuler, G. & Hambrecht, R.
234
(2005), ‘Transplantation of blood-derived progenitor cells after recanalization
of chronic coronary artery occlusion: first randomized and placebo-controlled
study’, Circulation Research 97(8), 756–762.
Erlebacher, J. A., Weiss, J. L., Eaton, L. W., Kallman, C., Weisfeldt, M. L. &
Bulkley, B. H. (1982), ‘Late effects of acute infarct dilation on heart size:
a two dimensional echocardiographic study’, American Journal of Cardiology
49(5), 1120–1126.
Fabiato, A. (1983), ‘Calcium-induced release of calcium from the cardiac sarcoplas-
mic reticulum’, American Journal of Physiology 245(1), C1–14.
Fabiato, A. (1985), ‘Time and calcium dependence of activation and inactivation of
calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned
canine cardiac Purkinje cell’, The Journal of General Physiology 85(2), 247–
289.
Fabiato, A. & Fabiato, F. (1975), ‘Effects of magnesium on contractile activation of
skinned cardiac cells’, The Journal of Physiology 249(3), 497–517.
Fabiato, A. & Fabiato, F. (1978), ‘Effects of pH on the myofilaments and the sar-
coplasmic reticulum of skinned cells from cardiace and skeletal muscles’, The
Journal of Physiology 276, 233–255.
Farrell, M. H., Foody, J. M. & Krumholz, H. M. (2002), ‘β-Blockers in heart fail-
ure: clinical applications’, The Journal of the American Medical Association
287(7), 890–897.
Fazel, S., Cimini, M., Chen, L., Li, S., Angoulvant, D., Fedak, P., Verma, S., Weisel,
R. D., Keating, A. & Li, R. K. (2006), ‘Cardioprotective c-kit+ cells are from
the bone marrow and regulate the myocardial balance of angiogenic cytokines’,
The Journal of Clinical Investigation 116(7), 1865–1877.
235
Fenwick, E. M., Marty, A. & Neher, E. (1982), ‘A patch-clamp study of bovine chro-
maffin cells and of their sensitivity to acetylcholine’, The Journal of Physiology
331, 577–597.
Ferrara, N. (2001), ‘Role of vascular endothelial growth factor in regulation of
physiological angiogenesis’, American Journal of Physiology - Cell Physiology
280(6), C1358–C1366.
Finkel, A. S. & Redman, S. (1984), ‘Theory and operation of a single microelectrode
voltage clamp’, Journal of Neuroscience Methods 11(2), 101–127.
Fleckenstein, A. (1983), ‘History of calcium antagonists’, Circulation Research 52(2
Pt 2), I3–16.
Florini, J. R., Ewton, D. Z. & Roof, S. L. (1991), ‘Insulin-like growth factor-I stim-
ulates terminal myogenic differentiation by induction of myogenin gene expres-
sion’, Molecular Endocrinology 5(5), 718–724.
Foody, J. M., Farrell, M. H. & Krumholz, H. M. (2002), ‘β-Blocker therapy in heart
failure: scientific review’, The Journal of the American Medical Association
287(7), 883–889.
Frangogiannis, N. G., Dewald, O., Xia, Y., Ren, G., Haudek, S., Leucker, T., Krae-
mer, D., Taffet, G., Rollins, B. J. & Entman, M. L. (2007), ‘Critical role of
monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogen-
esis of ischemic cardiomyopathy’, Circulation 115(5), 584–592.
Freestone, N. S., Ribaric, S. & Mason, W. T. (1996), ‘The effect of insulin-like growth
factor-1 on adult rat cardiac contractility’, Molecular and Cellular Biochemistry
163-164, 223–229.
Frey, N. & Olson, E. N. (2003), ‘Cardiac hypertrophy: the good, the bad, and the
ugly’, Annual Review of Physiology 65, 45–79.
236
Fukushima, S., Varela-Carver, A., Coppen, S. R., Yamahara, K., Felkin, L. E., Lee,
J., Barton, P. J., Terracciano, C. M., Yacoub, M. H. & Suzuki, K. (2007),
‘Direct intramyocardial but not intracoronary injection of bone marrow cells
induces ventricular arrhythmias in a rat chronic ischemic heart failure model’,
Circulation 115(17), 2254–2261.
Garg, R. & Yusuf, S. (1995), ‘Overview of randomized trials of angiotensin-
converting enzyme inhibitors on mortality and morbidity in patients with heart
failure. Collaborative Group on ACE Inhibitor Trials’, The Journal of the
American Medical Association 273(18), 1450–1456.
Gavira, J. J., Herreros, J., Perez, A., Garcia-Velloso, M. J., Barba, J., Martin-
Herrero, F., Canizo, C., Martin-Arnau, A., Marti-Climent, J. M., Hernandez,
M., Lopez-Holgado, N., Gonzalez-Santos, J. M., Martin-Luengo, C., Alegria,
E. & Prosper, F. (2006), ‘Autologous skeletal myoblast transplantation in pa-
tients with nonacute myocardial infarction: 1-year follow-up’, The Journal of
Thoracic and Cardiovascular Surgery 131(4), 799–804.
Ge, J., Li, Y., Qian, J., Shi, J., Wang, Q., Niu, Y., Fan, B., Liu, X., Zhang, S., Sun,
A. & Zou, Y. (2006), ‘Efficacy of emergent transcatheter transplantation of
stem cells for treatment of acute myocardial infarction (TCT-STAMI)’, Heart
92(12), 1764–1767.
George, I., Xydas, S., Mancini, D. M., Lamanca, J., DiTullio, M., Marboe, C. C.,
Shane, E., Schulman, A. R., Colley, P. M., Petrilli, C. M., Naka, Y., Oz, M. C.
& Maybaum, S. (2006), ‘Effect of clenbuterol on cardiac and skeletal muscle
function during left ventricular assist device support’, The Journal of Heart &
Lung Transplantation 25(9), 1084–1090.
Ginsburg, K. S. & Bers, D. M. (2005), ‘Isoproterenol does not enhance Ca2+-
dependent Na+/Ca2+ exchange current in intact rabbit ventricular myocytes’,
Journal of Molecular and Cellular Cardiology 39(6), 972–981.
237
Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., Morello, F., Mu, H., Melo,
L. G., Pratt, R. E., Ingwall, J. S. & Dzau, V. J. (2006), ‘Evidence supporting
paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac
protection and functional improvement’, FASEB Journal 20(6), 661–669.
Gomez, A. M., Guatimosim, S., Dilly, K. W., Vassort, G. & Lederer, W. J. (2001),
‘Heart failure after myocardial infarction: altered excitation-contraction cou-
pling’, Circulation 104(6), 688–693.
Gomez, A. M., Valdivia, H. H., Cheng, H., Lederer, M. R., Santana, L. F., Cannell,
M. B., McCune, S. A., Altschuld, R. A. & Lederer, W. J. (1997), ‘Defective
excitation-contraction coupling in experimental cardiac hypertrophy and heart
failure’, Science 276(5313), 800–806.
Gould, L., Zahir, M., DeMartino, A. & Gomprecht, R. F. (1971), ‘Cardiac effects of
a cocktail’, The Journal of the American Medical Association 218(12), 1799–
1802.
Grady, K. L., Naftel, D. C., White-Williams, C., Bellg, A. J., Young, J. B., Pelegrin,
D., Patton-Schroeder, K., Kobashigawa, J., Chait, J., Kirklin, J. K., W. Pic-
cione, J., McLeod, M. & Heroux, A. (2005), ‘Predictors of quality of life at 5 to
6 years after heart transplantation’, The Journal of Heart & Lung Transplan-
tation 24(9), 1431–1439.
Green, K. J. & Jones, J. C. (1996), ‘Desmosomes and hemidesmosomes: structure
and function of molecular components’, FASEB Journal 10(8), 871–881.
Grossman, W., Jones, D. & McLaurin, L. P. (1975), ‘Wall stress and patterns of
hypertrophy in the human left ventricle’, The Journal of Clinical Investigation
56(1), 56–64.
Grynkiewicz, G., Poenie, M. & Tsien, R. Y. (1985), ‘A new generation of Ca2+
indicators with greatly improved fluorescence properties’, Journal of Biological
Chemistry 260(6), 3440–3450.
238
Gwathmey, J. K., Copelas, L., MacKinnon, R., Schoen, F. J., Feldman, M. D.,
Grossman, W. & Morgan, J. P. (1987), ‘Abnormal intracellular calcium han-
dling in myocardium from patients with end-stage heart failure’, Circulation
Research 61(1), 70–76.
Gyo¨rke, S. & Fill, M. (1993), ‘Ryanodine receptor adaptation: control mechanism
of Ca2+-induced Ca2+ release in heart’, Science 260(5109), 807–809.
Hage`ge, A. A., Carrion, C., Menasche´, P., Vilquin, J. T., Duboc, D., Marolleau,
J. P., Desnos, M. & Bruneval, P. (2003), ‘Viability and differentiation of au-
tologous skeletal myoblast grafts in ischæmic cardiomyopathy’, The Lancet
361(9356), 491–492.
Hage`ge, A. A., Marolleau, J. P., Vilquin, J. T., Alheritiere, A., Peyrard, S., Duboc,
D., Abergel, E., Messas, E., Mousseaux, E., Schwartz, K., Desnos, M. &
Menasche´, P. (2006), ‘Skeletal myoblast transplantation in ischemic heart fail-
ure: long-term follow-up of the first phase I cohort of patients’, Circulation
114(1 Suppl), I108–I113.
Hagiwara, S., Ozawa, S. & Sand, O. (1975), ‘Voltage clamp analysis of two inward
current mechanisms in the egg cell membrane of a starfish’, The Journal of
General Physiology 65(5), 617–644.
Hamill, O. P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F. J. (1981), ‘Im-
proved patch-clamp techniques for high-resolution current recording from cells
and cell-free membrane patches’, Pflu¨gers Archiv 391(2), 85–100.
Hanouz, J. L., Vivien, B., Gueugniaud, P. Y., LeCarpentier, Y., Coriat, P. & Riou,
B. (1998), ‘Comparison of the effects of sevoflurane, isoflurane and halothane
on rat myocardium’, British Journal of Anæsthesia 80(5), 621–627.
Harding, S. E. & Gong, H. (2004), ‘β-adrenoceptor blockers as agonists: coupling of
β2-adrenoceptors to multiple G-proteins in the failing human heart’, Congestive
Heart Failure 10(4), 181–185.
239
Hasenfuss, G. (1998), ‘Animal models of human cardiovascular disease, heart failure
and hypertrophy’, Cardiovascular Research 39(1), 60–76.
Hasenfuss, G. & Pieske, B. (2002), ‘Calcium cycling in congestive heart failure’,
Journal of Molecular and Cellular Cardiology 34(8), 951–969.
Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E. & Iwata, K. (1992),
‘Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-
1) for a wide range of cells. A possible new growth factor in serum’, FEBS
Letters 298(1), 29–32.
Hendrikx, M., Hensen, K., Clijsters, C., Jongen, H., Koninckx, R., Bijnens, E., In-
gels, M., Jacobs, A., Geukens, R., Dendale, P., Vijgen, J., Dilling, D., Steels, P.,
Mees, U. & Rummens, J. L. (2006), ‘Recovery of regional but not global contrac-
tile function by the direct intramyocardial autologous bone marrow transplan-
tation: results from a randomized controlled clinical trial’, Circulation 114(1
Suppl), I101–I107.
Hering, S., Bodewei, R. & Wollenberger, A. (1983), ‘Sodium current in freshly
isolated and in cultured single rat myocardial cells: frequency and voltage-
dependent block by mexiletine’, Journal of Molecular and Cellular Cardiology
15(7), 431–444.
Hess, P. (1988), ‘Elementary properties of cardiac calcium channels: a brief review’,
Canadian Journal of Physiology and Pharmacology 66(9), 1218–1223.
Hilgemann, D. W. & Noble, D. (1987), ‘Excitation-contraction coupling and ex-
tracellular calcium transients in rabbit atrium: reconstruction of basic cellular
mechanisms’, Proceedings of The Royal Society of London B: Biological Sciences
230(1259), 163–205.
Ho, K. K., Anderson, K. M., Kannel, W. B., Grossman, W. & Levy, D. (1993),
‘Survival after the onset of congestive heart failure in Framingham Heart Study
subjects’, Circulation 88(1), 107–115.
240
Hobbs, F. D., Kenkre, J. E., Roalfe, A. K., Davis, R. C., Hare, R. & Davies,
M. K. (2002), ‘Impact of heart failure and left ventricular systolic dysfunction
on quality of life: a cross-sectional study comparing common chronic cardiac
and medical disorders and a representative adult population’, European Heart
Journal 23(23), 1867–1876.
Hodgkin, A. L. & Huxley, A. F. (1952), ‘A quantitative description of membrane
current and its application to conduction and excitation in nerve’, The Journal
of Physiology 117(4), 500–544.
Ho¨fer, G. F., Hohenthanner, K., Baumgartner, W., Groschner, K., Klugbauer, N.,
Hofmann, F. & Romanin, C. (1997), ‘Intracellular Ca2+ inactivates L-type Ca2+
channels with a Hill coefficient of approximately 1 and an inhibition constant
of approximately 4 µM by reducing channel’s open probability’, Biophysical
Journal 73(4), 1857–1865.
Huang, R. P. (2003), ‘Cytokine antibody arrays: a promising tool to identify molec-
ular targets for drug discovery’, Combinatorial Chemistry and High Throughput
Screening 6(8), 769–775.
Huang, R. P., Huang, R., Fan, Y. & Lin, Y. (2001), ‘Simultaneous detection of
multiple cytokines from conditioned media and patient’s sera by an antibody-
based protein array system’, Analytical Biochemistry 294(1), 55–62.
Humbel, R. E. (1990), ‘Insulin-like growth factors I and II’, European Journal of
Biochemistry 190(3), 445–462.
Hunt, S. A. (2006), ‘Taking heart–cardiac transplantation past, present, and future’,
The New England Journal of Medicine 355(3), 231–235.
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ga-
niats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates,
J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W., Antman,
241
E. M., S. C. Smith, J., Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V.,
Halperin, J. L., Hiratzka, L. F., Jacobs, A. K., Nishimura, R., Ornato, J. P.,
Page, R. L. & Riegel, B. (2005), ‘ACC/AHA 2005 Guideline Update for the
Diagnosis and Management of Chronic Heart Failure in the Adult: a report
of the ACC/AHA Task Force on Practice Guidelines: developed in collabora-
tion with the ACCP and the ISHLT: endorsed by the Heart Rhythm Society’,
Circulation 112(12), e154–e235.
Hutchins, G. M. & Bulkley, B. H. (1978), ‘Infarct expansion versus extension: two
different complications of acute myocardial infarction’, American Journal of
Cardiology 41(7), 1127–1132.
Ito, K., Nakayama, M., Hasan, F., Yan, X., Schneider, M. D. & Lorell, B. H. (2003),
‘Contractile reserve and calcium regulation are depressed in myocytes from
chronically unloaded hearts’, Circulation 107(8), 1176–1182.
Janssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., Desmet, W.,
Kalantzi, M., Herbots, L., Sinnaeve, P., Dens, J., Maertens, J., Rademakers,
F., Dymarkowski, S., Gheysens, O., Van Cleemput, J., Bormans, G., Nuyts, J.,
Belmans, A., Mortelmans, L., Boogaerts, M. & Van de Werf, F. (2006), ‘Au-
tologous bone marrow-derived stem-cell transfer in patients with ST-segment
elevation myocardial infarction: double-blind, randomised controlled trial’, The
Lancet 367(9505), 113–121.
Jessup, M. & Brozena, S. (2003), ‘Heart failure’, The New England Journal of
Medicine 348(20), 2007–2018.
Jiang, D., Xiao, B., Yang, D., Wang, R., Choi, P., Zhang, L., Cheng, H. & Chen,
S. R. (2004), ‘RyR2 mutations linked to ventricular tachycardia and sudden
death reduce the threshold for store-overload-induced Ca2+ release (SOICR)’,
Proceedings of the National Academy of Sciences of the United States of Amer-
ica 101(35), 13062–13067.
242
Johns, T. N. & Olson, B. J. (1954), ‘Experimental myocardial infarction. I. A method
of coronary occlusion in small animals’, Annals of Surgery 140(5), 675–682.
Johnson, F. H., Shimomura, O., Saiga, Y., Gershman, L. C., Rerynolds, T. & Wa-
ters, J. R. (1962), ‘Quantum efficiency of Cypridina Luminescence, with a note
on that of Aequorea’, Journal of Cellular and Comparative Physiology 60, 85–
103.
Jugdutt, B. I. & Michorowski, B. L. (1987), ‘Role of infarct expansion in rupture
of the ventricular septum after acute myocardial infarction: a two-dimensional
echocardiographic study’, Clinical Cardiology 10(11), 641–652.
Kang, H. J., Lee, H. Y., Na, S. H., Chang, S. A., Park, K. W., Kim, H. K., Kim,
S. Y., Chang, H. J., Lee, W., Kang, W. J., Koo, B. K., Kim, Y. J., Lee,
D. S., Sohn, D. W., Han, K. S., Oh, B. H., Park, Y. B. & Kim, H. S. (2006),
‘Differential effect of intracoronary infusion of mobilized peripheral blood stem
cells by granulocyte colony-stimulating factor on left ventricular function and
remodeling in patients with acute myocardial infarction versus old myocardial
infarction: the MAGIC Cell–3–DES randomized, controlled trial’, Circulation
114(1 Suppl), I145–I151.
Kass, D. A., Chen, C. H., Curry, C., Talbot, M., Berger, R., Fetics, B. & Nevo, E.
(1999), ‘Improved left ventricular mechanics from acute VDD pacing in patients
with dilated cardiomyopathy and ventricular conduction delay’, Circulation
99(12), 1567–1573.
Kass, R. S. & Sanguinetti, M. C. (1984), ‘Inactivation of calcium channel current
in the calf cardiac Purkinje fiber. Evidence for voltage- and calcium-mediated
mechanisms’, The Journal of General Physiology 84(5), 705–726.
Kaumann, A. J., Sanders, L., Lynham, J. A., Bartel, S., Kuschel, M., Karczewski, P.
& Krause, E. G. (1996), ‘β2-adrenoceptor activation by zinterol causes protein
243
phosphorylation, contractile effects and relaxant effects through a cAMP path-
way in human atrium’, Molecular and Cellular Biochemistry 163-164, 113–123.
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W., Benjamin, E. J., Larson,
M. G., Kannel, W. B. & Vasan, R. S. (2002), ‘Obesity and the risk of heart
failure’, The New England Journal of Medicine 347(5), 305–313.
Keung, E. C., Keung, C. S. & Aronson, R. S. (1982), ‘Passive electrical properties of
normal and hypertrophied rat myocardium’, American Journal of Physiology
243(6), H917–H926.
Keung, E. C., Toll, L., Ellis, M. & Jensen, R. A. (1991), ‘L-type cardiac calcium
channels in doxorubicin cardiomyopathy in rats morphological, biochemical,
and functional correlations’, The Journal of Clinical Investigation 87(6), 2108–
2113.
Kimura, J., Miyamae, S. & Noma, A. (1987), ‘Identification of sodium-calcium
exchange current in single ventricular cells of guinea-pig’, The Journal of Phys-
iology 384, 199–222.
Kinnaird, T., Stabile, E., Burnett, M. S., Shou, M., Lee, C. W., Barr, S., Fuchs, S. &
Epstein, S. E. (2004), ‘Local delivery of marrow-derived stromal cells augments
collateral perfusion through paracrine mechanisms’, Circulation 109(12), 1543–
1549.
Kocher, A. A., Schuster, M. D., Szabolcs, M. J., Takuma, S., Burkhoff, D., Wang, J.,
Homma, S., Edwards, N. M. & Itescu, S. (2001), ‘Neovascularization of ischemic
myocardium by human bone-marrow-derived angioblasts prevents cardiomy-
ocyte apoptosis, reduces remodeling and improves cardiac function’, Nature
Medicine 7(4), 430–436.
Kolattukudy, P. E., Quach, T., Bergese, S., Breckenridge, S., Hensley, J., Altschuld,
R., Gordillo, G., Klenotic, S., Orosz, C. & Parker-Thornburg, J. (1998), ‘My-
244
ocarditis induced by targeted expression of the MCP–1 gene in murine cardiac
muscle’, American Journal of Pathology 152(1), 101–111.
Kono, T. (1969), ‘Roles of collagenases and other proteolytic enzymes in the dispersal
of animal tissues’, Biochimica et Biophysica Acta 178(2), 397–400.
Kurihara, S. & Sakai, T. (1985), ‘Effects of rapid cooling on mechanical and elec-
trical responses in ventricular muscle of guinea-pig’, The Journal of Physiology
361, 361–378.
Laflamme, M. A., Zbinden, S., Epstein, S. E. & Murry, C. E. (2007), ‘Cell-Based
Therapy for Myocardial Iaschemia and Infarction: Pathophysiological Mecha-
nisms’, Annual Review of Pathology: Mechanisms of Disease 2, 307–339.
Lagadic-Gossmann, D., Buckler, K. J. & Vaughan-Jones, R. D. (1992), ‘Role of
bicarbonate in pH recovery from intracellular acidosis in the guinea-pig ven-
tricular myocyte’, The Journal of Physiology 458, 361–384.
Lands, A. M., Arnold, A., McAuliff, J. P., Luduena, F. P. & Brown, T. G. (1967),
‘Differentiation of receptor systems activated by sympathomimetic amines’, Na-
ture 214(5088), 597–598.
LeBlanc, N. & Hume, J. R. (1990), ‘Sodium current-induced release of calcium from
cardiac sarcoplasmic reticulum’, Science 248(4953), 372–376.
Lee, K. S., Marban, E. & Tsien, R. W. (1985), ‘Inactivation of calcium channels in
mammalian heart cells: joint dependence on membrane potential and intracel-
lular calcium’, The Journal of Physiology 364, 395–411.
Leobon, B., Garcin, I., Menasche´, P., Vilquin, J. T., Audinat, E. & Charpak, S.
(2003), ‘Myoblasts transplanted into rat infarcted myocardium are functionally
isolated from their host’, Proceedings of the National Academy of Sciences of
the United States of America 100(13), 7808–7811.
245
Levine, T. B., Olivari, M. T., Garberg, V., Sharkey, S. W. & Cohn, J. N. (1984),
‘Hemodynamic and clinical response to enalapril, a long-acting converting-
enzyme inhibitor, in patients with congestive heart failure’, Circulation
69(3), 548–553.
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K.,
Murabito, J. M. & Vasan, R. S. (2002), ‘Long-term trends in the incidence
of and survival with heart failure’, The New England Journal of Medicine
347(18), 1397–1402.
Li, Q., Li, B., Wang, X., Leri, A., Jana, K. P., Liu, Y., Kajstura, J., Baserga, R.
& Anversa, P. (1997), ‘Overexpression of insulin-like growth factor-1 in mice
protects from myocyte death after infarction, attenuating ventricular dilation,
wall stress, and cardiac hypertrophy’, The Journal of Clinical Investigation
100(8), 1991–1999.
Li, R. K., Jia, Z. Q., Weisel, R. D., Mickle, D. A., Zhang, J., Mohabeer, M. K.,
Rao, V. & Ivanov, J. (1996), ‘Cardiomyocyte transplantation improves heart
function’, The Annals of Thoracic Surgery 62(3), 654–660.
Li, Z. Q., Zhang, M., Jing, Y. Z., Zhang, W. W., Liu, Y., Cui, L. J., Yuan, L.,
Liu, X. Z., Yu, X. & Hu, T. S. (2007), ‘The clinical study of autologous pe-
ripheral blood stem cell transplantation by intracoronary infusion in patients
with acute myocardial infarction (AMI)’, International Journal of Cardioliology
115(1), 52–56.
Linde, C., LeClercq, C., Rex, S., Garrigue, S., Lavergne, T., Cazeau, S., McKenna,
W., Fitzgerald, M., Deharo, J. C., Alonso, C., Walker, S., Braunschweig, F.,
Bailleul, C. & Daubert, J. C. (2002), ‘Long-term benefits of biventricular pac-
ing in congestive heart failure: results from the MUltisite STimulation in car-
diomyopathy (MUSTIC) study’, Journal of the American College of Cardiology
40(1), 111–118.
246
Lindner, M., Erdmann, E. & Beuckelmann, D. J. (1998), ‘Calcium content of the
sarcoplasmic reticulum in isolated ventricular myocytes from patients with ter-
minal heart failure’, Journal of Molecular and Cellular Cardiology 30(4), 743–
749.
Lindsey, M. L., Mann, D. L., Entman, M. L. & Spinale, F. G. (2003), ‘Extracellular
matrix remodeling following myocardial injury’, Annals of Medicine 35(5), 316–
326.
Lip, G. Y., Gibbs, C. R. & Beevers, D. G. (2000), ‘ABC of heart failure: ætiology’,
The British Medical Journal 320(7227), 104–107.
Lip, G., Zarifis, J. & Beevers, D. G. (1997), ‘Acute admissions with heart failure
to a district general hospital serving a multiracial population’, International
Journal of Clinical Practice 51(4), 223–227.
Lipinski, M. J., Biondi-Zoccai, G. G., Abbate, A., Khianey, R., Sheiban, I., Bar-
tunek, J., Vanderheyden, M., Kim, H. S., Kang, H. J., Strauer, B. E. & Vetro-
vec, G. W. (2007), ‘Impact of intracoronary cell therapy on left ventricular func-
tion in the setting of acute myocardial infarction: a collaborative systematic
review and meta-analysis of controlled clinical trials’, Journal of the American
College of Cardiology 50(18), 1761–1767.
Litwin, S., Kohmoto, O., Levi, A. J., Spitzer, K. W. & Bridge, J. H. (1996), ‘Evi-
dence that reverse Na+/Ca2+ exchange can trigger SR calcium release’, Annals
of The New York Academy of Sciences 779, 451–463.
Lukyanenko, V. & Gyo¨rke, S. (1999), ‘Ca2+ sparks and Ca2+ waves in
saponin-permeabilized rat ventricular myocytes’, The Journal of Physiology
521(3), 575–585.
Lunde, K., Solheim, S., Aakhus, S., Arnesen, H., Abdelnoor, M., Egeland, T., En-
dresen, K., Ilebekk, A., Mangschau, A., Fjeld, J. G., Smith, H. J., Taraldsrud,
247
E., gaard, H. K. G., Bjornerheim, R., Brekke, M., Mu¨ller, C., Hopp, E., Rag-
narsson, A., Brinchmann, J. E. & Forfang, K. (2006), ‘Intracoronary injection
of mononuclear bone marrow cells in acute myocardial infarction’, The New
England Journal of Medicine 355(12), 1199–1209.
Luo, C. H. & Rudy, Y. (1994), ‘A dynamic model of the cardiac ventricular action
potential. I. Simulations of ionic currents and concentration changes’, Circula-
tion Research 74(6), 1071–1096.
MacIntyre, K., Capewell, S., Stewart, S., Chalmers, J. W., Boyd, J., Finlayson,
A., Redpath, A., Pell, J. P. & McMurray, J. J. (2000), ‘Evidence of improving
prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized
between 1986 and 1995’, Circulation 102(10), 1126–1131.
MacLennan, P. A. & Edwards, R. H. (1989), ‘Effects of clenbuterol and propranolol
on muscle mass. Evidence that clenbuterol stimulates muscle β-adrenoceptors
to induce hypertrophy’, Biochemical Journal 264(2), 573–579.
Maier, L. S., Zhang, T., Chen, L., DeSantiago, J., Brown, J. H. & Bers, D. M. (2003),
‘Transgenic CaMKIIδC overexpression uniquely alters cardiac myocyte Ca2+
handling: reduced SR Ca2+ load and activated SR Ca2+ release’, Circulation
Research 92(8), 904–911.
Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., Sano, M.,
Takahashi, T., Hori, S., Abe, H., Hata, J., Umezawa, A. & Ogawa, S. (1999),
‘Cardiomyocytes can be generated from marrow stromal cells in vitro’, The
Journal of Clinical Investigation 103(5), 697–705.
Mancini, D. & Burkhoff, D. (2005), ‘Mechanical device-based methods of managing
and treating heart failure’, Circulation 112(3), 438–448.
Mancini, D. M., Beniaminovitz, A., Levin, H., Catanese, K., Flannery, M., DiTullio,
M., Savin, S., Cordisco, M. E., Rose, E. & Oz, M. (1998), ‘Low incidence of
248
myocardial recovery after left ventricular assist device implantation in patients
with chronic heart failure’, Circulation 98(22), 2383–2389.
Mangi, A. A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J. S. & Dzau,
V. (2003), ‘Mesenchymal stem cells modified with Akt prevent remodeling and
restore performance of infarcted hearts’, Nature Medicine 9, 1195–1201.
Mann, D. L., Acker, M. A., Jessup, M., Sabbah, H. N., Starling, R. C. & Kubo, S. H.
(2007), ‘Clinical evaluation of the CorCap Cardiac Support Device in patients
with dilated cardiomyopathy’, The Annals of Thoracic Surgery 84(4), 1226–
1235.
Mann, D. L. & Bristow, M. R. (2005), ‘Mechanisms and models in heart failure: the
biomechanical model and beyond’, Circulation 111(21), 2837–2849.
Mann, D. L., Deswal, A., Bozkurt, B. & Torre-Amione, G. (2002), ‘New therapeutics
for chronic heart failure’, Annual Review of Medicine 53, 59–74.
Marx, S. O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit,
N. & Marks, A. R. (2000), ‘PKA phosphorylation dissociates FKBP12.6 from
the calcium release channel (ryanodine receptor): defective regulation in failing
hearts’, Cell 101(4), 365–376.
Maybaum, S., Mancini, D., Xydas, S., Starling, R. C., Aaronson, K., Pagani,
F. D., Miller, L. W., Margulies, K., McRee, S., Frazier, O. H. & Torre-
Amione, G. (2007), ‘Cardiac improvement during mechanical circulatory sup-
port: a prospective multicenter study of the LVADWorking Group’, Circulation
115(19), 2497–2505.
McKee, P. A., Castelli, W. P., McNamara, P. M. & Kannel, W. B. (1971), ‘The
natural history of congestive heart failure: the Framingham study’, The New
England Journal of Medicine 285(26), 1441–1446.
249
McMurray, J., McDonagh, T., Morrison, C. E. & Dargie, H. J. (1993), ‘Trends
in hospitalization for heart failure in Scotland 1980 ∼ 1990’, European Heart
Journal 14(9), 1158–1162.
Meluzin, J., Mayer, J., Groch, L., Janousek, S., Hornacek, I., Hlinomaz, O., Kala, P.,
Panovsky, R., Prasek, J., Kaminek, M., Stanicek, J., Klabusay, M., Koristek, Z.,
Navratil, M., Dusek, L. & Vinklarkova, J. (2006), ‘Autologous transplantation
of mononuclear bone marrow cells in patients with acute myocardial infarction:
the effect of the dose of transplanted cells on myocardial function’, American
Heart Journal 152(5), 975–15.
Menasche´, P., Alfieri, O., Janssens, S., McKenna, W., Reichenspurner, H., Trin-
quart, L., Vilquin, J. T., Marolleau, J. P., Seymour, B., Larghero, J., Lake,
S., Chatellier, G., Solomon, S., Desnos, M. & Hage`ge, A. A. (2008), ‘The My-
oblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first
randomized placebo-controlled study of myoblast transplantation’, Circulation
117(9), 1189–1200.
Menasche´, P., Hage`ge, A. A., Scorsin, M., Pouzet, B., Desnos, M., Duboc, D.,
Schwartz, K., Vilquin, J. T. & Marolleau, J. P. (2001), ‘Myoblast transplanta-
tion for heart failure’, The Lancet 357(9252), 279–280.
Meyer, G. P., Wollert, K. C., Lotz, J., Steffens, J., Lippolt, P., Fichtner, S., Hecker,
H., Schaefer, A., Arseniev, L., Hertenstein, B., Ganser, A. & Drexler, H. (2006),
‘Intracoronary bone marrow cell transfer after myocardial infarction: eighteen
months’ follow-up data from the randomized, controlled BOOST (BOne mar-
rOw transfer to enhance ST-elevation infarct regeneration) trial’, Circulation
113(10), 1287–1294.
Milano, C. A., Allen, L. F., Rockman, H. A., Dolber, P. C., McMinn, T. R., Chien,
K. R., Johnson, T. D., Bond, R. A. & Lefkowitz, R. J. (1994), ‘Enhanced myo-
250
cardial function in transgenic mice overexpressing the β2-adrenergic receptor’,
Science 264(5158), 582–586.
Morise, H., Shimomura, O., Johnson, F. H. & Winant, J. (1974), ‘Intermolecu-
lar energy transfer in the bioluminescent system of Aequorea’, Biochemistry
13(12), 2656–2662.
Mosterd, A., Agostino, R. B. D., Silbershatz, H., Sytkowski, P. A., Kannel, W. B.,
Grobbee, D. E. & Levy, D. (1999), ‘Trends in the prevalence of hypertension,
antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989’,
The New England Journal of Medicine 340(16), 1221–1227.
Mukherjee, R. & Spinale, F. G. (1998), ‘L-type calcium channel abundance and
function with cardiac hypertrophy and failure: a review’, Journal of Molecular
and Cellular Cardiology 30(10), 1899–1916.
Muller, J., Wallukat, G., Weng, Y. G., Dandel, M., Spiegelsberger, S., Semrau,
S., Brandes, K., Theodoridis, V., Loebe, M., Meyer, R. & Hetzer, R. (1997),
‘Weaning from mechanical cardiac support in patients with idiopathic dilated
cardiomyopathy’, Circulation 96(2), 542–549.
Murry, C. E., Field, L. J. & Menasche´, P. (2005), ‘Cell-based cardiac repair: reflec-
tions at the 10-year point’, Circulation 112(20), 3174–3183.
Murry, C. E., Soonpaa, M. H., Reinecke, H., Nakajima, H., Nakajima, H. O., Rubart,
M., Pasumarthi, K. B., Virag, J. I., Bartelmez, S. H., Poppa, V., Bradford, G.,
Dowell, J. D., Williams, D. A. & Field, L. J. (2004), ‘Hæmatopoietic stem cells
do not transdifferentiate into cardiac myocytes in myocardial infarcts’, Nature
428(6983), 664–668.
Murry, C. E., Wiseman, R. W., Schwartz, S. M. & Hauschka, S. D. (1996), ‘Skeletal
myoblast transplantation for repair of myocardial necrosis’, The Journal of
Clinical Investigation 98(11), 2512–2523.
251
Murtuza, B., Suzuki, K., Bou-Gharios, G., Beauchamp, J. R., Smolenski, R. T.,
Partridge, T. A. & Yacoub, M. H. (2004), ‘Transplantation of skeletal myoblasts
secreting an IL–1 inhibitor modulates adverse remodeling in infarcted murine
myocardium’, Proceedings of the National Academy of Sciences of the United
States of America 101(12), 4216–4221.
Na¨bauer, M., Beuckelmann, D. J. & Erdmann, E. (1993), ‘Characteristics of tran-
sient outward current in human ventricular myocytes from patients with ter-
minal heart failure’, Circulation Research 73(2), 386–394.
Na¨bauer, M., Callewaert, G., Cleemann, L. & Morad, M. (1989), ‘Regulation of
calcium release is gated by calcium current, not gating charge, in cardiac my-
ocytes’, Science 244(4906), 800–803.
Na¨bauer, M. & Ka¨a¨b, S. (1998), ‘Potassium channel down-regulation in heart fail-
ure’, Cardiovascular Research 37(2), 324–334.
Nadal-Ginard, B. & Fuster, V. (2007), ‘Myocardial cell therapy at the crossroads’,
Nature Clinical Practice Cardiovascular Medicine 4(1), 1.
Nag, A. C. (1980), ‘Study of non-muscle cells of the adult mammalian heart: a fine
structural analysis and distribution’, Cytobios 28(109), 41–61.
Nag, A. C. & Cheng, M. (1986), ‘Biochemical evidence for cellular dedifferentiation
in adult rat cardiac muscle cells in culture: expression of myosin isozymes’,
Biochemical and Biophysical Research Communications 137(2), 855–862.
Nagaya, N., Kangawa, K., Itoh, T., Iwase, T., Murakami, S., Miyahara, Y., Fujii,
T., Uematsu, M., Ohgushi, H., Yamagishi, M., Tokudome, T., Mori, H., Miy-
atake, K. & Kitamura, S. (2005), ‘Transplantation of mesenchymal stem cells
improves cardiac function in a rat model of dilated cardiomyopathy’, Circula-
tion 112(8), 1128–1135.
252
Nakai, J., Imagawa, T., Hakamat, Y., Shigekawa, M., Takeshima, H. & Numa, S.
(1990), ‘Primary structure and functional expression from cDNA of the cardiac
ryanodine receptor/calcium release channel’, FEBS Letters 271(1-2), 169–177.
Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J.,
Schmidt, U., Semigran, M. J., Dec, G. W. & Khaw, B. A. (1996), ‘Apoptosis
in myocytes in end-stage heart failure’, The New England Journal of Medicine
335(16), 1182–1189.
Nerbonne, J. M. (2000), ‘Molecular basis of functional voltage-gated K+ channel
diversity in the mammalian myocardium’, The Journal of Physiology 525 Pt
2, 285–298.
Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. (1999), ‘Vascular endothe-
lial growth factor (VEGF) and its receptors’, FASEB Journal 13(1), 9–22.
Nygren, J. M., Jovinge, S., Breitbach, M., Sawen, P., Roll, W., Hescheler, J., Ta-
neera, J., Fleischmann, B. K. & Jacobsen, S. E. (2004), ‘Bone marrow-derived
hæmatopoietic cells generate cardiomyocytes at a low frequency through cell
fusion, but not transdifferentiation’, Nature Medicine 10(5), 494–501.
Oakley, C. (1997), ‘Aetiology, diagnosis, investigation, and management of the car-
diomyopathies’, The British Medical Journal 315(7121), 1520–1524.
O’Donnell, S. R. & Wanstall, J. C. (1980), ‘Evidence that ICI 118,551 is a potent,
highly β2-selective adrenoceptor antagonist and can be used to characterize
β-adrenoceptor populations in tissues’, Life Sciences 27(8), 671–677.
Olivetti, G., Capasso, J. M., Meggs, L. G., Sonnenblick, E. H. & Anversa, P. (1991),
‘Cellular basis of chronic ventricular remodeling after myocardial infarction in
rats’, Circulation Research 68(3), 856–869.
253
Olivetti, G., Giordano, G., Corradi, D., Melissari, M., Lagrasta, C., Gambert, S. R.
& Anversa, P. (1995), ‘Gender differences and aging: effects on the human
heart’, Journal of the American College of Cardiology 26(4), 1068–1079.
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel,
J., McKay, R., Nadal-Ginard, B., Bodine, D. M., Leri, A. & Anversa, P. (2001),
‘Bone marrow cells regenerate infarcted myocardium’, Nature 410(6829), 701–
705.
O’Rourke, B., Kass, D. A., Tomaselli, G. F., Ka¨a¨b, S., Tunin, R. & Marban,
E. (1999), ‘Mechanisms of altered excitation-contraction coupling in canine
tachycardia-induced heart failure, I: experimental studies’, Circulation Research
84(5), 562–570.
Ouadid, H., Albat, B. & Nargeot, J. (1995), ‘Calcium currents in diseased human
cardiac cells’, Journal of Cardiovascular Pharmacology 25(2), 282–291.
Pagani, F. D., DerSimonian, H., Zawadzka, A., Wetzel, K., Edge, A. S., Jacoby,
D. B., Dinsmore, J. H., Wright, S., Aretz, T. H., Eisen, H. J. & Aaronson, K. D.
(2003), ‘Autologous skeletal myoblasts transplanted to ischemia-damaged my-
ocardium in humans. Histological analysis of cell survival and differentiation’,
Journal of the American College of Cardiology 41(5), 879–888.
Penicka, M., Horak, J., Kobylka, P., Pytlik, R., Kozak, T., Belohlavek, O., Lang, O.,
Skalicka, H., Simek, S., Palecek, T., Linhart, A., Aschermann, M. & Widimsky,
P. (2007), ‘Intracoronary injection of autologous bone marrow-derived mononu-
clear cells in patients with large anterior acute myocardial infarction: a pre-
maturely terminated randomized study’, Journal of the American College of
Cardiology 49(24), 2373–2374.
Perchenet, L., Hinde, A. K., Patel, K. C., Hancox, J. C. & Levi, A. J. (2000), ‘Stim-
ulation of Na+/Ca2+ exchange by the β-adrenergic/protein kinase A pathway
in guinea-pig ventricular myocytes at 37 ℃’, Pflu¨gers Archiv 439(6), 822–828.
254
Perin, E. C., Dohmann, H. F., Borojevic, R., Silva, S. A., Sousa, A. L., Silva,
G. V., Mesquita, C. T., Belem, L., Vaughn, W. K., Rangel, F. O., Assad, J. A.,
Carvalho, A. C., Branco, R. V., Rossi, M. I., Dohmann, H. J. & Willerson,
J. T. (2004), ‘Improved exercise capacity and ischemia 6 and 12 months after
transendocardial injection of autologous bone marrow mononuclear cells for
ischemic cardiomyopathy’, Circulation 110(11 Suppl 1), II213–II218.
Petrou, M., Wynne, D. G., Boheler, K. R. & Yacoub, M. H. (1995), ‘Clenbuterol
induces hypertrophy of the latissimus dorsi muscle and heart in the rat with
molecular and phenotypic changes’, Circulation 92(9 Suppl), II483–II489.
Pfeffer, M. A. & Braunwald, E. (1990), ‘Ventricular remodeling after myocardial
infarction. Experimental observations and clinical implications’, Circulation
81(4), 1161–1172.
Pfeffer, M. A. & Pfeffer, J. M. (1987), ‘Ventricular enlargement and reduced survival
after myocardial infarction’, Circulation 75(5 Pt 2), IV93–IV97.
Philipson, K. D. & Nicoll, D. A. (2000), ‘Sodium-calcium exchange: a molecular
perspective’, Annual Review of Physiology 62, 111–133.
Pieske, B., Maier, L. S., Bers, D. M. & Hasenfuss, G. (1999), ‘Ca2+ handling and
sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human
myocardium’, Circulation Research 85(1), 38–46.
Pieske, B., Sutterlin, M., Schmidt-Schweda, S., Minami, K., Meyer, M., Olschewski,
M., Holubarsch, C., Just, H. & Hasenfuss, G. (1996), ‘Diminished post-rest
potentiation of contractile force in human dilated cardiomyopathy. Functional
evidence for alterations in intracellular Ca2+ handling’, The Journal of Clinical
Investigation 98(3), 764–776.
Pitt, B. (1995), ‘“Escape” of aldosterone production in patients with left ventricular
dysfunction treated with an angiotensin converting enzyme inhibitor: implica-
tions for therapy’, Cardiovascular Drugs and Therapy 9(1), 145–149.
255
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm,
A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., Sharma, D.
& Thiyagarajan, B. (2000), ‘Effect of losartan compared with captopril on
mortality in patients with symptomatic heart failure: randomised trial–the
Losartan Heart Failure Survival Study ELITE II’, The Lancet 355(9215), 1582–
1587.
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky,
J. & Wittes, J. (1999), ‘The effect of spironolactone on morbidity and mortality
in patients with severe heart failure. Randomized Aldactone Evaluation Study
Investigators’, The New England Journal of Medicine 341(10), 709–717.
Pogwizd, S. M., Qi, M., Yuan, W., Samarel, A. M. & Bers, D. M. (1999), ‘Upreg-
ulation of Na+/Ca2+ exchanger expression and function in an arrhythmogenic
rabbit model of heart failure’, Circulation Research 85(11), 1009–1019.
Pouzet, B., Vilquin, J. T., Hage`ge, A. A., Scorsin, M., Messas, E., Fiszman, M.,
Schwartz, K. & Menasche´, P. (2001), ‘Factors affecting functional outcome after
autologous skeletal myoblast transplantation’, The Annals of Thoracic Surgery
71(3), 844–850.
Prasher, D. C. (1995), ‘Using GFP to see the light’, Trends in Genetics 11(8), 320–
323.
Prestle, J., Janssen, P. M., Janssen, A. P., Zeitz, O., Lehnart, S. E., Bruce, L.,
Smith, G. L. & Hasenfuss, G. (2001), ‘Overexpression of FK506-binding pro-
tein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca2+
leak from the sarcoplasmic reticulum and increases contractility’, Circulation
Research 88(2), 188–194.
Quinn, F. R., Currie, S., Duncan, A. M., Miller, S., Sayeed, R., Cobbe, S. M. &
Smith, G. L. (2003), ‘Myocardial infarction causes increased expression but
256
decreased activity of the myocardial Na+/Ca2+ exchanger in the rabbit’, The
Journal of Physiology 553(Pt 1), 229–242.
Rasband, W. S. (1997), ‘ImageJ. United States National Institutes of Health,
Bethesda, Maryland, USA’, http://rsb. info. nih. gov/ij/ .
Rector, T. S. & Cohn, J. N. (1994), ‘Prognosis in congestive heart failure’, Annual
Review of Medicine 45, 341–350.
Reffelmann, T., Dow, J. S., Dai, W., Hale, S. L., Simkhovich, B. Z. & Kloner, R. A.
(2003), ‘Transplantation of neonatal cardiomyocytes after permanent coronary
artery occlusion increases regional blood flow of infarcted myocardium’, Journal
of Molecular and Cellular Cardiology 35(6), 607–613.
Reitz, B. A., Burton, N. A., Jamieson, S. W., Bieber, C. P., Pennock, J. L., Stinson,
E. B. & Shumway, N. E. (1980), ‘Heart and lung transplantation: autotrans-
plantation and allotransplantation in primates with extended survival’, The
Journal of Thoracic and Cardiovascular Surgery 80(3), 360–372.
Reuter, H. (1967), ‘The dependence of slow inward current in Purkinje fibres on the
extracellular calcium-concentration’, The Journal of Physiology 192(2), 479–
492.
Richard, S., LeClercq, F., Lemaire, S., Piot, C. & Nargeot, J. (1998), ‘Ca2+ cur-
rents in compensated hypertrophy and heart failure’, Cardiovascular Research
37(2), 300–311.
Ringer, S. (1883), ‘A further Contribution regarding the influence of the different
Constituents of the Blood on the Contraction of the Heart’, The Journal of
Physiology 4(1), 29–42.
Rohrer, D. K., Desai, K. H., Jasper, J. R., Stevens, M. E., D. P. Regula, J., Barsh,
G. S., Bernstein, D. & Kobilka, B. K. (1996), ‘Targeted disruption of the mouse
257
β1-adrenergic receptor gene: developmental and cardiovascular effects’, Pro-
ceedings of the National Academy of Sciences of the United States of America
93(14), 7375–7380.
Roos, A. & Boron, W. F. (1981), ‘Intracellular pH’, Physiological Reviews
61(2), 296–434.
Rose, E. A., Gelijns, A. C., Moskowitz, A. J., Heitjan, D. F., Stevenson, L. W.,
Dembitsky, W., Long, J. W., Ascheim, D. D., Tierney, A. R., Levitan, R. G.,
Watson, J. T., Meier, P., Ronan, N. S., Shapiro, P. A., Lazar, R. M., Miller,
L. W., Gupta, L., Frazier, O. H., Desvigne-Nickens, P., Oz, M. C. & Poirier,
V. L. (2001), ‘Long-term mechanical left ventricular assistance for end-stage
heart failure’, The New England Journal of Medicine 345(20), 1435–1443.
Rosenberg, R. L., Hess, P. & Tsien, R. W. (1988), ‘Cardiac calcium channels in
planar lipid bilayers. L-type channels and calcium-permeable channels open at
negative membrane potentials’, The Journal of General Physiology 92(1), 27–
54.
Rosenblatt, J. D., Lunt, A. I., Parry, D. J. & Partridge, T. A. (1995), ‘Culturing
satellite cells from living single muscle fiber explants’, In Vitro Cellular and
Developmental Biology - Animal 31(10), 773–779.
Rosenzweig, A. (2006), ‘Cardiac cell therapy–mixed results from mixed cells’, The
New England Journal of Medicine 355(12), 1274–1277.
Rottbauer, W., Just, S., Wessels, G., Trano, N., Most, P., Katus, H. A. & Fishman,
M. C. (2005), ‘VEGF–PLCγ1 pathway controls cardiac contractility in the
embryonic heart’, Genes & Development 19(13), 1624–1634.
Rubart, M., Pasumarthi, K. B., Nakajima, H., Soonpaa, M. H., Nakajima, H. O. &
Field, L. J. (2003), ‘Physiological coupling of donor and host cardiomyocytes
after cellular transplantation’, Circulation Research 92(11), 1217–1224.
258
Rubart, M., Soonpaa, M. H., Nakajima, H. & Field, L. J. (2004), ‘Spontaneous
and evoked intracellular calcium transients in donor-derived myocytes following
intracardiac myoblast transplantation’, The Journal of Clinical Investigation
114(6), 775–783.
Sakmann, B. & Neher, E. (1984), ‘Patch clamp techniques for studying ionic chan-
nels in excitable membranes’, Annual Review of Physiology 46, 455–472.
Salorinne, Y., Stenius, B., Tukiainen, P. & Poppius, H. (1975), ‘Double-blind
cross-over comparison of clenbuterol and salbutamol tablets in asthmatic out-
patients’, European Journal of Clinical Pharmacology 8(3-4), 189–195.
Sandow, A. (1952), ‘Excitation-contraction coupling in muscular response’, Yale
Journal of Biology & Medicine 25(3), 176–201.
Santos, P. E., Barcellos, L. C., Mill, J. G. & Masuda, M. O. (1995), ‘Ventricular
action potential and L-type calcium channel in infarct-induced hypertrophy in
rats’, Journal of Cardiovascular Electrophysiology 6(11), 1004–1014.
Sauer, B. (1998), ‘Inducible gene targeting in mice using the Cre/lox system’, Meth-
ods 14(4), 381–392.
Scha¨chinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Ho¨lscher-
mann, H., Yu, J., Corti, R., Mathey, D. G., Hamm, C. W., Suselbeck, T.,
Assmus, B., Tonn, T., Dimmeler, S. & Zeiher, A. M. (2006), ‘Intracoronary
bone marrow-derived progenitor cells in acute myocardial infarction’, The New
England Journal of Medicine 355(12), 1210–1221.
Schwinger, R. H., Bo¨hm, M., Schmidt, U., Karczewski, P., Bavendiek, U., Flesch,
M., Krause, E. G. & Erdmann, E. (1995), ‘Unchanged protein levels of SERCA
II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of
cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared
with patients with nonfailing hearts’, Circulation 92(11), 3220–3228.
259
Scorsin, M., Hage`ge, A., Vilquin, J. T., Fiszman, M., Marotte, F., Samuel, J. L.,
Rappaport, L., Schwartz, K. & Menasche´, P. (2000), ‘Comparison of the effects
of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction
left ventricular function’, The Journal of Thoracic and Cardiovascular Surgery
119(6), 1169–1175.
Scriven, D. R., Dan, P. & Moore, E. D. (2000), ‘Distribution of proteins implicated in
excitation-contraction coupling in rat ventricular myocytes’, Biophysical Jour-
nal 79(5), 2682–2691.
Seko, Y., Seko, Y., Takahashi, N., Shibuya, M. & Yazaki, Y. (1999), ‘Pulsatile stretch
stimulates vascular endothelial growth factor (VEGF) secretion by cultured
rat cardiac myocytes’, Biochemical and Biophysical Research Communications
254(2), 462–465.
Selye, H., Bajusz, E., Grasso, S. & Mendell, P. (1960), ‘Simple techniques for the
surgical occlusion of coronary vessels in the rat’, Angiology 11, 398–407.
Sham, J. S., Song, L. S., Chen, Y., Deng, L. H., Stern, M. D., Lakatta, E. G.
& Cheng, H. (1998), ‘Termination of Ca2+ release by a local inactivation of
ryanodine receptors in cardiac myocytes’, Proceedings of the National Academy
of Sciences of the United States of America 95(25), 15096–15101.
Shweiki, D., Itin, A., Soffer, D. & Keshet, E. (1992), ‘Vascular endothelial growth
factor induced by hypoxia may mediate hypoxia-initiated angiogenesis’, Nature
359(6398), 843–845.
Siminiak, T., Kalawski, R., Fiszer, D., Jerzykowska, O., Rzez´niczak, J., Rozwad-
owska, N. & Kurpisz, M. (2004), ‘Autologous skeletal myoblast transplantation
for the treatment of postinfarction myocardial injury: phase I clinical study
with 12 months of follow-up’, American Heart Journal 148(3), 531–537.
260
Sipido, K. R., Callewaert, G. & Carmeliet, E. (1995), ‘Inhibition and rapid recovery
of Ca2+ current during Ca2+ release from sarcoplasmic reticulum in guinea pig
ventricular myocytes’, Circulation Research 76(1), 102–109.
Sipido, K. R., Maes, M. & Van de Werf, F. (1997), ‘Low efficiency of Ca2+ entry
through the Na+/Ca2+ exchanger as trigger for Ca2+ release from the sarcoplas-
mic reticulum. A comparison between L-type Ca2+ current and reverse-mode
Na+-Ca2+ exchange’, Circulation Research 81(6), 1034–1044.
Sipido, K. R., Volders, P. G., Vos, M. A. & Verdonck, F. (2002), ‘Altered Na+/Ca2+
exchange activity in cardiac hypertrophy and heart failure: a new target for
therapy?’, Cardiovascular Research 53(4), 782–805.
Sitsapesan, R., Montgomery, R. A. & Williams, A. J. (1995), ‘New insights into the
gating mechanisms of cardiac ryanodine receptors revealed by rapid changes in
ligand concentration’, Circulation Research 77(4), 765–772.
Siveski-Iliskovic, N., Hill, M., Chow, D. A. & Singal, P. K. (1995), ‘Probucol pro-
tects against adriamycin cardiomyopathy without interfering with its antitumor
effect’, Circulation 91(1), 10–15.
Solaro, R. J. (1999), ‘Integration of myofilament response to Ca2+ with cardiac
pump regulation and pump dynamics’, American Journal of Physiology 277(6
Pt 2), S155–S163.
Soppa, G. K., Lee, J., Stagg, M. A., Felkin, L. E., Barton, P. J. R., Siedlecka, U.,
Youssef, S. J., Yacoub, M. H. & Terracciano, C. M. N. (2008), ‘Role and possible
mechanisms of clenbuterol in enhancing reverse remodelling during mechanical
unloading in murine heart failure’, Cardiovascular Research 77(4), 695–706.
Soppa, G. K., Smolenski, R. T., Latif, N., Yuen, A. H., Malik, A., Karbowska, J.,
Kochan, Z., Terracciano, C. M. & Yacoub, M. H. (2005), ‘Effects of chronic
administration of clenbuterol on function and metabolism of adult rat cardiac
261
muscle’, American Journal of Physiology - Heart and Circulatory Physiology
288(3), H1468–H1476.
Spinale, F. G., Mukherjee, R., Iannini, J. P., Whitebread, S., Hebbar, L., Clair,
M. J., Melton, D. M., Cox, M. H., Thomas, P. B. & de Gasparo, M. (1997),
‘Modulation of the renin-angiotensin pathway through enzyme inhibition and
specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte
contractile processes’, Circulation 96(7), 2397–2406.
Sprague, D. H., Yang, J. C. & Ngai, S. H. (1974), ‘Effects of isoflurane and halothane
on contractility and the cyclic 3´, 5´-adenosine monophosphate system in the
rat aorta’, Anesthesiology 40(2), 162–167.
Spurgeon, H. A., Stern, M. D., Baartz, G., Raffaeli, S., Hansford, R. G., Talo,
A., Lakatta, E. G. & Capogrossi, M. C. (1990), ‘Simultaneous measurement
of Ca2+, contraction, and potential in cardiac myocytes’, American Journal of
Physiology 258(2 Pt 2), H574–H586.
Srivastava, D. & Ivey, K. N. (2006), ‘Potential of stem-cell-based therapies for heart
disease’, Nature 441(7097), 1097–1099.
Stagg, M. A., Coppen, S. R., Suzuki, K., Varela-Carver, A., Lee, J., Brand, N. J.,
Fukushima, S., Yacoub, M. H. & Terracciano, C. M. (2006), ‘Evaluation of
frequency, type, and function of gap junctions between skeletal myoblasts over-
expressing connexin43 and cardiomyocytes: relevance to cell transplantation’,
FASEB Journal 20(6), 744–746.
Starling, R. C., Jessup, M., Oh, J. K., Sabbah, H. N., Acker, M. A., Mann, D. L. &
Kubo, S. H. (2007), ‘Sustained benefits of the CorCap Cardiac Support Device
on left ventricular remodeling: three year follow-up results from the Acorn
clinical trial’, The Annals of Thoracic Surgery 84(4), 1236–1242.
Stellbrink, C., Breithardt, O. A., Franke, A., Sack, S., Bakker, P., Auricchio, A.,
Pochet, T., Salo, R., Kramer, A. & Spinelli, J. (2001), ‘Impact of cardiac
262
resynchronization therapy using hemodynamically optimized pacing on left
ventricular remodeling in patients with congestive heart failure and ventric-
ular conduction disturbances’, Journal of the American College of Cardiology
38(7), 1957–1965.
Stern, M. D. (1992), ‘Theory of excitation-contraction coupling in cardiac muscle’,
Biophysical Journal 63(2), 497–517.
Studer, R., Reinecke, H., Bilger, J., Eschenhagen, T., Bohm, M., Hasenfuss, G., Just,
H., Holtz, J. & Drexler, H. (1994), ‘Gene expression of the cardiac Na+/Ca2+
exchanger in end-stage human heart failure’, Circulation Research 75(3), 443–
453.
Sun, B., Leem, C. H. & Vaughan-Jones, R. D. (1996), ‘Novel chloride-dependent
acid loader in the guinea-pig ventricular myocyte: part of a dual acid-loading
mechanism’, The Journal of Physiology 495 ( Pt 1), 65–82.
Suzuki, K., Murtuza, B., Beauchamp, J. R., Smolenski, R. T., Varela-Carver, A.,
Fukushima, S., Coppen, S. R., Partridge, T. A. & Yacoub, M. H. (2004), ‘Dy-
namics and mediators of acute graft attrition after myoblast transplantation to
the heart’, FASEB Journal 18(10), 1153–1155.
Takahashi, M., Li, T. S., Suzuki, R., Kobayashi, T., Ito, H., Ikeda, Y., Matsuzaki, M.
& Hamano, K. (2006), ‘Cytokines produced by bone marrow cells can contribute
to functional improvement of the infarcted heart by protecting cardiomyocytes
from ischemic injury’, American Journal of Physiology - Heart and Circulatory
Physiology 291(2), H886–H893.
Tambara, K., Sakakibara, Y., Sakaguchi, G., Lu, F., Premaratne, G. U., Lin, X.,
Nishimura, K. & Komeda, M. (2003), ‘Transplanted skeletal myoblasts can
fully replace the infarcted myocardium when they survive in the host in large
numbers’, Circulation 108 Suppl 1, II259–II263.
263
Taylor, D. A., Atkins, B. Z., Hungspreugs, P., Jones, T. R., Reedy, M. C., Hutch-
eson, K. A., Glower, D. D. & Kraus, W. E. (1998), ‘Regenerating functional
myocardium: improved performance after skeletal myoblast transplantation’,
Nature Medicine 4(8), 929–933.
Taylor, D. O., Edwards, L. B., Boucek, M. M., Trulock, E. P., Deng, M. C., Keck,
B. M. & Hertz, M. I. (2005), ‘Registry of the International Society for Heart and
Lung Transplantation: twenty-second official adult heart transplant report–
2005’, The Journal of Heart & Lung Transplantation 24(8), 945–955.
Terracciano, C. M. & MacLeod, K. T. (1994), ‘Effects of acidosis on Na+/Ca2+ ex-
change and consequences for relaxation in guinea pig cardiac myocytes’, Amer-
ican Journal of Physiology 267(2 Pt 2), H477–H487.
Terracciano, C. M. & MacLeod, K. T. (2001), ‘Overexpression of the Na+/Ca2+
exchanger and reduced SERCA function’, Cardiovascular Research 50(1), 167–
169.
The DEFIBRILAT Study Group (1991), ‘Actuarial risk of sudden death while await-
ing cardiac transplantation in patients with atherosclerotic heart disease. DE-
FIBRILAT Study Group’, American Journal of Cardiology 68(5), 545–546.
The Digitalis Investigation Group (1997), ‘The effect of digoxin on mortality and
morbidity in patients with heart failure. The Digitalis Investigation Group’,
The New England Journal of Medicine 336(8), 525–533.
The RALES Investigators (1996), ‘Effectiveness of spironolactone added to
an angiotensin-converting enzyme inhibitor and a loop diuretic for severe
chronic congestive heart failure (the Randomized Aldactone Evaluation Study
[RALES])’, American Journal of Cardiology 78(8), 902–907.
The SOLVD Investigators (1991), ‘Effect of enalapril on survival in patients with
reduced left ventricular ejection fractions and congestive heart failure. The
SOLVD Investigators’, The New England Journal of Medicine 325(5), 293–302.
264
Theroux, P., J. Ross, J., Franklin, D., Covell, J. W., Bloor, C. M. & Sasayama, S.
(1977), ‘Regional myocardial function and dimensions early and late after my-
ocardial infarction in the unanesthetized dog’, Circulation Research 40(2), 158–
165.
Thum, T., Bauersachs, J., Poole-Wilson, P. A., Volk, H. D. & Anker, S. D. (2005),
‘The dying stem cell hypothesis: immune modulation as a novel mechanism for
progenitor cell therapy in cardiac muscle’, The Journal of the American College
of Cardiology 46(10), 1799–1802.
Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J. & Kessler, P. D. (2002),
‘Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in
the adult murine heart’, Circulation 105(1), 93–98.
Tomaselli, G. F. & Marban, E. (1999), ‘Electrophysiological remodeling in hyper-
trophy and heart failure’, Cardiovascular Research 42(2), 270–283.
Tomita, F., Bassett, A. L., Myerburg, R. J. & Kimura, S. (1994), ‘Diminished tran-
sient outward currents in rat hypertrophied ventricular myocytes’, Circulation
Research 75(2), 296–303.
Tsien, R. Y. (1981), ‘A non-disruptive technique for loading calcium buffers and
indicators into cells’, Nature 290(5806), 527–528.
Tsien, R. Y. (1998), ‘The green fluorescent protein’, Annual Review of Biochemistry
67, 509–544.
Tsien, R. Y. & Poenie, M. (1986), ‘Fluorescence ratio imaging: a new window into
intracellular ionic signaling’, Trends in Biochemical Sciences 11(11), 450–455.
Tytgat, J. (1994), ‘How to isolate cardiac myocytes’, Cardiovascular Research
28(2), 280–283.
265
Uemura, R., Xu, M., Ahmad, N. & Ashraf, M. (2006), ‘Bone marrow stem cells pre-
vent left ventricular remodeling of ischemic heart through paracrine signaling’,
Circulation Research 98(11), 1414–1421.
Valdivia, H. H., Kaplan, J. H., Ellis-Davies, G. C. & Lederer, W. J. (1995), ‘Rapid
adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phospho-
rylation’, Science 267(5206), 1997–2000.
van Weemen, B. K. & Schuurs, A. H. (1971), ‘Immunoassay using antigen-enzyme
conjugates’, FEBS Letters 15(3), 232–236.
Vliegen, H. W., van der Laarse, A., Cornelisse, C. J. & Eulderink, F. (1991), ‘My-
ocardial changes in pressure overload-induced left ventricular hypertrophy. A
study on tissue composition, polyploidization and multinucleation’, European
Heart Journal 12(4), 488–494.
Volz, A., Piper, H. M., Siegmund, B. & Schwartz, P. (1991), ‘Longevity of adult
ventricular rat heart muscle cells in serum-free primary culture’, Journal of
Molecular and Cellular Cardiology 23(2), 161–173.
von Lewinski, D., Voß, K., Hu¨lsmann, S., Ko¨gler, H. & Pieske, B. (2003), ‘Insulin-
like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing
human myocardium’, Circulation Research 92(2), 169–176.
Wasserstrom, J. A., Holt, E., Sjaastad, I., Lunde, P. K., Ødegaard, A. & Sejer-
sted, O. M. (2000), ‘Altered E-C coupling in rat ventricular myocytes from
failing hearts 6 weeks after MI’, American Journal of Physiology - Heart and
Circulatory Physiology 279(2), H798–H807.
Wasserstrom, J. A. & Vites, A. M. (1996), ‘The role of Na+/Ca2+ exchange in
activation of excitation-contraction coupling in rat ventricular myocytes’, The
Journal of Physiology 493 ( Pt 2), 529–542.
266
Wehrens, X. H., Lehnart, S. E., Huang, F., Vest, J. A., Reiken, S. R., Mohler,
P. J., Sun, J., Guatimosim, S., Song, L. S., Rosemblit, N., D’Armiento, J. M.,
Napolitano, C., Memmi, M., Priori, S. G., Lederer, W. J. & Marks, A. R.
(2003), ‘FKBP12.6 deficiency and defective calcium release channel (ryan-
odine receptor) function linked to exercise-induced sudden cardiac death’, Cell
113(7), 829–840.
Weinberg, E. O., Thienelt, C. D., Katz, S. E., Bartunek, J., Tajima, M., Rohrbach,
S., Douglas, P. S. & Lorell, B. H. (1999), ‘Gender differences in molecular
remodeling in pressure overload hypertrophy’, Journal of the American College
of Cardiology 34(1), 264–273.
Wettwer, E., Amos, G., Gath, J., Zerkowski, H. R., Reidemeister, J. C. & Ravens,
U. (1993), ‘Transient outward current in human and rat ventricular myocytes’,
Cardiovascular Research 27(9), 1662–1669.
White, H. D., Norris, R. M., Brown, M. A., Brandt, P. W., Whitlock, R. M. & Wild,
C. J. (1987), ‘Left ventricular end-systolic volume as the major determinant of
survival after recovery from myocardial infarction’, Circulation 76(1), 44–51.
Wier, W. G., Egan, T. M., Lopez-Lopez, J. R. & Balke, C. W. (1994), ‘Local control
of excitation-contraction coupling in rat heart cells’, The Journal of Physiology
474(3), 463–471.
Wilensky, R. L., Yudelman, P., Cohen, A. I., Fletcher, R. D., Atkinson, J., Virmani,
R. & Roberts, W. C. (1988), ‘Serial electrocardiographic changes in idiopathic
dilated cardiomyopathy confirmed at necropsy’, American Journal of Cardiol-
ogy 62(4), 276–283.
Wohlschlaeger, J., Schmitz, K. J., Schmid, C., Schmid, K. W., Keul, P., Takeda,
A., Weis, S., Levkau, B. & Baba, H. A. (2005), ‘Reverse remodeling following
insertion of left ventricular assist devices (LVAD): a review of the morphological
and molecular changes’, Cardiovascular Research 68(3), 376–386.
267
Wong, K., Boheler, K. R., Petrou, M. & Yacoub, M. H. (1997), ‘Pharmacological
modulation of pressure-overload cardiac hypertrophy: changes in ventricular
function, extracellular matrix, and gene expression’, Circulation 96(7), 2239–
2246.
Xiao, B., Jiang, M. T., Zhao, M., Yang, D., Sutherland, C., Lai, F. A., Walsh, M. P.,
Warltier, D. C., Cheng, H. & Chen, S. R. (2005), ‘Characterization of a novel
PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation
of the cardiac ryanodine receptor in canine heart failure’, Circulation Research
96(8), 847–855.
Xiao, R. P. (2001), ‘β-adrenergic signaling in the heart: dual coupling of the
β2-adrenergic receptor to Gs and Gi proteins’, Science’s Signal Transduction
Knowledge Environment 2001(104), RE15.
Xiao, R. P., Ji, X. & Lakatta, E. G. (1995), ‘Functional coupling of the β2-
adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes’,
Molecular Pharmacology 47(2), 322–329.
Xiao, R. P. & Lakatta, E. G. (1993), ‘β1-adrenoceptor stimulation and β2-
adrenoceptor stimulation differ in their effects on contraction, cytosolic
Ca2+, and Ca2+ current in single rat ventricular cells’, Circulation Research
73(2), 286–300.
Xiao, R. P., Zhang, S. J., Chakir, K., Avdonin, P., Zhu, W., Bond, R. A., Balke,
C. W., Lakatta, E. G. & Cheng, H. (2003), ‘Enhanced Gi signaling selec-
tively negates β2-adrenergic receptor (AR)–but not β1-AR-mediated positive
inotropic effect in myocytes from failing rat hearts’, Circulation 108(13), 1633–
1639.
Xu, X., Xu, Z., Xu, Y. & Cui, G. (2005), ‘Effects of mesenchymal stem cell trans-
plantation on extracellular matrix after myocardial infarction in rats’, Coronary
Artery Disease 16(4), 245–255.
268
Yacoub, M. H. (2001), ‘A novel strategy to maximize the efficacy of left ventricular
assist devices as a bridge to recovery’, European Heart Journal 22(7), 534–540.
Yang, X. P., Liu, Y. H., Rhaleb, N. E., Kurihara, N., Kim, H. E. & Carretero,
O. A. (1999), ‘Echocardiographic assessment of cardiac function in conscious
and anesthetized mice’, American Journal of Physiology 277(5 Pt 2), H1967–
H1974.
Yoshimura, T., Yuhki, N., Moore, S. K., Appella, E., Lerman, M. I. & Leonard,
E. J. (1989), ‘Human monocyte chemoattractant protein-1 (MCP-1). Full-
length cDNA cloning, expression in mitogen-stimulated blood mononuclear
leukocytes, and sequence similarity to mouse competence gene JE’, FEBS Let-
ters 244(2), 487–493.
Young, J. B., Abraham, W. T., Smith, A. L., Leon, A. R., Lieberman, R., Wilkoff,
B., Canby, R. C., Schroeder, J. S., Liem, L. B., Hall, S. & Wheelan, K. (2003),
‘Combined cardiac resynchronization and implantable cardioversion defibrilla-
tion in advanced chronic heart failure: the MIRACLE ICD Trial’, The Journal
of the American Medical Association 289(20), 2685–2694.
Yue, D. T., Backx, P. H. & Imredy, J. P. (1990), ‘Calcium-sensitive inactivation in
the gating of single calcium channels’, Science 250(4988), 1735–1738.
Zeltsman, D. & Acker, M. A. (2002), ‘Surgical management of heart failure: an
overview’, Annual Review of Medicine 53, 383–391.
Zhang, X. Q., Musch, T. I., Zelis, R. & Cheung, J. Y. (1999), ‘Effects of impaired
Ca2+ homeostasis on contraction in postinfarction myocytes’, Journal of Ap-
plied Physiology 86(3), 943–950.
Zhang, X. Q., Tillotson, D. L., Moore, R. L., Zelis, R. & Cheung, J. Y. (1996),
‘Na+/Ca2+ exchange currents and SR Ca2+ contents in postinfarction my-
ocytes’, American Journal of Physiology 271(6 Pt 1), C1800–C1807.
269
Zheng, M., Zhu, W., Han, Q. & Xiao, R. P. (2005), ‘Emerging concepts and thera-
peutic implications of β-adrenergic receptor subtype signaling’, Pharmacology
& Therapeutics 108(3), 257–268.
Zhou, L., Azfer, A., Niu, J., Graham, S., Choudhury, M., Adamski, F. M., Younce,
C., Binkley, P. F. & Kolattukudy, P. E. (2006), ‘Monocyte chemoattractant
protein-1 induces a novel transcription factor that causes cardiac myocyte apop-
tosis and ventricular dysfunction’, Circulation Research 98(9), 1177–1185.
Zhou, Y. Y., Wang, S. Q., Zhu, W. Z., Chruscinski, A., Kobilka, B. K., Ziman,
B., Wang, S., Lakatta, E. G., Cheng, H. & Xiao, R. P. (2000), ‘Culture and
adenoviral infection of adult mouse cardiac myocytes: methods for cellular
genetic physiology’, American Journal of Physiology - Heart and Circulatory
Physiology 279(1), H429–H436.
Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K. & Xiao, R. P.
(2001), ‘Dual modulation of cell survival and cell death by β2-adrenergic sig-
naling in adult mouse cardiac myocytes’, Proceedings of the National Academy
of Sciences of the United States of America 98(4), 1607–1612.
270
Appendix A
MatLabr script for detection and
morphometric analysis of Ca2+
sparks
Below is the computer script, written by Dr. Mark A. Stagg, to be run in the
computer programme MatLabr R2006b. This script processed the exported TIFF
digital image files containing the Ca2+ spark data. The output data include Ca2+
spark frequency, amplitude, FWHM, and FDHM. For details of applications, see
section 2.13 on page 115.
%--------------- 26-Apr-07 --------------%
%----------- Dr Mark A. Stagg -----------%
%----------- Zeiss tiff Files -----------%
% INSTRUCTIONS:
% You need to cut the lsm file to the width of the cell and
% then save as a tiff file format. This can be done by exporting
% with the lsm browser software to imageJ for cropping. Open the
% mdb file for the experiments saved and extract the size of scan
% data (pixel size and line scan speed). Set the current directory
% in matlab to the exported tiff files, and then run this script.
%
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% IMPORTANT - clear command window and close any open images
% before running.
% -----< BEGIN >----- %
% open file and get x and y dimensions
[fileName, pathName] = uigetfile(’*.tif’, ’Select tiff file’);
imageName = strcat(pathName,fileName);
imA = imread(imageName);
imA = double(imA);
fileInfo = imfinfo(imageName);
[xSize] = fileInfo.Width;
[ySize] = fileInfo.Height;
% user input of pixel size and time for a linescan
pixelInfo = struct( ...
’dlg_title’ , ’Input information about pixel acquisition’ ,...
’prompt’ , {’Enter pixel size (m):’,’Enter scan speed (ms):’,
’Enter criterion (S.D.):’} ,...
’num_lines’ , 1 ,...
’def’ , {’0.2222’,’0.76364’,’3.8’}, ...
’input’ , 0 ...
);
pInfo = inputdlg({pixelInfo(1,1).prompt,pixelInfo(1,2).prompt,
pixelInfo(1,3).prompt},pixelInfo(1,1).dlg_title,pixelInfo(1,1).num_lines,
{pixelInfo(1,1).def,pixelInfo(1,2).def,pixelInfo(1,3).def},’on’);
pixelInfo(1,1).input = pInfo(1);
pixelInfo(1,2).input = pInfo(2);
pixelInfo(1,3).input = pInfo(3);
pSize = str2double(pixelInfo(1,1).input);
tScan = str2double(pixelInfo(1,2).input);
cri = str2double(pixelInfo(1,3).input);
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clear pInfo;
% % display imA
% figure(’Name’, ’imA’,’Position’,[32 128 256 768]); % Fig 1
% get(imagesc(imA));
% colormap jet;
% colorbar(’location’,’EastOutside’);
% calculate variance
imA = double(medfilt2(imA,[3 3]));
% minimal median filter to remove data points at extremes
% imA = double(medfilt2(imA,[5 5]));
% minimal median filter to remove data points at extremes
imMedian = imA;
% % display imMedian
% figure(’Name’, ’imMedian’,’Position’,[344 128 256 768]); % Fig 2
% get(imagesc(imMedian));
% colormap jet;
% colorbar(’location’,’EastOutside’);
% 0.8 m and 10 ms spatio-temporal filter
ss = (0.8/pSize); % ss = no. of pixels in 0.8 m
st = (10/tScan); % st = no. of pixels in 10 ms
imB = zeros(ySize,xSize,’double’); % set up image array Fig 3
shiftX = round(ss/2);
shiftY = round(st/2);
ct = 0; % ct = iteration counter
for ia = - shiftX : shiftX; % for groups of 2 m
imB = imB + circshift(imA,[0,ia]); % shift image 2 m
ct = ct + 1;
end
for ib = - shiftY : shiftY; % for groups of 10 ms
imB = imB + circshift(imA,[ib,0]); % shift image 10 ms
ct = ct + 1;
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end
imA = imB./ct;
% imB = imA;
% normalise to background
imMean = mean(imA); % find mean value for
% each x (column)
imBx = zeros(ySize,xSize,’double’); % Preallocate matrix Fig 4
for m = 1:ySize;
imBx(m,:) = imMean(1,:); % fill each row with mean
end
clear m;
imA = imA./imBx; % initial normalization -
sd = std(imA(:)); % divide image by mean at each x
ave = mean(imA(:));
imB = imA;
%clear shiftX;
%clear shiftY;
% display imB
figure(’Name’, ’imB’,’Position’,[656 128 256 768]); % Fig 3
get(imagesc(imB));
colormap jet;
colorbar(’location’,’EastOutside’);
% % display imBx
% figure(’Name’, ’imBx’,’Position’,[968 128 256 768]); % Fig 4
% get(imagesc(imBx));
% colormap jet;
% colorbar(’location’,’EastOutside’);
% % re-draw imA
% figure(1); % select the figure
% get(imagesc(imA)); % redraw the updated data
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% colormap jet;
% colorbar(’location’,’EastOutside’);
% mask for potential spark regions > m+2*SD
thresh = ave+2*sd;
mask = logical(imA > thresh); % set everything above 2*SD in imA
mask = medfilt2(mask,[5 5]); % median filter (need toolbox) blur edges
imA = imB.*(not(mask)); % excise possible spark regions
% % display mask
% figure(’Name’, ’mask’,’Position’,[56 96 256 768]); % Fig 5
% get(imagesc(mask));
% colormap gray;
% colorbar(’YLim’,[0;1],’YTick’,[0;1],’YTickLabel’,{’0’,’1’},’location’,
% ’EastOutside’);
% % re-draw imA
% figure(1); % select the figure
% get(imagesc(imA)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
% % re-draw imB
% figure(3); % select the figure
% get(imagesc(imB)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
% calculate baseline spatial profile with potential spark regions excised
% ** this is also used later for spark detection
imBack = imA;
imBase = imA;
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% imBase = zeros(ySize,xSize,’double’); % Preallocate matrix Fig 6
%for m = 1:ySize
% imBase(m,:) = imBack(1,:); % fill each row with mean
%end
%clear m;
%aveFilter = fspecial(’average’,[3 3]); % smooth 3x3 boxcar average
%imBase = imfilter(imA,aveFilter,’replicate’);
%imB = imB./imBase;
%imBase = double(imB.*(1-mask));
imIndex = find(imBase > 0);
aveLessSp = mean(imBase(imIndex)); % find index of array
% with non-zero values
sdLessSp = std(imBase(imIndex)); % and calculate mean and sd
ave = aveLessSp; % update mean and sd
sd = sdLessSp;
imIndex = find(imBack == 0);
imBase(imIndex) = ave;
% sd = std(imBase(:));
% ave = mean(imBase(:));
% % display imBase
% figure(’Name’, ’imBase’,’Position’,[368 96 256 768]); % Fig 6
% get(imagesc(imBase));
% colormap jet;
% colorbar(’location’,’EastOutside’);
% % display imBack
% figure(’Name’, ’imBack’,’Position’,[682 96 256 768]); % Fig 7
% get(imagesc(imBack));
% colormap jet;
% colorbar(’location’,’EastOutside’);
% % re-draw imB
% figure(3); % select the figure
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% get(imagesc(imB)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
% % re-draw imA
% figure(1); % select the figure
% get(imagesc(imA)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
% spark detection bit:
% make a binary image of cri*SD i.e. spark sites
% cri = criteria for spark region folds of SD above mean
thresh = ave+cri*sd;
im = logical(imB > thresh); % set everything above cri*SD
im = medfilt2(im,[3 3]); % need image processing toolbox
im = medfilt2(im,[5 5]); % need image processing toolbox
% **Use the median filtered image imageMedian (with sparks) and
% baseline image (spark areas removed - imBase).
imBack = imB./imBase; % imB = new image (normalised with minimal filtering on sparks)
% re-draw imB
%figure(3); % select the figure
figure(1); % select the figure if all others commented out
get(imagesc(imB)); % redraw the updated data
colormap jet;
colorbar(’location’,’EastOutside’);
% % re-draw imBack
% figure(7); % select the figure
% get(imagesc(imBack)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
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% % display im
% figure(’Name’, ’im’,’Position’,[992 96 256 768]); % Fig 8
% get(imagesc(im));
% colormap gray;
% colorbar(’YLim’,[0;1],’YTick’,[0;1],’YTickLabel’,{’0’,’1’},’location’,
% ’EastOutside’);
% assess possible sparks regions in imB
% define search area
xLOrR = round(6/pSize); % 3 m from xCoord
yUpOrDown = round(60/tScan); % 30 ms from tScan
% locate possible sparks from im (cri*SD)
[events,numPossSp] = bwlabeln(im,8);
possSp = regionprops(events);
% % display events as im
% figure(8); % select the figure
% get(imagesc(events)); % redraw the updated data
% colormap jet;
% colorbar(’location’,’EastOutside’);
clear imBack;
clear imBase;
clear imBx;
clear imIndex;
clear imA;
clear imMedian;
clear imMean;
clear mask;
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% set up structure to hold possible sparks
% include file name, date etc as a header
sparkCell = cell([(numPossSp+1),15]);
sparkCell{1,1} = (’file’);
sparkCell{1,2} = (’date’);
sparkCell{1,3} = (’cellWidth (m)’);
sparkCell{1,4} = (’scanTime (s)’);
sparkCell{1,5} = (’spFreq (sparks/100m/s)’);
sparkCell{1,6} = (’SpCounted’);
sparkCell{1,7} = (’possSp’);
sparkCell{1,8} = (’xCoord’);
sparkCell{1,9} = (’yCoord’);
sparkCell{1,10} = (’spBound’);
sparkCell{1,11} = (’peak (F/Fo)’);
sparkCell{1,12} = (’xPeak’);
sparkCell{1,13} = (’yPeak’);
sparkCell{1,14} = (’fWhm (m)’);
sparkCell{1,15} = (’fDhm (ms)’);
% sparkCell{16,1} = (’aveP’); % peak with 3x3 filter
% sparkCell{17,1} = (’xAveP’);
% sparkCell{18,1} = (’yAveP’);
% sparkCell{19,1} = (’avefWhm (m)’);
% sparkCell{20,1} = (’avefDhm (ms)’);
sparkCell{2,1} = fileInfo.Filename;
sparkCell{2,2} = datestr(now,’yyyy-mm-dd’);
sparkCell{2,3} = (xSize*pSize);
sparkCell{2,4} = ((ySize*tScan)/1000);
% assess possible sparks in im and imB
for i = 1:numPossSp;
xy = fix(possSp(i).Centroid); % find x and y from im (cri*SD)
yCoord = xy(2);
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xCoord = xy(1);
spBound = [xCoord-xLOrR,xCoord+xLOrR,yCoord-yUpOrDown,
yCoord+yUpOrDown];
sparkCell{(1+i),7} = i;
sparkCell{(1+i),8} = xCoord(1);
sparkCell{(1+i),9} = yCoord(1);
sparkCell{(1+i),10} = (spBound);
% find possible spark in imB and assess parameter
rROI = [spBound(3),spBound(4),spBound(4),spBound(3)];
cROI = [spBound(1),spBound(1),spBound(2),spBound(2)];
spROI = roipoly(imB,cROI,rROI);
imSpark = imB.*spROI;
aveFilter = fspecial(’average’,[3 3]); % smooth 3x3 boxcar average
imSpark = imfilter(imSpark,aveFilter,’replicate’);
peak = max(max(imSpark)); % find peak of possible spark
[yPeak,xPeak] = find(imSpark >= peak);
% re-align centre of spROI to peak
rROI = [(yPeak - yUpOrDown),(yPeak + yUpOrDown),
(yPeak + yUpOrDown),(yPeak - yUpOrDown)];
cROI = [(xPeak - xLOrR),(xPeak - xLOrR),(xPeak + xLOrR),
(xPeak + xLOrR)];
spROI = roipoly(imB,cROI,rROI);
imSpark = imB.*spROI;
aveFilter = fspecial(’average’,[3 3]); % smooth 3x3 boxcar average
imSpark = imfilter(imSpark,aveFilter,’replicate’);
thresh = ave+((peak-ave)/2);
% calculate local F/Fo threshold for half-maximal
maskHM = logical(imSpark >= thresh); % set everything above HM
[probEvent,numProbSp] = bwlabel(maskHM,8);
probSp = regionprops(probEvent);
for j = 1:numProbSp;
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% get spark bounding box with peak, fDhm
checkSp = probSp(j).BoundingBox;
if (xPeak(1) > checkSp(1)) ...
&& (xPeak(1) < (checkSp(1)+checkSp(3)))...
&& (yPeak(1) > checkSp(2))...
&& (yPeak(1) < (checkSp(2)+checkSp(4)));
% calculate fDhm and fWhm
% find duration at peak (calculate fDhm)
yLimBottom = ySize;
if yLimBottom > spBound(4);
yLimBottom = spBound(4);
end
yLimTop = 1;
if spBound(3) > yLimTop;
yLimTop = spBound(3);
end;
dTest = maskHM(yLimTop:yLimBottom,xPeak(1));
[dTest,dTestNum] = bwlabel(dTest);
dTest = regionprops(dTest);
fDhm = 0;
for k=1:dTestNum;
dTestChk = dTest(k).BoundingBox;
if yPeak(1) > (dTestChk(2)+spBound(3))...
&& yPeak(1) < (dTestChk(2)+dTestChk(4)+spBound(3));
fDhm = dTestChk(4);
end
end
% at each y assess maximum x (calculate fWhm)
fWhm = 0;
xLimRight = xSize;
if xLimRight > spBound(2);
xLimRight = spBound(2);
end;
xLimLeft = 1;
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if spBound(1) > xLimLeft;
xLimLeft = spBound(1);
end;
for k = yLimTop:yLimBottom;
dTest = maskHM(k,xLimLeft:xLimRight);
[dTest,dTestNum] = bwlabel(dTest);
dTest = regionprops(dTest);
kk = 0;
for kk=1:dTestNum;
dTestChk = dTest(kk).BoundingBox;
if (dTestChk(3) > fWhm);
fWhm = dTestChk(3);
end
end
end
% write spark parameters
sparkCell{(1+i),11} = peak;
sparkCell{(1+i),12} = xPeak(1);
sparkCell{(1+i),13} = yPeak(1);
sparkCell{(1+i),14} = (fWhm*pSize);
sparkCell{(1+i),15} = (fDhm*tScan);
end
end
% % fig of possible caSp?
% % display CaSpPNG
% caSpBox = [(xPeak - xLOrR) (yPeak - yUpOrDown) (xLOrR*2)
% (yUpOrDown*2)];
% caSpFig = imcrop(imB,caSpBox);
% figure(’Name’, ’CaSpPNG’,’Position’,[384 256 512 512]);
% % Fig 9
% get(surf(caSpFig));
% colormap jet;
% shading interp;
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% axis square;
% saveas(9,(strcat((datestr(now,’yyyymmdd’)),
% ’_CaSp_’,num2str(i),’.png’)),’png’);
% % saveas(9,(strcat(pathName,(datestr(now,’yyyymmdd’)),
% ’\’,strrep(fileName,’.tif’,’’),’_CaSp_’,num2str(i),
% ’.jpg’)),’jpg’);
% close(’CaSpPNG’);
end;
% remove duplicate peaks from spark ROI overlap and fWhm < 2 m
xyDuplSpCell = sparkCell;
xyDuplTest = zeros(2,i);
for i = 1:numPossSp;
xyDuplTest(i,1) = sparkCell{(1+i),12};
xyDuplTest(i,2) = sparkCell{(1+i),13};
end;
% check each i in cell...
for i = 1:numPossSp;
for j = 1:numPossSp;
if (xyDuplTest(j,1) == xyDuplTest(i,1)) && (xyDuplTest(j,2)
== xyDuplTest(i,2))...
&& i ~= j;
xyDuplTest(j,1) = 0;
xyDuplTest(j,2) = 0;
for k = 1:15;
xyDuplSpCell{(1+j),k} = [];
end;
end;
if (xyDuplSpCell{(1+j),14} < 2)
for k = 1:15;
xyDuplSpCell{(1+j),k} = [];
end;
end;
283
end;
end;
sparkCellEnd = xyDuplSpCell;
% select figure imB and draw on sparks and labels
% figure(3);
figure(1); % if all other figures not rendered
% freq of sparks
spCount = 0;
for j = 1:numPossSp;
if find(sparkCellEnd{(1+j),7} ~= (j-1));
spCount = spCount + 1;
sparkCellEnd{(1+j),6} = spCount;
%rectangle(’Position’,[x,y,w,h])
rectangle(’Position’,[sparkCellEnd{(1+j),10}(1),...
sparkCellEnd{(1+j),10}(3),...
(sparkCellEnd{(1+j),10}(2)-sparkCellEnd{(1+j),10}(1)),...
(sparkCellEnd{(1+j),10}(4)-sparkCellEnd{(1+j),10}(3))]);
%text(x,y,key);
key = num2str(spCount);
text((sparkCellEnd{(1+j),10}(1)+3),(sparkCellEnd{(1+j),10}(3)+30),key);
end;
end;
spFreq = spCount/(100/xSize/pSize)/(1000/ySize/tScan);
sparkCellEnd{2,5} = spFreq;
sparkCellEnd{2,1} = fileInfo.Filename;
sparkCellEnd{2,2} = datestr(now,’yyyy-mm-dd’);
sparkCellEnd{2,3} = (xSize*pSize);
sparkCellEnd{2,4} = ((ySize*tScan)/1000);
[pathstr, fName, ext, versn] = fileparts(fileName);
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xlsName = strcat(pathName,fName,’.xls’);
pngName = strcat(pathName,fName,’.png’);
xlswrite(xlsName, sparkCellEnd); % this works but is slow
saveas(1,pngName,’png’);
% -----< ALL DONE >----- %
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